Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in Hepatology Retrieve available abstracts of 1187 articles: HTML format

Single Articles

June 2024
1. 
   Erratum: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
   Hepatology. 2024;79:E171-E172.
   PubMed    
   
   
   
2. 
   Hepatology Highlights.
   Hepatology. 2024;79:1239-1240.
   PubMed    
   
   
   
3. LI Z, Zhang Y, Li Y, Lan J, et al
   Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
   Hepatology. 2024;79:E169-E170.
   PubMed    
   
   
   
4. LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
   Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
   Hepatology. 2024;79:E155-E156.
   PubMed    
   
   
   
5. CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
   Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
   Hepatology. 2024;79:E153-E154.
   PubMed    
   
   
   
6. YEH JG, Newsome PN
   Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
   Hepatology. 2024;79:1255-1257.
   PubMed    
   
   
   
7. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
   Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
   Hepatology. 2024;79:1279-1292.
   PubMed     Abstract available
   
   
   
8. ABDELMALEK MF, Rinella ME
   Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
   Hepatology. 2024;79:1252-1254.
   PubMed    
   
   
   
9. ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
   Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
   Hepatology. 2024;79:1401-1411.
   PubMed     Abstract available
   
   
   
10. ZHAO G, Ma Q, Yang H, Jiang H, et al
    Base editing of the mutated TERT promoter inhibits liver tumor growth.
    Hepatology. 2024;79:1310-1323.
    PubMed     Abstract available
    
    
    
11. SCHMIDT KA, Simonetto DA
    The telomere tango: Liver disease in the genomic spotlight.
    Hepatology. 2024;79:1249-1251.
    PubMed    
    
    
    
12. SIDALI S, Borie R, Sicre de Fontbrune F, El Husseini K, et al
    Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
    Hepatology. 2024;79:1365-1380.
    PubMed     Abstract available
    
    
    
13. UMBAUGH DS, Nguyen NT, Curry SC, Rule JA, et al
    The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure.
    Hepatology. 2024;79:1352-1364.
    PubMed     Abstract available
    
    
    
14. WANG A, Blackford AL, Behling C, Wilson LA, et al
    Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1381-1392.
    PubMed     Abstract available
    
    
    
15. JIN Y, Shou Y, Lei Q, Du C, et al
    An entropy weight method to integrate big omics and mechanistically evaluate DILI.
    Hepatology. 2024;79:1264-1278.
    PubMed     Abstract available
    
    
    
16. AFONSO MB, Marques V, van Mil SWC, Rodrigues CMP, et al
    Human liver organoids: From generation to applications.
    Hepatology. 2024;79:1432-1451.
    PubMed     Abstract available
    
    
    May 2024
17. KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
    Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1212-1219.
    PubMed     Abstract available
    
    
    
18. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
    Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
    Hepatology. 2024;79:E130-E131.
    PubMed    
    
    
    
19. ZAHRAWI FM, Mehal WZ
    Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
    Hepatology. 2024;79:E129.
    PubMed    
    
    
    
20. STOCKDALE AJ, Degasperi E
    HDV RNA and liver disease progression: What do we know?
    Hepatology. 2024;79:983-985.
    PubMed    
    
    
    
21. DESERT R, Foucher F, Guillout M, Nieto N, et al
    Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E141-E143.
    PubMed    
    
    
    
22. WANG TC, Xiao YD, Zhou P
    Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E140.
    PubMed    
    
    
    
23. LIU H, Li H, Wang DX, Li T, et al
    Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:E144-E145.
    PubMed    
    
    
    
24. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
    Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hepatology. 2024;79:E146-E147.
    PubMed    
    
    
    
25. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
    Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
    Hepatology. 2024;79:1065-1074.
    PubMed     Abstract available
    
    
    
26. SQUIRES JE, Horslen SP
    Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
    Hepatology. 2024;79:970-972.
    PubMed    
    
    
    
27. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
    Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:1107-1116.
    PubMed     Abstract available
    
    
    
28. LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
    Genetic landscape of pediatric acute liver failure of indeterminate origin.
    Hepatology. 2024;79:1075-1087.
    PubMed     Abstract available
    
    
    
29. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
    Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
    Hepatology. 2024;79:1098-1106.
    PubMed     Abstract available
    
    
    
30. TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
    Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
    Hepatology. 2024;79:1141-1157.
    PubMed     Abstract available
    
    
    
31. SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
    Spatial metabolomics and its application in the liver.
    Hepatology. 2024;79:1158-1179.
    PubMed     Abstract available
    
    
    
32. 
    Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
    Hepatology. 2024;79:E150-E151.
    PubMed    
    
    
    April 2024
33. KUMAR M, Venishetty S
    Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
    Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
    PubMed    
    
    
    
34. ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
    Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
    PubMed     Abstract available
    
    
    
35. LI X, Zhang Y, Li S, Shi J, et al
    Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
    PubMed     Abstract available
    
    
    
36. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
    Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
    PubMed    
    
    
    
37. LEE YT, Tseng HR, Yang JD
    Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
    Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
    PubMed    
    
    
    
38. GUO C, Liu Z, Fan H, Wang H, et al
    Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
    Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
    PubMed     Abstract available
    
    
    
39. HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
    ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
    PubMed     Abstract available
    
    
    
40. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
    Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
    PubMed    
    
    
    
41. GARCIA-TSAO G, Kaplan DE
    Reply: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
    PubMed    
    
    
    
42. VOLK ML
    Innovations in Healthcare Delivery for Patients with Cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
    PubMed    
    
    
    
43. MOGHE A, McGuire BM, Levy C
    Acute hepatic porphyrias - a guide for Hepatologists.
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880.
    PubMed     Abstract available
    
    
    
44. SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
    Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
    Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
    PubMed     Abstract available
    
    
    
45. LI J, Allen AM, Yin M
    Reply: Comparing quantitative MRI technologies in steatotic liver disease.
    Hepatology. 2024;79:E121-E122.
    PubMed    
    
    
    
46. ALKHOURI N, Harisinghani M
    Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
    Hepatology. 2024;79:E119-E120.
    PubMed    
    
    
    
47. FRANSES JW, Duda DG
    Scirrhous HCC: Another 'omic thread in the HCC tapestry.
    Hepatology. 2024;79:747-748.
    PubMed    
    
    
    
48. VOLKERT I, Fromme M, Schneider C, Candels L, et al
    Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
    Hepatology. 2024;79:898-911.
    PubMed     Abstract available
    
    
    
49. LADD AD, Duarte S, Sahin I, Zarrinpar A, et al
    Mechanisms of drug resistance in HCC.
    Hepatology. 2024;79:926-940.
    PubMed     Abstract available
    
    
    
50. 
    Erratum: Identification and characterization of a hepatic IL-13-producing ILC3-like population potentially involved in liver fibrosis.
    Hepatology. 2024;79:E128.
    PubMed    
    
    
    
51. 
    Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
    Hepatology. 2024;79:E127.
    PubMed    
    
    
    
52. 
    April 2024 Hepatology Highlights.
    Hepatology. 2024;79:745-746.
    PubMed    
    
    
    
53. TAFALENG EN, Li J, Wang Y, Hidvegi T, et al
    Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in alpha1-antitrypsin deficiency.
    Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000865.
    PubMed     Abstract available
    
    
    
54. TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
    Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
    Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
    PubMed     Abstract available
    
    
    March 2024
55. 
    Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
    Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
    PubMed    
    
    
    
56. DENG T, Chen G
    Single-cell based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000874.
    PubMed    
    
    
    
57. CRUZ C, Prado CM, Gillis C, Martindale R, et al
    Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
    PubMed     Abstract available
    
    
    
58. FENG X, Feng B, Zhou J, Yang J, et al
    Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
    PubMed     Abstract available
    
    
    
59. GOLDBERG DT, Yaskolka Meir A, Tsaban G, Rinott E, et al
    Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000867.
    PubMed     Abstract available
    
    
    
60. ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
    NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
    PubMed     Abstract available
    
    
    
61. CHEN Y, Deng X, Li Y, Han Y, et al
    Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000869.
    PubMed     Abstract available
    
    
    
62. CULLARO G, Allegretti AS, Fenton C, Ge J, et al
    The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
    PubMed     Abstract available
    
    
    
63. MEROUEH C, Warasnhe K, Tizhoosh HR, Shah VH, et al
    Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
    PubMed     Abstract available
    
    
    
64. STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
    AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
    PubMed    
    
    
    
65. STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
    AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
    PubMed    
    
    
    
66. STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
    AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
    PubMed    
    
    
    
67. ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
    Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
    PubMed     Abstract available
    
    
    
68. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
    Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
    PubMed     Abstract available
    
    
    
69. MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
    Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
    PubMed     Abstract available
    
    
    
70. BU W, Sun X, Xue X, Geng S, et al
    Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
    PubMed     Abstract available
    
    
    
71. MUNOZ AE, Rodger EG
    Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
    PubMed    
    
    
    
72. SHARPTON S, Loomba R
    Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
    PubMed    
    
    
    
73. GUO Q, Wang J, Wang G, Wang X, et al
    Letter to the Editor: Is right heart assessment vital for evaluating Terlipressin-related outcomes in Hepatorenal Syndrome-AKI?
    Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000832.
    PubMed    
    
    
    
74. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    PubMed     Abstract available
    
    
    
75. SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
    Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
    PubMed     Abstract available
    
    
    
76. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    PubMed     Abstract available
    
    
    
77. ROY A, Kajal K, Izzy M, Sihag BK, et al
    Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in Hepatorenal Syndrome-AKI ?
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000833.
    PubMed    
    
    
    
78. KUMAR M, Venishetty S, Jindal A, Bihari C, et al
    Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
    PubMed     Abstract available
    
    
    
79. 
    Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
    Hepatology. 2024;79:E105.
    PubMed    
    
    
    
80. HOOFNAGLE JH, Doo E
    Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E91-E92.
    PubMed    
    
    
    
81. LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
    Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E93-E94.
    PubMed    
    
    
    
82. BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
    Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E87-E88.
    PubMed    
    
    
    
83. LEVY C, Dickey AK, Anderson KE, Keel SB, et al
    Reply: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E89-E90.
    PubMed    
    
    
    
84. NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
    Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
    Hepatology. 2024;79:624-635.
    PubMed     Abstract available
    
    
    
85. WANG F, Chen L, Kong D, Zhang X, et al
    Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
    Hepatology. 2024;79:606-623.
    PubMed     Abstract available
    
    
    
86. LEE BP, Dodge JL, Terrault NA
    National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Hepatology. 2024;79:666-673.
    PubMed     Abstract available
    
    
    
87. BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
    Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
    Hepatology. 2024;79:551-559.
    PubMed     Abstract available
    
    
    
88. LEDENKO M, Antwi SO, Patel T
    Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
    Hepatology. 2024;79:575-588.
    PubMed     Abstract available
    
    
    
89. LEVY C, Dickey AK, Wang B, Thapar M, et al
    Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
    Hepatology. 2024;79:731-743.
    PubMed    
    
    
    
90. 
    Hepatology Highlights.
    Hepatology. 2024;79:525-526.
    PubMed    
    
    
    February 2024
91. WONG YJ, Teng M, Sim A, Thet HM, et al
    Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
    PubMed     Abstract available
    
    
    
92. HASSAN MM, Li D, Han Y, Byun J, et al
    Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
    PubMed     Abstract available
    
    
    
93. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    PubMed     Abstract available
    
    
    
94. PENG Z, Wei G, Huang P, Matta H, et al
    ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
    PubMed     Abstract available
    
    
    
95. HE B, Huang Z, Qin S, Peng P, et al
    Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
    PubMed     Abstract available
    
    
    
96. CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
    A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
    Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
    PubMed     Abstract available
    
    
    
97. PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
    Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
    PubMed    
    
    
    
98. PAPATHERODORIDIS G, Lampertico P
    Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
    PubMed    
    
    
    
99. ZHU M, Liu Z, Chen S, Luo Z, et al
    Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
    PubMed     Abstract available
    
    
    
100. PARK JG, Roh PR, Kang MW, Cho SW, et al
     Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
     Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
     PubMed     Abstract available
     
     
     
101. AGRAWAL D, Ariga KK
     Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
     PubMed    
     
     
     
102. ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
     From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
     PubMed     Abstract available
     
     
     
103. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
     Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
     Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
     PubMed    
     
     
     
104. EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
     Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
     Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
     PubMed     Abstract available
     
     
     
105. RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
     Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' dagger.
     Hepatology. 2024;79:E16-E17.
     PubMed    
     
     
     
106. CUSI K, Younossi Z, Roden M
     From NAFLD to MASLD: Promise and pitfalls of a new definition dagger.
     Hepatology. 2024;79:E13-E15.
     PubMed    
     
     
     
107. BALAKRISHNAN M, Rehm J
     A public health perspective on mitigating the global burden of chronic liver disease.
     Hepatology. 2024;79:451-459.
     PubMed     Abstract available
     
     
     
108. KHALID M, Khan ZM, Sheraz Kahloon A
     Letter to the Editor: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
     Hepatology. 2024;79:E18-E19.
     PubMed    
     
     
     
109. KIM Y, Chang Y, Ryu S, Wild SH, et al
     Reply: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
     Hepatology. 2024;79:E20-E21.
     PubMed    
     
     
     
110. BARR RG, Bolondi L
     Contrast-enhanced US for HCC: Finally out from the waiting list?
     Hepatology. 2024;79:267-268.
     PubMed    
     
     
     
111. LYSHCHIK A, Wessner CE, Bradigan K, Eisenbrey JR, et al
     Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.
     Hepatology. 2024;79:380-391.
     PubMed     Abstract available
     
     
     
112. HUANG H, Tsui YM, Ho DW, Chung CY, et al
     LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
     Hepatology. 2024;79:323-340.
     PubMed     Abstract available
     
     
     
113. LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
     A global action agenda for turning the tide on fatty liver disease.
     Hepatology. 2024;79:502-523.
     PubMed     Abstract available
     
     
     
114. MENG Z, Zhou L, Hong S, Qiu X, et al
     Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
     Hepatology. 2024;79:409-424.
     PubMed     Abstract available
     
     
     
115. SINHA S, Hassan N, Schwartz RE
     Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
     Hepatology. 2024;79:482-501.
     PubMed     Abstract available
     
     
     
116. 
     Hepatology Highlights.
     Hepatology. 2024;79:255-256.
     PubMed    
     
     
     
117. 
     Hepatology Highlights.
     Hepatology. 2024;79:255-256.
     PubMed    
     
     
     January 2024
118. 
     Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
     Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
     PubMed    
     
     
     
119. WANG Y, Wang X, Bai B, Shaha A, et al
     Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000763.
     PubMed     Abstract available
     
     
     
120. XIA Y, Wang Y, Xiong Q, He J, et al
     Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
     PubMed     Abstract available
     
     
     
121. 
     Hepatology highlights.
     Hepatology. 2024 Jan 23. doi: 10.1097/HEP.0000000000000742.
     PubMed    
     
     
     
122. NAKAGAWA H, Lin A
     The translation of oncogenic mRNAs regulated by pseudouridylation: A new player in hepatocellular carcinoma.
     Hepatology. 2024 Jan 22. doi: 10.1097/HEP.0000000000000761.
     PubMed    
     
     
     
123. NIEMIETZ P, Peiseler M, Kohlhepp M, Horn P, et al
     C-C chemokine receptor type 7 (CCR7) regulates hepatic CD8+ T cell homeostasis and response to acute liver injury.
     Hepatology. 2024 Jan 17. doi: 10.1097/HEP.0000000000000757.
     PubMed     Abstract available
     
     
     
124. TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
     Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
     Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
     PubMed     Abstract available
     
     
     
125. 
     Hepatology Highlights.
     Hepatology. 2024;79:1-2.
     PubMed    
     
     
     
126. BARGELLINI I, Rimassa L, Masi G
     SIRT and chemotherapy in unresectable iCCA: Ready to take off.
     Hepatology. 2024;79:9-11.
     PubMed    
     
     
     
127. EMANUELE E, Minoretti P
     Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
     Hepatology. 2024;79:E4.
     PubMed    
     
     
     
128. NEWSOME P, Rinella ME, Lazarus JV, Terrault N, et al
     Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
     Hepatology. 2024;79:E5-E6.
     PubMed    
     
     
     
129. ROWE IA
     Prediction of outcomes in patients with acute variceal bleeding.
     Hepatology. 2024;79:15-17.
     PubMed    
     
     
     
130. WANG CC, Cheng YM, Kao JH
     Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
     Hepatology. 2024;79:E7-E8.
     PubMed    
     
     
     
131. GARCIA-CRIADO A, Bruix J
     Screening for liver cancer: The good, the bad, and the ugly.
     Hepatology. 2024;79:12-14.
     PubMed    
     
     
     
132. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
     Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
     Hepatology. 2024;79:39-48.
     PubMed     Abstract available
     
     
     
133. LEE EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, et al
     AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.
     Hepatology. 2024;79:224-250.
     PubMed    
     
     
     
134. 
     Hepatology Highlights.
     Hepatology. 2024;79:1-2.
     PubMed    
     
     
     December 2023
135. HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
     Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
     PubMed     Abstract available
     
     
     
136. VAJRO P, Mandato C
     Letter to the Editor: More on Non-Alcohol/Non-Metabolic Dysfunction-Associated Steatohepatitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000734.
     PubMed    
     
     
     
137. JENG WJ, Chien RN, Liaw YF
     Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
     PubMed    
     
     
     
138. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
     Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
     PubMed    
     
     
     
139. WIEGAND J, Franke A, Stein K, Trautwein C, et al
     Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
     PubMed    
     
     
     
140. WATT KD, Khan MQ
     Reply to "more on non-alcohol/non-metabolic dysfunction-associated steatohepatitis".
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000739.
     PubMed    
     
     
     
141. CHEN J, Tu T, Cohen C, Wang S, et al
     Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
     PubMed    
     
     
     
142. ZABRANSKY DJ, Yarchoan M, Ho WJ
     Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
     Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000738.
     PubMed    
     
     
     
143. LU T, Zhang J, Li H, Li G, et al
     Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
     Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000733.
     PubMed    
     
     
     
144. RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
     Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
     Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
     PubMed     Abstract available
     
     
     
145. VOGEL A, Grant RC, Meyer T, Sapisochin G, et al
     Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
     Hepatology. 2023 Dec 18. doi: 10.1097/HEP.0000000000000726.
     PubMed     Abstract available
     
     
     
146. SCHULZE RJ, Strom SC, Nyberg SL
     From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria.
     Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000713.
     PubMed    
     
     
     
147. YU S, Liu X, Xu Y, Pan L, et al
     m6A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
     Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000716.
     PubMed     Abstract available
     
     
     
148. YIN C, Zhang C, Wang Y, Liu G, et al
     ALDOB/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis.
     Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000704.
     PubMed     Abstract available
     
     
     
149. CHAN FF, Yuen VW, Shen J, Chin DW, et al
     Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.
     Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000709.
     PubMed     Abstract available
     
     
     
150. MALHI H, Brown RS Jr, Lim JK, Reau N, et al
     Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.
     Hepatology. 2023;78:1680-1681.
     PubMed    
     
     
     
151. RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
     A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
     Hepatology. 2023;78:1966-1986.
     PubMed     Abstract available
     
     
     
152. DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
     PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
     Hepatology. 2023;78:1788-1799.
     PubMed     Abstract available
     
     
     
153. ABERG F
     Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
     Hepatology. 2023;78:E101-E102.
     PubMed    
     
     
     
154. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
     Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
     Hepatology. 2023;78:E103-E104.
     PubMed    
     
     
     
155. ZHANG X, Yip TC, Tse YK, Hui VW, et al
     Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
     Hepatology. 2023;78:1816-1827.
     PubMed     Abstract available
     
     
     
156. GAO R, Li Y, Xu Z, Zhang F, et al
     Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease.
     Hepatology. 2023;78:1800-1815.
     PubMed     Abstract available
     
     
     
157. 
     Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
     Hepatology. 2023;78:E110.
     PubMed    
     
     
     
158. 
     Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
     Hepatology. 2023;78:E108.
     PubMed    
     
     
     
159. 
     Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
     Hepatology. 2023;78:E107.
     PubMed    
     
     
     
160. MAIWALL R, Piano S, Singh V, Caraceni P, et al
     Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
     Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
     PubMed     Abstract available
     
     
     
161. 
     Ending stigmatizing language in alcohol and liver disease: A liver societies' statement dagger.
     Hepatology. 2023;78:1682-1683.
     PubMed    
     
     
     November 2023
162. HU YX, Diao LT, Hou YR, Lv G, et al
     PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
     Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000702.
     PubMed     Abstract available
     
     
     
163. PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
     Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
     Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
     PubMed     Abstract available
     
     
     
164. MICHALOPOULOS GK
     Hepatocytes of mice and men: Different regenerative signals?
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000693.
     PubMed    
     
     
     
165. KE L, Rui Z, Fukai W, Yunzheng Z, et al
     Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000673.
     PubMed     Abstract available
     
     
     
166. 
     February 2024 Hepatology Highlights.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000681.
     PubMed    
     
     
     
167. LIU N, Tian J, Steer CJ, Han Q, et al
     MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux.
     Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000672.
     PubMed     Abstract available
     
     
     
168. KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
     AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
     Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
     PubMed    
     
     
     
169. QASIM KHAN M, Hassan S, Lizaola-Mayo BC, Bhat M, et al
     Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis.
     Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000674.
     PubMed    
     
     
     
170. BRENNER DA
     Alternatives to animal testing to assess NASH drugs and hepatotoxicity.
     Hepatology. 2023 Nov 6. doi: 10.1097/HEP.0000000000000669.
     PubMed     Abstract available
     
     
     
171. SCHERR AL, Nader L, Xu K, Elssner C, et al
     Etiology-independent activation of the LTbeta-LTbetaR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma.
     Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657.
     PubMed     Abstract available
     
     
     
172. D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
     Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
     Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
     PubMed     Abstract available
     
     
     
173. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
     Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening.
     Hepatology. 2023;78:E91-E92.
     PubMed    
     
     
     
174. ARIAS-LOSTE MT, Crespo J, Iruzubieta P
     Letter to the Editor: Updated guidance on NAFLD screening.
     Hepatology. 2023;78:E89-E90.
     PubMed    
     
     
     
175. SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
     Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
     Hepatology. 2023;78:E87-E88.
     PubMed    
     
     
     
176. YANG Z, Ding WX
     The pre-mRNA alternative splicing regulated by SRPK2: A new player in alcohol-associated liver disease?
     Hepatology. 2023;78:1329-1331.
     PubMed    
     
     
     
177. LAZARUS JV, Kopka CJ, Younossi ZM, Allen AM, et al
     It is time to expand the fatty liver disease community of practice.
     Hepatology. 2023;78:1325-1328.
     PubMed    
     
     
     
178. TILG H, Adolph TE, Tacke F
     Therapeutic modulation of the liver immune microenvironment.
     Hepatology. 2023;78:1581-1601.
     PubMed     Abstract available
     
     
     
179. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
     ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
     Hepatology. 2023;78:1337-1351.
     PubMed     Abstract available
     
     
     
180. WU Q, Pan C, Zhou Y, Wang S, et al
     Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.
     Hepatology. 2023;78:1402-1417.
     PubMed     Abstract available
     
     
     
181. SONG Y, Wei J, Li R, Fu R, et al
     Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
     Hepatology. 2023;78:1433-1447.
     PubMed     Abstract available
     
     
     
182. CHIU YT, Husain A, Sze KM, Ho DW, et al
     Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC.
     Hepatology. 2023;78:1368-1383.
     PubMed     Abstract available
     
     
     
183. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
     Metabolic reprogramming and its clinical implication for liver cancer.
     Hepatology. 2023;78:1602-1624.
     PubMed     Abstract available
     
     
     
184. LEE CM, Yoon EL, Kim M, Kang BK, et al
     Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
     Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
     PubMed     Abstract available
     
     
     
185. BRAILLON A, Naudet F
     Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
     Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
     PubMed    
     
     
     October 2023
186. JENG WJ, Chien RN, Liaw YF
     Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
     PubMed    
     
     
     
187. DENG R, Wang Z, Liu Y, Sun J, et al
     Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
     PubMed    
     
     
     
188. GRATACOS-GINES J, Lopez-Pelayo H, Pose E
     Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
     PubMed    
     
     
     
189. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
     Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
     Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
     PubMed     Abstract available
     
     
     
190. SONG Y, Ye T, Roberts LR, Larson NB, et al
     Randomization in hepatology: A review of principles, opportunities, and challenges.
     Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000649.
     PubMed     Abstract available
     
     
     
191. KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
     AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
     PubMed    
     
     
     
192. YANG T, Qu X, Wang X, Xu D, et al
     Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000638.
     PubMed     Abstract available
     
     
     
193. CHANG CW, Chen YS, Huang CH, Lin CH, et al
     A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000637.
     PubMed     Abstract available
     
     
     
194. OLIVA-VILARNAU N, Beusch CM, Sabatier P, Sakaraki E, et al
     Wnt/beta-catenin and NFkappaB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000648.
     PubMed     Abstract available
     
     
     
195. CAMPANI C, Vallot A, Ghannouchi H, Allaire M, et al
     Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000636.
     PubMed     Abstract available
     
     
     
196. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
     Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
     PubMed     Abstract available
     
     
     
197. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
     Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
     PubMed    
     
     
     
198. LIAW YF, Jeng WJ, Chien RN
     Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
     Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
     PubMed    
     
     
     
199. 
     Erratum: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
     Hepatology. 2023 Oct 16. doi: 10.1097/HEP.0000000000000621.
     PubMed    
     
     
     
200. VONADA A, Wakefield L, Martinez M, Harding CO, et al
     Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
     Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
     PubMed     Abstract available
     
     
     
201. CHEN P, Dong Z, Zhu W, Chen J, et al
     Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
     Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
     PubMed     Abstract available
     
     
     
202. MA S, Chew V
     Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
     Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
     PubMed    
     
     
     
203. THIELE M, Johansen S, Israelsen M, Trebicka J, et al
     Non-invasive assessment of hepatic decompensation.
     Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
     PubMed     Abstract available
     
     
     
204. PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
     Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
     Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
     PubMed     Abstract available
     
     
     
205. XANTHAKOS S
     Rising tide of NAFLD in youth: A warning bell and call to action.
     Hepatology. 2023;78:1017-1019.
     PubMed    
     
     
     
206. ANTON A, Shalaby S, Hernandez-Gea V
     Coagulation meets senescence in NASH!
     Hepatology. 2023;78:1023-1025.
     PubMed    
     
     
     
207. YONEDA M, Nakajima A
     The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities.
     Hepatology. 2023;78:1020-1022.
     PubMed    
     
     
     
208. CHEN W, Sun Y, Chen S, Ge X, et al
     Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
     Hepatology. 2023;78:1118-1132.
     PubMed     Abstract available
     
     
     
209. LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
     Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
     Hepatology. 2023;78:1200-1208.
     PubMed     Abstract available
     
     
     
210. KIM ??? WR, Iwakiri ???? Y, Lok ??? ASF
     What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.
     Hepatology. 2023;78:1032-1034.
     PubMed    
     
     
     
211. MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
     Intermittent fasting-the future treatment in NASH patients?
     Hepatology. 2023;78:1290-1305.
     PubMed     Abstract available
     
     
     
212. CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
     Predicting liver-related events in NAFLD: A predictive model.
     Hepatology. 2023;78:1240-1251.
     PubMed     Abstract available
     
     
     
213. SEIMIYA T, Otsuka M, Fujishiro M
     Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy.
     Hepatology. 2023;78:1009-1011.
     PubMed    
     
     
     
214. 
     Erratum: Down-Regulation of the Cyclin-Dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
     Hepatology. 2023;78:E85.
     PubMed    
     
     
     
215. STRAVITZ RT, Fontana RJ, Karvellas C, Durkalski V, et al
     Future directions in acute liver failure.
     Hepatology. 2023;78:1266-1289.
     PubMed     Abstract available
     
     
     
216. HARTMANN P, Zhang X, Loomba R, Schnabl B, et al
     Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019.
     Hepatology. 2023;78:1168-1181.
     PubMed     Abstract available
     
     
     
217. KOTULKAR M, Paine-Cabrera D, Abernathy S, Robarts DR, et al
     Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury.
     Hepatology. 2023;78:1106-1117.
     PubMed     Abstract available
     
     
     
218. DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
     Semaphorin 3C exacerbates liver fibrosis.
     Hepatology. 2023;78:1092-1105.
     PubMed     Abstract available
     
     
     September 2023
219. NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
     The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
     Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
     PubMed     Abstract available
     
     
     
220. LI M, Wang L, Cong L, Wong CC, et al
     Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000591.
     PubMed     Abstract available
     
     
     
221. RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
     A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
     PubMed     Abstract available
     
     
     
222. ZHAO X, Kotha S, Nayyar D, Ma X, et al
     Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis.
     Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000605.
     PubMed     Abstract available
     
     
     
223. FAILLI M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, et al
     Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
     Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601.
     PubMed     Abstract available
     
     
     
224. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
     Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
     PubMed     Abstract available
     
     
     
225. WATT KD, Paul S, Khan MQ, Siddiqui M, et al
     Obesity management for the hepatologist - what to do, how to do it and why.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000598.
     PubMed     Abstract available
     
     
     
226. CHEN S, Liao C, Hu H, Liao J, et al
     Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000599.
     PubMed     Abstract available
     
     
     
227. MAESTRI E, Kedei N, Khatib S, Forgues M, et al
     Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000600.
     PubMed     Abstract available
     
     
     
228. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
     Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
     PubMed     Abstract available
     
     
     
229. 
     December 2023 Hepatology Highlights.
     Hepatology. 2023 Sep 14. doi: 10.1097/HEP.0000000000000594.
     PubMed    
     
     
     
230. LAZARUS JV, Han H, Mark HE, Alqahtani SA, et al
     The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories.
     Hepatology. 2023;78:911-928.
     PubMed     Abstract available
     
     
     
231. AWAN MZUA, Patel T
     Letter to the Editor: Dynamic risk profiling of HCC recurrence after curative intent liver resection.
     Hepatology. 2023;78:E55.
     PubMed    
     
     
     
232. HUANG CH, Hsieh SY
     More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC.
     Hepatology. 2023;78:706-708.
     PubMed    
     
     
     
233. YOU M, Gao Y, Fu J, Xie R, et al
     Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC.
     Hepatology. 2023;78:943-958.
     PubMed     Abstract available
     
     
     
234. LLORENTE C, Rungratanawanich W, Liangpunsakul S
     Intestinal dendritic cells, gatekeepers preventing ethanol-induced liver disease.
     Hepatology. 2023;78:697-701.
     PubMed    
     
     
     
235. UCHIDA T, Imamura M, Hayes CN, Suehiro Y, et al
     HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice.
     Hepatology. 2023;78:929-942.
     PubMed     Abstract available
     
     
     
236. GOIKOETXEA-USANDIZAGA N, Bravo M, Egia-Mendikute L, Abecia L, et al
     The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent.
     Hepatology. 2023;78:878-895.
     PubMed     Abstract available
     
     
     
237. WONG C, Dash A, Fredrickson J, Lewin-Koh N, et al
     Fibroblast growth factor receptor 1/Klothobeta agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial.
     Hepatology. 2023;78:847-862.
     PubMed     Abstract available
     
     
     
238. LAM KH, Ma S
     Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications.
     Hepatology. 2023;78:991-1005.
     PubMed     Abstract available
     
     
     
239. WU T, Chen X, Xu K, Dai C, et al
     LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.
     Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000585.
     PubMed     Abstract available
     
     
     August 2023
240. SHIMADA S, Tanaka S
     The chronicles of hepatocellular carcinoma classification: Subtyping, modeling and treatment.
     Hepatology. 2023 Aug 30. doi: 10.1097/HEP.0000000000000588.
     PubMed    
     
     
     
241. GRATACOS-GINES J, Bruguera P, Perez-Guasch M, Lopez-Lazcano A, et al
     Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis.
     Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000570.
     PubMed     Abstract available
     
     
     
242. JENG WJ, Chien RN, Chen YC, Lin CL, et al
     Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis.
     Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000575.
     PubMed     Abstract available
     
     
     
243. CHIN A, Bastaich DR, Dahman B, Kaplan DE, et al
     Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites.
     Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000577.
     PubMed     Abstract available
     
     
     
244. GE J, Fontil V, Ackerman S, Pletcher MJ, et al
     Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
     Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
     PubMed     Abstract available
     
     
     
245. PEISELER M, Tacke F
     Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
     Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
     PubMed    
     
     
     
246. 
     November hepatology highlights.
     Hepatology. 2023 Aug 21. doi: 10.1097/HEP.0000000000000565.
     PubMed    
     
     
     
247. KOWALIK MA, Taguchi K, Serra M, Caddeo A, et al
     Metabolic reprogramming in Nrf2-driven proliferation of normal rat hepatocytes.
     Hepatology. 2023 Aug 21. doi: 10.1097/HEP.0000000000000568.
     PubMed     Abstract available
     
     
     
248. LV Y, Bai W, Zhu X, Xue H, et al
     Development and validation of a prognostic score to identify the optimal candidate for preemptive TIPS in patients with cirrhosis and acute variceal bleeding.
     Hepatology. 2023 Aug 18. doi: 10.1097/HEP.0000000000000548.
     PubMed     Abstract available
     
     
     
249. TREBICKA J, Garcia-Tsao G
     Controversies regarding albumin therapy in cirrhosis.
     Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000521.
     PubMed     Abstract available
     
     
     
250. LI B, Li Y, Zhou H, Xu Y, et al
     Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
     Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000553.
     PubMed     Abstract available
     
     
     
251. BOWLUS CL, Levy C
     Optimizing treatment of primary biliary cholangitis: Is good, good enough?
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
     PubMed    
     
     
     
252. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
     Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
     PubMed     Abstract available
     
     
     
253. HU Y, Li Z, He W, Wang X, et al
     Letter to the Editor: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations.
     Hepatology. 2023;78:E29-E30.
     PubMed    
     
     
     
254. VAN KLEEF LA, Sonneveld MJ, de Knegt RJ
     Reply: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations.
     Hepatology. 2023;78:E31-E32.
     PubMed    
     
     
     
255. RONOT M, Nahon P, Rimola J
     Screening of liver cancer with abbreviated MRI.
     Hepatology. 2023;78:670-686.
     PubMed     Abstract available
     
     
     
256. MCCONNELL MJ, Kostallari E, Ibrahim SH, Iwakiri Y, et al
     The evolving role of liver sinusoidal endothelial cells in liver health and disease.
     Hepatology. 2023;78:649-669.
     PubMed     Abstract available
     
     
     
257. AN J, Oh JH, Oh B, Oh YJ, et al
     Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient hepatocellular carcinoma.
     Hepatology. 2023;78:452-467.
     PubMed     Abstract available
     
     
     
258. GUO X, Tan S, Wang T, Sun R, et al
     NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity.
     Hepatology. 2023;78:468-485.
     PubMed     Abstract available
     
     
     July 2023
259. LI Y, Li B, Xiao X, Qian Q, et al
     Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
     Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
     PubMed     Abstract available
     
     
     
260. SENZOLO M, Shalaby S, Grasso M, Vitale A, et al
     Role of non-neoplastic portal vein thrombosis in the natural history of patients with cirrhosis and first diagnosis of hepatocellular carcinoma.
     Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000538.
     PubMed     Abstract available
     
     
     
261. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
     Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
     Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
     PubMed     Abstract available
     
     
     
262. NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
     Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).
     Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000542.
     PubMed     Abstract available
     
     
     
263. 
     October Hepatology Highlights.
     Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000543.
     PubMed    
     
     
     
264. MA X, Ding WX
     Reply: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
     Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000541.
     PubMed    
     
     
     
265. HU X, Shen J, Wang T, Liu M, et al
     Letter to the Editor: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitichondria and mitochondrial maladaptation.
     Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000540.
     PubMed    
     
     
     
266. 
     Retraction: Protein kinase a-dependent pSer675-beta-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis.
     Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000486.
     PubMed    
     
     
     
267. GE J, Digitale JC, Pletcher MJ, Lai JC, et al
     Reply: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
     Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000536.
     PubMed    
     
     
     
268. XIANG X, Hao Y, Cheng C, Hu H, et al
     A TGF-beta-dominant chemo-resistant phenotype of hepatoblastoma associated with aflatoxin exposure in children.
     Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000534.
     PubMed     Abstract available
     
     
     
269. HU Y, Li Z, He W, Wang X, et al
     Letter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
     Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000533.
     PubMed    
     
     
     
270. NARASIMMAN M, Hernaez R, Cerda V, Lee M, et al
     Hepatocellular carcinoma surveillance may be associated with potential psychological harms of in patients with cirrhosis.
     Hepatology. 2023 Jul 4. doi: 10.1097/HEP.0000000000000528.
     PubMed     Abstract available
     
     
     
271. IAVARONE M, Nault JC, Cabibbo G, Torres F, et al
     Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology.
     Hepatology. 2023 Jul 3. doi: 10.1097/HEP.0000000000000527.
     PubMed     Abstract available
     
     
     
272. 
     A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.
     Hepatology. 2023;78:3-5.
     PubMed    
     
     
     
273. CHEEMA MRS
     Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2023;78:E18.
     PubMed    
     
     
     
274. LEE J, Westphal M, Vali Y, Boursier J, et al
     Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
     Hepatology. 2023;78:258-271.
     PubMed     Abstract available
     
     
     
275. WEGERMANN K, Diehl AM
     Population-based proteomics: Platforms to advance diagnosis and treatment of metabolic liver diseases.
     Hepatology. 2023;78:8-9.
     PubMed    
     
     
     
276. CHE Y, Chen G, Guo Q, Duan Y, et al
     Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.
     Hepatology. 2023;78:88-102.
     PubMed     Abstract available
     
     
     
277. IRFAN R, Kumar S
     Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
     Hepatology. 2023;78:E8.
     PubMed    
     
     
     
278. PENNISI G, Enea M, Falco V, Aithal GP, et al
     Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
     Hepatology. 2023;78:195-211.
     PubMed     Abstract available
     
     
     
279. DO A, Lim JK
     Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI.
     Hepatology. 2023;78:6-7.
     PubMed    
     
     
     
280. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
     Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study).
     Hepatology. 2023;78:272-283.
     PubMed     Abstract available
     
     
     
281. ABOZAID YJ, Ayada I, van Kleef LA, Vallerga CL, et al
     Plasma proteomic signature of fatty liver disease: The Rotterdam Study.
     Hepatology. 2023;78:284-294.
     PubMed     Abstract available
     
     
     
282. KONG M, Dong W, Kang A, Kuai Y, et al
     Regulatory role and translational potential of CCL11 in liver fibrosis.
     Hepatology. 2023;78:120-135.
     PubMed     Abstract available
     
     
     
283. GUO C, Liu W, Liu Z, Cai J, et al
     Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
     Hepatology. 2023;78:45-57.
     PubMed     Abstract available
     
     
     
284. ZHU H, Yang B
     Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
     Hepatology. 2023;78:E3.
     PubMed    
     
     
     
285. VERMA M, Brahmania M, Fortune BE, Asrani SK, et al
     Patient-centered care: Key elements applicable to chronic liver disease.
     Hepatology. 2023;78:307-318.
     PubMed     Abstract available
     
     
     
286. 
     July 2023 Hepatology Highlights.
     Hepatology. 2023;78:1-2.
     PubMed    
     
     
     June 2023
287. 
     September Hepatology highlights.
     Hepatology. 2023 Jun 13. doi: 10.1097/HEP.0000000000000515.
     PubMed    
     
     
     
288. PINTER M, Reig M, Cabibbo G
     Analysis of individual patient data in patients with hepatocellular carcinoma treated with immunotherapy: A step forward for clinical trial design.
     Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000511.
     PubMed    
     
     
     
289. DHANASEKARAN R, Suzuki H, Lemaitre L, Kubota N, et al
     Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making.
     Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000513.
     PubMed     Abstract available
     
     
     
290. TAPPER EB, Lai JC
     Time to embrace PROMIS-29 as the standard health-related quality of life instrument for patients with cirrhosis.
     Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000508.
     PubMed    
     
     
     
291. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
     Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
     Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
     PubMed     Abstract available
     
     
     
292. YIM SY, Lee JS
     Reply: Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
     Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000501.
     PubMed    
     
     
     
293. HENRY L, Younossi ZM
     Reply: NAFLD/MAFLD: One size does not fit all, certainly not for children!
     Hepatology. 2023;77:E191.
     PubMed    
     
     
     
294. HEGARTY R, Dhawan A
     Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!
     Hepatology. 2023;77:E190.
     PubMed    
     
     
     
295. SARKAR M, Flemming JA
     Letter to the Editor: Influence of maternal NAFLD on infant weight-the real precursor to NAFLD in offspring?
     Hepatology. 2023;77:E180.
     PubMed    
     
     
     
296. LEE JM, Joo I
     The international quest for the imaging diagnosis of liver cancer.
     Hepatology. 2023;77:1839-1842.
     PubMed    
     
     
     
297. CANNELLA R, Dioguardi Burgio M, Sartoris R, Gregory J, et al
     Adherence to LI-RADS and EASL high-risk population criteria: A systematic review.
     Hepatology. 2023;77:1958-1967.
     PubMed     Abstract available
     
     
     
298. BOMMENA S, Mahmud N, Boike JR, Thornburg BG, et al
     The impact of right atrial pressure on outcomes in patients undergoing TIPS, an ALTA group study.
     Hepatology. 2023;77:2041-2051.
     PubMed     Abstract available
     
     
     
299. HSU CL, Lang S, Demir M, Fouts DE, et al
     Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome.
     Hepatology. 2023;77:2073-2083.
     PubMed     Abstract available
     
     
     
300. NAGALO BM, Zhou Y, Loeuillard EJ, Dumbauld C, et al
     Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.
     Hepatology. 2023;77:1943-1957.
     PubMed     Abstract available
     
     
     
301. LIM M, Muquith M, Miramontes B, Lee CJ, et al
     Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
     Hepatology. 2023 Jun 1. doi: 10.1097/HEP.0000000000000494.
     PubMed     Abstract available
     
     
     May 2023
302. AWAN MZUA
     Letter to the editor: Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
     Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000493.
     PubMed    
     
     
     
303. JESUDIAN AB, Fortune BE
     The PROs and cons of crystalline lactulose for suspected covert hepatic encephalopathy among patients with cirrhosis and activity impairment: Are we using the right assessments?
     Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000497.
     PubMed    
     
     
     
304. NEJAK-BOWEN K, Monga SP
     Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
     Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
     PubMed     Abstract available
     
     
     
305. 
     Erratum: Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
     Hepatology. 2023 May 26. doi: 10.1097/HEP.0000000000000450.
     PubMed    
     
     
     
306. CARR RM, Li Y, Chau L, Friedman ES, et al
     An integrated analysis of fecal microbiome and metabolomic features distinguish Non-cirrhotic NASH from healthy control populations.
     Hepatology. 2023 May 25. doi: 10.1097/HEP.0000000000000474.
     PubMed     Abstract available
     
     
     
307. GILGENKRANTZ H, Paradis V, Lotersztajn S
     Cell metabolism-based therapy for liver fibrosis, repair and hepatocellular carcinoma.
     Hepatology. 2023 May 23. doi: 10.1097/HEP.0000000000000479.
     PubMed     Abstract available
     
     
     
308. LV Y, Han G
     Reply: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
     Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000475.
     PubMed    
     
     
     
309. YIN HJ, Wan YM
     Letter to the editor: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
     Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000476.
     PubMed    
     
     
     
310. KIM BK, Bergstrom J, Loomba R, Tamaki N, et al
     Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study.
     Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000470.
     PubMed     Abstract available
     
     
     
311. 
     August Hepatology Highlights.
     Hepatology. 2023 May 19. doi: 10.1097/HEP.0000000000000468.
     PubMed    
     
     
     
312. SINGAL AG, Llovet JM, Yarchoan M, Mehta N, et al
     AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
     Hepatology. 2023 May 19. doi: 10.1097/HEP.0000000000000466.
     PubMed    
     
     
     
313. TONON M, Balcar L, Semmler G, Calvino V, et al
     Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
     Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
     PubMed     Abstract available
     
     
     
314. VITTAL A, Niewisch MR, Bhala S, Kudaravalli P, et al
     Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.
     Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000461.
     PubMed     Abstract available
     
     
     
315. HUANG DQ, Tran A, Yeh ML, Yasuda S, et al
     Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase.
     Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
     PubMed     Abstract available
     
     
     
316. MALLET M, Silaghi CA, Sultanik P, Conti F, et al
     Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis.
     Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000456.
     PubMed     Abstract available
     
     
     
317. JI J, Ji F, Bayarsaikhan E
     Intratumoral microbiota in hepatocellular carcinoma: A new kid on the block?
     Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000454.
     PubMed    
     
     
     
318. ANDRISANI O
     Two important players in poor prognosis hepatocellular carcinoma (HCC): Extrachromosomal circular DNA (eccDNA) and its passenger, the oncogenic miR-17~92 locus.
     Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000453.
     PubMed    
     
     
     
319. MEHTA N, Kelley RK, Yao FY
     Refining the approach to down-staging for hepatocellular carcinoma prior to liver transplantation: Patient selection, local-regional treatments, and systemic therapies.
     Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000452.
     PubMed    
     
     
     
320. 
     Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
     Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
     PubMed    
     
     
     
321. KANZAKI H, Katz C, Hoshida Y
     Matrisomic characterization of hepatocellular carcinoma to inform individualized patient management.
     Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000443.
     PubMed    
     
     
     
322. ANSTEE QM, Lucas KJ, Francque S, Abdelmalek MF, et al
     Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study.
     Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000439.
     PubMed     Abstract available
     
     
     
323. LI G, Chen H, Shen F, Smithson SB, et al
     Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis.
     Hepatology. 2023 May 3. doi: 10.1097/HEP.0000000000000433.
     PubMed     Abstract available
     
     
     
324. SANGHA K, Chang ST, Cheung R, Deshpande VS, et al
     Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
     Hepatology. 2023;77:1702-1711.
     PubMed     Abstract available
     
     
     
325. EBRAHIMI F, Ludvigsson JF
     Letter to the editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
     Hepatology. 2023;77:E107-E108.
     PubMed    
     
     
     
326. RINELLA ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, et al
     AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
     Hepatology. 2023;77:1797-1835.
     PubMed    
     
     
     
327. KNIGHT GM, Thornburg B, Salem R
     Reply: Discussing the place of TIPS in non-cirrhotic patients with chronic extra hepatic portal vein occlusion refractory to standard of care therapy.
     Hepatology. 2023;77:E93-E94.
     PubMed    
     
     
     
328. GU W, Queck A, Trebicka J, Praktiknjo M, et al
     Reply: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
     Hepatology. 2023;77:E101.
     PubMed    
     
     
     
329. ARTRU F, Rautou PE, Denys A
     Letter to the editor: discussing the place of TIPS in noncirrhotic patients with chronic extrahepatic portal vein occlusion (EHPVO).
     Hepatology. 2023;77:E91-E92.
     PubMed    
     
     
     
330. BERARDI G, Ratti F, Sposito C, Nebbia M, et al
     Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.
     Hepatology. 2023;77:1527-1539.
     PubMed     Abstract available
     
     
     
331. CUCCHETTI A, Casadei-Gardini A
     Liver resection for HCC in patients with metabolic syndrome: questions answered, questions raised.
     Hepatology. 2023;77:1463-1464.
     PubMed    
     
     
     
332. WEN Y, Emontzpohl C, Xu L, Atkins CL, et al
     Interleukin-33 facilitates liver regeneration through serotonin-involved gut-liver axis.
     Hepatology. 2023;77:1580-1592.
     PubMed     Abstract available
     
     
     
333. ZHANG S, Wan D, Zhu M, Wang G, et al
     CD11b + CD43 hi Ly6C lo splenocyte-derived macrophages exacerbate liver fibrosis via spleen-liver axis.
     Hepatology. 2023;77:1612-1629.
     PubMed     Abstract available
     
     
     
334. LUO W, Wang Y, Li Y, Zhang T, et al
     Letter to the editor: Adipose lipolysis is important for ethanol to induce fatty liver in the NIAAA murine model of chronic and binge ethanol feeding.
     Hepatology. 2023;77:E88-E89.
     PubMed    
     
     
     
335. ZABRANSKY DJ, Danilova L, Leatherman JM, Lopez-Vidal TY, et al
     Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.
     Hepatology. 2023;77:1566-1579.
     PubMed     Abstract available
     
     
     
336. JUAREZ-FERNANDEZ M, Goikoetxea-Usandizaga N, Porras D, Garcia-Mediavilla MV, et al
     Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
     Hepatology. 2023;77:1654-1669.
     PubMed     Abstract available
     
     
     
337. MATHUR M, Yeh YT, Arya RK, Jiang L, et al
     Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding.
     Hepatology. 2023;77:1688-1701.
     PubMed     Abstract available
     
     
     
338. LI S, Xia H, Wang Z, Zhang X, et al
     Intratumoural microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related hepatocellular carcinoma.
     Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000427.
     PubMed     Abstract available
     
     
     
339. ZOU S, Chen S, Rao G, Zhang G, et al
     Extrachromosomal circular MiR-17-92 amplicon promotes hepatocellular carcinoma.
     Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000435.
     PubMed     Abstract available
     
     
     
340. AHMED A, Arshad MW, Ibrahim H
     Letter to the editor: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
     Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000429.
     PubMed    
     
     
     
341. CULLARO G
     Reply: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
     Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000434.
     PubMed    
     
     
     
342. 
     May 2023 Hepatology Highlights.
     Hepatology. 2023;77:1461-1462.
     PubMed    
     
     
     April 2023
343. KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al
     Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
     Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428.
     PubMed     Abstract available
     
     
     
344. 
     July 2023 Hepatology Highlights.
     Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000425.
     PubMed    
     
     
     
345. ADAMS LA, Schulte PJ, Allen AM
     Use of non-invasive scores to predict hepatic steatosis: Flaws and caveats.
     Hepatology. 2023 Apr 27. doi: 10.1097/HEP.0000000000000419.
     PubMed    
     
     
     
346. HUNG MH, Chang CW, Wang KC, Chaisaingmongkol J, et al
     Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma via m6A-mediated epitranscriptomic regulation.
     Hepatology. 2023 Apr 26. doi: 10.1097/HEP.0000000000000420.
     PubMed     Abstract available
     
     
     
347. UFERE NN
     Home is where the liver is?: moving beyond readmissions to time at home as a patient-centered and pragmatic quality measure in cirrhosis care.
     Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000415.
     PubMed    
     
     
     
348. MALHI H, Shah V, Gores GJ
     Thematic reviews: the future of hepatology.
     Hepatology. 2023 Apr 19. doi: 10.1097/HEP.0000000000000409.
     PubMed    
     
     
     
349. TAPPER EB, Ospina E, Salim N, Chen X, et al
     Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient reported outcomes - the Mi-Kristal RCT.
     Hepatology. 2023 Apr 18. doi: 10.1097/HEP.0000000000000408.
     PubMed     Abstract available
     
     
     
350. DANIEL N, Genua F, Jenab M, Mayen AL, et al
     The role of the gut microbiome in the development of hepatobiliary cancers.
     Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
     PubMed     Abstract available
     
     
     
351. MAESO-DIAZ R, Du K, Pan C, Guy CD, et al
     Targeting senescent hepatocytes using the THBD-PAR1 inhibitor Vorapaxar ameliorates NAFLD progression.
     Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000401.
     PubMed     Abstract available
     
     
     
352. JILG N, Baumert TF
     Unfolding the mechanism of hepatocyte injury of HBV precore and core promoter variants.
     Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000400.
     PubMed    
     
     
     
353. HARTL L, Reiberger T, Trauner M
     Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
     Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
     PubMed    
     
     
     
354. UMAR S, Nadeem A, Nadeem M
     Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
     Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
     PubMed    
     
     
     
355. RAABE J, Kaiser KM, ToVinh M, Finnemann C, et al
     Identification and characterisation of a hepatic IL-13 producing ILC3-like population potentially involved in liver fibrosis.
     Hepatology. 2023 Apr 10. doi: 10.1097/HEP.0000000000000350.
     PubMed     Abstract available
     
     
     
356. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
     Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
     Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
     PubMed     Abstract available
     
     
     
357. FRIEDMAN SL, Sanyal AJ
     The future of hepatology.
     Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000389.
     PubMed     Abstract available
     
     
     
358. ARUMUGAM S, Li B, Boodapati SLT, Nathanson MH, et al
     Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation.
     Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000388.
     PubMed     Abstract available
     
     
     
359. TANG D, Kroemer G, Kang R
     Ferroptosis in hepatocellular carcinoma: from bench to bedside.
     Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000390.
     PubMed     Abstract available
     
     
     
360. 
     June 2023 Hepatology Highlights.
     Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000391.
     PubMed    
     
     
     
361. TIAN Y, Jellinek MJ, Mehta K, Seok SM, et al
     Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.
     Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000375.
     PubMed     Abstract available
     
     
     
362. DESERT R, Chen W, Ge X, Viel R, et al
     Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome.
     Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000362.
     PubMed     Abstract available
     
     
     
363. VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Samala N, et al
     CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population.
     Hepatology. 2023;77:1241-1252.
     PubMed     Abstract available
     
     
     
364. GUERRIERI F, Levrero M
     HBV, mitochondrial stress, and liver fibrosis: chicken or the egg.
     Hepatology. 2023;77:1088-1089.
     PubMed    
     
     
     
365. LIU Z, Tan M, Ding H
     Letter to the Editor: Contrast-enhanced CT and liver surface nodularity for the diagnosis of portosinusoidal vascular disorder: a case-control study.
     Hepatology. 2023;77:E71.
     PubMed    
     
     
     
366. SINGH SP, Mondia N
     Letter to the Editor: Much more needed in natural history of Alagille syndrome.
     Hepatology. 2023;77:E78.
     PubMed    
     
     
     
367. SCHILSKY ML, Roberts EA, Bronstein JM, Dhawan A, et al
     A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.
     Hepatology. 2023;77:1428-1455.
     PubMed    
     
     
     
368. YIP TC, Vilar-Gomez E, Petta S, Yilmaz Y, et al
     Geographical similarity and differences in the burden and genetic predisposition of NAFLD.
     Hepatology. 2023;77:1404-1427.
     PubMed     Abstract available
     
     
     
369. LI HX, Xie ZQ, Yang ZM, Tang CX, et al
     Letter to the Editor: Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
     Hepatology. 2023;77:E67-E68.
     PubMed    
     
     
     
370. AFONSO MB, Islam T, Magusto J, Amorim R, et al
     RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease.
     Hepatology. 2023;77:1319-1334.
     PubMed     Abstract available
     
     
     
371. TORRES S, Ortiz C, Bachtler N, Gu W, et al
     Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
     Hepatology. 2023;77:1228-1240.
     PubMed     Abstract available
     
     
     
372. KARDASHIAN A, Serper M, Terrault N, Nephew LD, et al
     Health disparities in chronic liver disease.
     Hepatology. 2023;77:1382-1403.
     PubMed     Abstract available
     
     
     
373. LOPEZ-VICARIO C, Sebastian D, Casulleras M, Duran-Guell M, et al
     Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease.
     Hepatology. 2023;77:1303-1318.
     PubMed     Abstract available
     
     
     
374. YANG F, Jiang S, Zheng Y
     Letter to the Editor: Is eliminating METTL1-mediated accumulation of PMN-MDSCs sufficient to prevent hepatocellular carcinoma recurrence after radiofrequency ablation?
     Hepatology. 2023;77:E62-E63.
     PubMed    
     
     
     
375. DEPRINCE A, Hennuyer N, Kooijman S, Pronk ACM, et al
     Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism.
     Hepatology. 2023;77:1287-1302.
     PubMed     Abstract available
     
     
     
376. JIANG M, Li F, Liu Y, Gu Z, et al
     Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation.
     Hepatology. 2023;77:1164-1180.
     PubMed     Abstract available
     
     
     
377. ZENG X, Liao G, Li S, Liu H, et al
     Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
     Hepatology. 2023;77:1122-1138.
     PubMed     Abstract available
     
     
     
378. ZHOU Y, Jia K, Wang S, Li Z, et al
     Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7-acetylated and cytoplasm-translocated G protein GalphaS.
     Hepatology. 2023;77:1106-1121.
     PubMed     Abstract available
     
     
     March 2023
379. ELHENCE H, Dodge JL, Farias AJ, Lee BP, et al
     Quantifying days at home in patients with cirrhosis: a national cohort study.
     Hepatology. 2023 Mar 31. doi: 10.1097/HEP.0000000000000370.
     PubMed     Abstract available
     
     
     
380. TRIPATHI D, Reiberger T
     Letter to the editor: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
     Hepatology. 2023 Mar 30. doi: 10.1097/HEP.0000000000000359.
     PubMed    
     
     
     
381. KWONG AJ, Zhang KY, Ebel N, Mannalithara A, et al
     MELD 3.0 for adolescent liver transplant candidates.
     Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000352.
     PubMed     Abstract available
     
     
     
382. ELIAS G, Schonfeld M, Saleh S, Parrish M, et al
     Sepsis induced endothelial dysfunction drives acute-on-chronic liver failure via Angiopoietin-2-HGF-C/EBPbeta pathway.
     Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000354.
     PubMed     Abstract available
     
     
     
383. HONG T, Xiong X, Chen Y, Wang Q, et al
     Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulating cAMP response element binding protein-like 2.
     Hepatology. 2023 Mar 21. doi: 10.1097/HEP.0000000000000333.
     PubMed     Abstract available
     
     
     
384. MAK LY, Yuen MF, Seto WK
     Reply: hepatic steatosis and glycemic burden in chronic hepatitis b.
     Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000374.
     PubMed    
     
     
     
385. HUANG SC, Kao JH
     Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B.
     Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.
     PubMed    
     
     
     
386. AHMED HS, Long MT
     Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
     Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000378.
     PubMed    
     
     
     
387. LI Z, Zhang L, Li J
     Letter to the Editor: the associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
     Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000377.
     PubMed    
     
     
     
388. ZHANG W, Wang MK, Yao D, Zhao HJ, et al
     Letter to the editor: hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy.
     Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000372.
     PubMed    
     
     
     
389. ROWE IA, Villanueva C, Shearer JE, Torres F, et al
     Quantifying the benefit of non-selective beta-blockers in the prevention of hepatic decompensation: a Bayesian re-analysis of the PREDESCI trial.
     Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000342.
     PubMed     Abstract available
     
     
     
390. ALLAIRE M, Thabut D
     Reply: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
     Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000358.
     PubMed    
     
     
     
391. 
     May 2023 Hepatology Highlights.
     Hepatology. 2023 Mar 8. doi: 10.1097/HEP.0000000000000355.
     PubMed    
     
     
     
392. SMITH ML, Wade JB, Wolstenholme J, Bajaj JS, et al
     Gut microbiome-brain-cirrhosis axis.
     Hepatology. 2023 Mar 6. doi: 10.1097/HEP.0000000000000344.
     PubMed     Abstract available
     
     
     
393. GE J, Digitale JC, Pletcher MJ, Lai JC, et al
     Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study.
     Hepatology. 2023;77:834-850.
     PubMed     Abstract available
     
     
     
394. VAN KLEEF LA, de Knegt RJ
     Modifiable risk factors for fatty liver disease: Time to act.
     Hepatology. 2023;77:712-714.
     PubMed    
     
     
     
395. LUO W, Gu Y, Zhang T
     Letter to the editor: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage HCC.
     Hepatology. 2023;77:E51-E52.
     PubMed    
     
     
     
396. SUN Y, Zhang J, Wang H, Wang W, et al
     Letter to the editor: Fatty liver and mortality in populations who are elderly.
     Hepatology. 2023;77:E47-E48.
     PubMed    
     
     
     
397. TARLOW BD, Kim WR, Mannalithara A, Kwo PY, et al
     Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
     Hepatology. 2023;77:851-861.
     PubMed     Abstract available
     
     
     
398. JIANG ST, Xu YY, Lu X
     Letter to the editor: Focus on metabolic dysfunction-associated fatty liver disease, even if patients have a history of excessive alcohol consumption.
     Hepatology. 2023;77:E43-E44.
     PubMed    
     
     
     
399. UDOMPAP P, Therneau TM, Canning RE, Benson JT, et al
     Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population.
     Hepatology. 2023;77:931-941.
     PubMed     Abstract available
     
     
     
400. XIE J, Huang H, Liu Z, Li Y, et al
     The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study.
     Hepatology. 2023;77:949-964.
     PubMed     Abstract available
     
     
     
401. FONTANA RJ, Liou I, Reuben A, Suzuki A, et al
     AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.
     Hepatology. 2023;77:1036-1065.
     PubMed    
     
     
     
402. NING C, Jiang ST, Sang XT
     Letter to the editor: Reflection on the no-association between the presence of fatty liver disease and mortality in the elderly.
     Hepatology. 2023;77:E39-E40.
     PubMed    
     
     
     
403. CANIVET CM, Costentin C, Irvine KM, Delamarre A, et al
     Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
     Hepatology. 2023;77:920-930.
     PubMed     Abstract available
     
     
     
404. VAN KLEEF LA, de Knegt RJ, Brouwer WP
     Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
     Hepatology. 2023;77:942-948.
     PubMed     Abstract available
     
     
     
405. LI S, Zhou B, Xue M, Zhu J, et al
     Macrophage-specific FGF12 promotes liver fibrosis progression in mice.
     Hepatology. 2023;77:816-833.
     PubMed     Abstract available
     
     
     
406. CRESPO M, Nikolic I, Mora A, Rodriguez E, et al
     Myeloid p38 activation maintains macrophage-liver crosstalk and BAT thermogenesis through IL-12-FGF21 axis.
     Hepatology. 2023;77:874-887.
     PubMed     Abstract available
     
     
     
407. CHAN CY, Yuen VW, Chiu DK, Goh CC, et al
     Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
     Hepatology. 2023;77:729-744.
     PubMed     Abstract available
     
     
     February 2023
408. ZANETTO A, Campello E, Senzolo M, Simioni P, et al
     The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review.
     Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000349.
     PubMed     Abstract available
     
     
     
409. TAPPER EB, Serper M, Goldberg D
     Implementing pragmatic clinical trials in hepatology.
     Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000345.
     PubMed     Abstract available
     
     
     
410. DU K, Maeso-Diaz R, Oh SH, Wang E, et al
     Targeting YAP-mediated hepatic stellate cell death susceptibility and senescence for treatment of liver fibrosis.
     Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000326.
     PubMed     Abstract available
     
     
     
411. LI J, Chen J, Lee PMY, Zhang J, et al
     Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
     Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
     PubMed     Abstract available
     
     
     
412. NICOARA-FARCAU O, Lozano JJ, Alonso C, Sidorova J, et al
     Metabolomics as a tool to predict the risk of decompensation or liver related death in patients with compensated cirrhosis.
     Hepatology. 2023 Feb 23. doi: 10.1097/HEP.0000000000000316.
     PubMed     Abstract available
     
     
     
413. GAWRIEH S, Lake JE, Debroy P, Sjoquist JA, et al
     Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
     Hepatology. 2023 Feb 22. doi: 10.1097/HEP.0000000000000313.
     PubMed     Abstract available
     
     
     
414. CHENG L, Deepak RNVK, Wang G, Meng Z, et al
     Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKalpha mediating lipid metabolism and tumorigenesis.
     Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000314.
     PubMed     Abstract available
     
     
     
415. 
     Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis: Erratum.
     Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000348.
     PubMed    
     
     
     
416. ZHANG J, Lyu Z, Li B, You Z, et al
     P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
     Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
     PubMed     Abstract available
     
     
     
417. WU N, Zhou T, Carpino G, Baiocchi L, et al
     Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
     Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
     PubMed     Abstract available
     
     
     
418. KUNDU D, Kennedy L, Zhou T, Ekser B, et al
     p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
     Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
     PubMed     Abstract available
     
     
     
419. AMENT CE, Steinmann S, Evert K, Pes GM, et al
     Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
     Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
     PubMed     Abstract available
     
     
     
420. HU Y, Li Z, Jiang Y, Wang X, et al
     Letter to the Editor: More efforts for the meta-analysis of the association between hepatic steatosis and HBV-related HCC.
     Hepatology. 2023 Feb 9. doi: 10.1097/HEP.0000000000000332.
     PubMed    
     
     
     
421. 
     April 2023 Hepatology Highlights.
     Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000325.
     PubMed    
     
     
     
422. SCHRADER JA, Burkard TL, Bruggemann Y, Gomer A, et al
     Epidermal growth factor receptor modulates hepatitis e virus entry in human hepatocytes -HEP-22-1113.
     Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000308.
     PubMed     Abstract available
     
     
     
423. ROWE IA, Allen AM
     Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease.
     Hepatology. 2023 Feb 6. doi: 10.1097/HEP.0000000000000327.
     PubMed    
     
     
     
424. PATOULIAS D
     Letter to the Editor: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?
     Hepatology. 2023 Feb 3. doi: 10.1097/HEP.0000000000000311.
     PubMed    
     
     
     
425. PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
     Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?
     Hepatology. 2023 Feb 3. doi: 10.1097/HEP.0000000000000312.
     PubMed    
     
     
     
426. 
     February 2023 Hepatology Highlights.
     Hepatology. 2023;77:339-340.
     PubMed    
     
     
     
427. WANG M, Sarkar M, Mehta N
     Now you see it, now you don't: Estrogen exposure and obesity effects on HCA development and regression.
     Hepatology. 2023;77:341-343.
     PubMed    
     
     
     
428. LARRUE H, Bureau C
     Transjugular intrahepatic portosystemic shunt in portal hypertension: How to go further while staying on track?
     Hepatology. 2023;77:344-346.
     PubMed    
     
     
     
429. LI J, Nguyen MH
     Letter to the editor: Screening for fatty liver disease and fibrosis in the elderly population: A call for action.
     Hepatology. 2023;77:E28-E29.
     PubMed    
     
     
     
430. VANDRIEL SM, Li LT, She H, Wang JS, et al
     Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
     Hepatology. 2023;77:512-529.
     PubMed     Abstract available
     
     
     
431. HABASH N, Ibrahim SH
     The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
     Hepatology. 2023;77:347-349.
     PubMed    
     
     
     
432. SHAN J, Megarbane A, Chouchane A, Karthik D, et al
     Genetic predisposition to porto-sinusoidal vascular disorder: A functional genomic-based, multigenerational family study.
     Hepatology. 2023;77:501-511.
     PubMed     Abstract available
     
     
     
433. HAGSTROM H, Shang Y
     Less is more? Screening for steatosis in older populations.
     Hepatology. 2023;77:350-351.
     PubMed    
     
     
     
434. LIN H, Yip TC, Zhang X, Li G, et al
     Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease.
     Hepatology. 2023;77:573-584.
     PubMed     Abstract available
     
     
     
435. MONDIA N, Singh SP, Mishra AK
     Letter to the editor: Risk factors of NAFLD in preterm and low birthweight. More questions than answers!
     Hepatology. 2023;77:E17.
     PubMed    
     
     
     
436. VAN KLEEF LA, Sonneveld MJ, Kavousi M, Ikram MA, et al
     Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study.
     Hepatology. 2023;77:585-593.
     PubMed     Abstract available
     
     
     
437. XU L, Yang Y, Jiang J, Wen Y, et al
     Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4/IL-13 production.
     Hepatology. 2023;77:456-465.
     PubMed     Abstract available
     
     
     
438. INDIRA CHANDRAN V, Wernberg CW, Lauridsen MM, Skytthe MK, et al
     Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness.
     Hepatology. 2023;77:558-572.
     PubMed     Abstract available
     
     
     
439. AJOOLABADY A, Kaplowitz N, Lebeaupin C, Kroemer G, et al
     Endoplasmic reticulum stress in liver diseases.
     Hepatology. 2023;77:619-639.
     PubMed     Abstract available
     
     
     January 2023
440. ADEJUMO AC, Yakovchenko V, Morgan TR, Spoutz P, et al
     The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 veterans.
     Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000306.
     PubMed     Abstract available
     
     
     
441. LUO J, Gong L, Yang Y, Zhang Y, et al
     Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in hepatocellular carcinoma.
     Hepatology. 2023 Jan 24. doi: 10.1097/HEP.0000000000000299.
     PubMed     Abstract available
     
     
     
442. AHMED HS, Wang N, Carr JJ, Ding J, et al
     The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multi-cohort study.
     Hepatology. 2023 Jan 19. doi: 10.1097/HEP.0000000000000286.
     PubMed     Abstract available
     
     
     
443. HUANG DQ, Tamaki N, Lee HW, Park SY, et al
     Outcome of untreated low-level viremia vs. antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000037.
     PubMed     Abstract available
     
     
     
444. CUNNINGHAM M, Gupta R, Butler M
     Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045.
     PubMed     Abstract available
     
     
     
445. EL HAJRA I, Sanduzzi-Zamparelli M, Sapena V, Munoz-Martinez S, et al
     Outcome of patients with hepatocellular carcinoma and liver dysfunction under Immunotherapy: a systematic review and meta-analysis.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000030.
     PubMed     Abstract available
     
     
     
446. 
     March 2023 Hepatology Highlights.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000289.
     PubMed    
     
     
     
447. ALLAIRE M, Thabut D
     Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000291.
     PubMed     Abstract available
     
     
     
448. LIU F, Liao Z, Qin L, Zhang Z, et al
     Targeting VPS72 inhibits ACTL6A/MYC axis activity in hepatocellular carcinoma progression.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000268.
     PubMed     Abstract available
     
     
     
449. CASTERA L, Cusi K
     Diabetes and cirrhosis: Current concepts on diagnosis and management.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000263.
     PubMed     Abstract available
     
     
     
450. YU H, Zhou L, Loong JH, Lam KH, et al
     SERPINA12 promotes the tumorigenic capacity of hepatocellular carcinoma stem cells through hyperactivation of AKT/ beta-catenin signaling.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000269.
     PubMed     Abstract available
     
     
     
451. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
     Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
     Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
     PubMed     Abstract available
     
     
     
452. GONG L, Wei F, Gonzalez FJ, Li G, et al
     Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000182.
     PubMed     Abstract available
     
     
     
453. BEHRENDT P, Gouttenoire J
     Editorial in Hepatology Urine: A place where HEV cannot hide!
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000017.
     PubMed    
     
     
     
454. HAO L, Zhong W, Woo J, Wei X, et al
     Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining A. muciniphila in alcoholic steatohepatitis.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000019.
     PubMed     Abstract available
     
     
     
455. YOUNOSSI Z, Golabi P, Paik J, Henry A, et al
     The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000004.
     PubMed     Abstract available
     
     
     
456. LV Y, Han G
     Reply to HEP-22-1980 Embolization of large spontaneous shunt for the prevention of hepatic encephalopathy after TIPS: more questions than answers.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000010.
     PubMed    
     
     
     
457. SHORT C, Zhong A, Xu J, Mahdi E, et al
     TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
     PubMed     Abstract available
     
     
     
458. LO GH
     Is embolization of large spontaneous shunt effective in the prevention of hepatic encephalopathy after TIPS?
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000007.
     PubMed    
     
     
     
459. LEE SH, So J, Shin D
     Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
     PubMed     Abstract available
     
     
     
460. FU S, Liu M, Zhu C, Zhang H, et al
     Regulatory MAIT cells controlled by beta1 adrenergic receptor signaling contribute to hepatocellular carcinoma progression.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000014.
     PubMed     Abstract available
     
     
     
461. WANG S, Wang R, Xu N, Wei X, et al
     SULT2B1-CS-DOCK2 axis regulates effector T cell exhaustion in hepatocellular carcinoma microenvironment.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000025.
     PubMed     Abstract available
     
     
     
462. KODAMA T, Takehara T
     Is it a prime time for germline genetic testing for hepatocellular carcinoma?
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000033.
     PubMed    
     
     
     
463. BHALA N, Ferguson JW, Rajoriya N, Newsome PN, et al
     Using global burden of hepatocellular cancer and liver cirrhosis as a driver to tackle preventable mortality and morbidity nationally and regionally.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000011.
     PubMed    
     
     
     
464. WANG CC, Kao JH
     Letter to the Editor Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000009.
     PubMed    
     
     
     
465. CABIBBO G, Celsa C, Alimenti E, Iavarone M, et al
     Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced hepatocellular carcinoma: the dark side of the moon.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000205.
     PubMed    
     
     
     
466. ZHANG L, Pan Q, Zhang L, Xia H, et al
     Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
     PubMed     Abstract available
     
     
     
467. FENG Y, Peng B, Li Y, Sun L, et al
     Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000209.
     PubMed    
     
     
     
468. KHORASANI S, Boike J, Duarte-Rojo A
     Will noninvasive screening for fibrosis/steatosis open Pandora's box? Sharing the healthcare burden of state-of-the-art hepatology practice.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000235.
     PubMed    
     
     
     
469. MA F, Liu Y, Hu Z, Xue Y, et al
     Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000042.
     PubMed     Abstract available
     
     
     
470. CHUNG HH
     Letter to the Editor: The pathological impact of PAR2 on hepatic insulin resistance.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000284.
     PubMed    
     
     
     
471. CHANG D, Truong E, Noureddin M
     Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: Accuracy and routine variables are the success keys.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000211.
     PubMed    
     
     
     
472. TANTAI X, Wang J, Dai S
     Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000271.
     PubMed    
     
     
     
473. DUAN S, Qin N, Pi J, Sun P, et al
     Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000185.
     PubMed     Abstract available
     
     
     
474. SHARPTON SR, Loomba R
     Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000278.
     PubMed     Abstract available
     
     
     
475. KARDASHIAN A, Kushner T, Au JS, Flemming JA, et al
     The key role of hepatology providers in optimizing reproductive care in patients with liver disease: a call to action.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000275.
     PubMed    
     
     
     
476. CAO J, Bai DS
     Letter to the editor: Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.
     Hepatology. 2023;77:E11.
     PubMed    
     
     
     
477. SEMMLER G, Thorhauge KH, Reiberger T, Thiele M, et al
     Letter to the editor: Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
     Hepatology. 2023;77:E1-E2.
     PubMed    
     
     
     
478. WADHWANI SI, Lai JC
     The digital determinants of liver disease.
     Hepatology. 2023;77:13-14.
     PubMed    
     
     
     
479. LINDBLAD KE, Lujambio A
     Imaging for better responses to immunotherapy in hepatocellular carcinoma.
     Hepatology. 2023;77:6-9.
     PubMed    
     
     
     
480. HENSON JB, Wegermann K, Patel YA, Wilder JM, et al
     Access to technology to support telehealth in areas without specialty care for liver disease.
     Hepatology. 2023;77:176-185.
     PubMed     Abstract available
     
     
     
481. GIDENER T, Dierkhising RA, Mara KC, Therneau TM, et al
     Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
     Hepatology. 2023;77:268-274.
     PubMed     Abstract available
     
     
     
482. ZHANG L, Guo GL
     Gut-specific inhibition of PPARalpha as a novel approach of NAFLD treatment.
     Hepatology. 2023;77:15-17.
     PubMed    
     
     
     
483. GOYAL NP, Rosenthal SB, Nasamran C, Behling CA, et al
     Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children.
     Hepatology. 2023;77:197-212.
     PubMed     Abstract available
     
     
     
484. HAGSTROM H
     A new model for estimation of significant fibrosis in primary care. SAFE to use?
     Hepatology. 2023;77:18-19.
     PubMed    
     
     
     
485. SRIPONGPUN P, Kim WR, Mannalithara A, Charu V, et al
     The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care.
     Hepatology. 2023;77:256-267.
     PubMed     Abstract available
     
     
     
486. REN Z, Simons PIHG, Wesselius A, Stehouwer CDA, et al
     Relationship between NAFLD and coronary artery disease: A Mendelian randomization study.
     Hepatology. 2023;77:230-238.
     PubMed     Abstract available
     
     
     
487. KOMUTA M, Ueno A, Sakamoto M
     The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer.
     Hepatology. 2023;77:10-12.
     PubMed    
     
     
     
488. 
     January 2023 Hepatology Highlights.
     Hepatology. 2023;77:1-2.
     PubMed    
     
     
     
489. 
     January 2023 Hepatology Highlights.
     Hepatology. 2023;77:1-2.
     PubMed    
     
     
     
490. 
     January 2023 Hepatology Highlights.
     Hepatology. 2023;77:1-2.
     PubMed    
     
     
     December 2022
491. ZHANG J, Xu Y, Lu X, Zhao H, et al
     Letter to the editor: NAFLD and sarcopenia: Association or causation?
     Hepatology. 2022;76:E119-E120.
     PubMed    
     
     
     
492. JIANG ST, Zhang L, Xu YY, Lu X, et al
     Letter to the editor: Complications following SARS-CoV-2 infection in patients with chronic liver disease.
     Hepatology. 2022;76:E116.
     PubMed    
     
     
     
493. XUN Z, Zhao H
     Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?
     Hepatology. 2022;76:E127-E128.
     PubMed    
     
     
     
494. SHEARER AM, Wang Y, Fletcher EK, Rana R, et al
     PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference.
     Hepatology. 2022;76:1778-1793.
     PubMed     Abstract available
     
     
     
495. SINN DH, Kang D, Kang M, Guallar E, et al
     Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study.
     Hepatology. 2022;76:1746-1754.
     PubMed     Abstract available
     
     
     
496. KIM Y, Chang Y, Ryu S, Wild SH, et al
     NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status.
     Hepatology. 2022;76:1755-1765.
     PubMed     Abstract available
     
     
     
497. SHARMA D, Ben Yakov G, Kapuria D, Viana Rodriguez G, et al
     Tip of the iceberg: A comprehensive review of liver disease in Inborn errors of immunity.
     Hepatology. 2022;76:1845-1861.
     PubMed     Abstract available
     
     
     
498. RATZIU V, Anstee QM, Wong VW, Schattenberg JM, et al
     An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project.
     Hepatology. 2022;76:1766-1777.
     PubMed     Abstract available
     
     
     
499. HUANG M, Jiao J, Cai H, Zhang Y, et al
     C-C motif chemokine ligand 5 confines liver regeneration by down-regulating reparative macrophage-derived hepatocyte growth factor in a forkhead box O 3a-dependent manner.
     Hepatology. 2022;76:1706-1722.
     PubMed     Abstract available
     
     
     
500. FENG R, Kan K, Sticht C, Li Y, et al
     A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions.
     Hepatology. 2022;76:1673-1689.
     PubMed     Abstract available
     
     
     
501. HONG F, Lin CY, Yan J, Dong Y, et al
     Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response-dependent destabilization of tumor protein P53.
     Hepatology. 2022;76:1587-1601.
     PubMed     Abstract available
     
     
     
502. ASIF B, Ortiz V, Conboy CB, Diaz LA, et al
     Hepatology Highlights.
     Hepatology. 2022;76:1555-1556.
     PubMed    
     
     
     November 2022
503. CHUNG HH
     Letter to the editor: The perspective of GLP-1/GLP-2 receptors against NASH via diverse regulation.
     Hepatology. 2022;76:E106-E107.
     PubMed    
     
     
     
504. ATTIA D, Gomaa A, Abdel Alem S
     Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD.
     Hepatology. 2022;76:E100.
     PubMed    
     
     
     
505. VAN KLEEF LA, de Knegt RJ
     The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach?
     Hepatology. 2022;76:1243-1245.
     PubMed    
     
     
     
506. AMADOU C, Nabi O, Serfaty L, Lacombe K, et al
     Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
     Hepatology. 2022;76:1438-1451.
     PubMed     Abstract available
     
     
     
507. SHANG Y, Nasr P, Widman L, Hagstrom H, et al
     Risk of cardiovascular disease and loss in life expectancy in NAFLD.
     Hepatology. 2022;76:1495-1505.
     PubMed     Abstract available
     
     
     
508. OLIVEIRA CP
     Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?
     Hepatology. 2022;76:1246-1247.
     PubMed    
     
     
     
509. YOUNOSSI ZM, Paik JM, Al Shabeeb R, Golabi P, et al
     Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
     Hepatology. 2022;76:1423-1437.
     PubMed     Abstract available
     
     
     
510. RIMOLA J, Sapena V, Brancatelli G, Darnell A, et al
     Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria.
     Hepatology. 2022;76:1318-1328.
     PubMed     Abstract available
     
     
     
511. VILAR-GOMEZ E, Pirola CJ, Sookoian S, Wilson LA, et al
     PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features.
     Hepatology. 2022;76:1482-1494.
     PubMed     Abstract available
     
     
     
512. ZHANG X, Wong GL, Yip TC, Cheung JTK, et al
     Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
     Hepatology. 2022;76:1409-1422.
     PubMed     Abstract available
     
     
     
513. LEI L, Bruneau A, El Mourabit H, Guegan J, et al
     Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis.
     Hepatology. 2022;76:1360-1375.
     PubMed     Abstract available
     
     
     
514. TOMLINSON JL, Penrice DD, Ramkissoon R, Udompap P, et al
     Hepatology highlights.
     Hepatology. 2022;76:1231-1232.
     PubMed    
     
     
     
515. FOUAD Y, Abdel Dayem WA, Mehrez M
     Letter to the editor: Apples should be compared with apples.
     Hepatology. 2022;76:E101.
     PubMed    
     
     
     October 2022
516. 
     Erratum for Jiang L, et al. calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway.
     Hepatology. 2022 Oct 26. doi: 10.1002/hep.32796.
     PubMed    
     
     
     
517. LAM YK, Yu J, Huang H, Ding X, et al
     TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk.
     Hepatology. 2022 Oct 11. doi: 10.1002/hep.32802.
     PubMed     Abstract available
     
     
     
518. RAHAL HK, Tabibian JH, Issaka RB, Quezada S, et al
     Diversity, equity, and inclusion in gastroenterology and hepatology: A survey of where we stand.
     Hepatology. 2022 Oct 11. doi: 10.1002/hep.32757.
     PubMed     Abstract available
     
     
     
519. WU T, Povero D, Parthasarathy G, Idalsoaga F, et al
     Hepatology highlights.
     Hepatology. 2022;76:901-902.
     PubMed    
     
     
     
520. SUCHMAN K, Da BL
     Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC.
     Hepatology. 2022;76:E78-E79.
     PubMed    
     
     
     
521. DEVARBHAVI H, Kurien SS
     Letter to the editor: A revised electronic version of RUCAM for the diagnosis of drug-induced liver injury.
     Hepatology. 2022;76:E71-E72.
     PubMed    
     
     
     
522. BARROW F, Revelo XS
     The B side of B cells in NAFLD.
     Hepatology. 2022;76:914-916.
     PubMed    
     
     
     
523. PAI RK, Jairath V, Hogan M, Zou G, et al
     Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
     Hepatology. 2022;76:1150-1163.
     PubMed     Abstract available
     
     
     
524. LASCHTOWITZ A, Tacke F
     Many roads lead to Rome: The FGF4-AMP-activated protein kinase-Caspase 6 signal axis in NAFLD and NASH.
     Hepatology. 2022;76:911-913.
     PubMed    
     
     
     
525. MARTINEZ-ARRANZ I, Bruzzone C, Noureddin M, Gil-Redondo R, et al
     Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
     Hepatology. 2022;76:1121-1134.
     PubMed     Abstract available
     
     
     
526. KARL M, Hasselwander S, Zhou Y, Reifenberg G, et al
     Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.
     Hepatology. 2022;76:1135-1149.
     PubMed     Abstract available
     
     
     
527. SONG L, Wang L, Hou Y, Zhou J, et al
     FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.
     Hepatology. 2022;76:1105-1120.
     PubMed     Abstract available
     
     
     
528. WANG H, Zhang B, Li R, Chen J, et al
     KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration.
     Hepatology. 2022;76:967-981.
     PubMed     Abstract available
     
     
     
529. BAPTISSART M, Bradish CM, Jones BS, Walsh E, et al
     Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome.
     Hepatology. 2022;76:1090-1104.
     PubMed     Abstract available
     
     
     
530. WANG H, Zhou Y, Xu H, Wang X, et al
     Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
     Hepatology. 2022;76:951-966.
     PubMed     Abstract available
     
     
     
531. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
     Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
     Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
     PubMed     Abstract available
     
     
     September 2022
532. VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
     Reply to the Letter to the Editor: "Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?"
     Hepatology. 2022 Sep 30. doi: 10.1002/hep.32813.
     PubMed    
     
     
     
533. VAZ K, Little R, Majeed A, Roberts S, et al
     Letter to the Editor: Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?
     Hepatology. 2022 Sep 28. doi: 10.1002/hep.32811.
     PubMed    
     
     
     
534. ALLEGRETTI AS
     NGAL in AKI and cirrhosis - ready for prime time?
     Hepatology. 2022 Sep 28. doi: 10.1002/hep.32807.
     PubMed    
     
     
     
535. YIP TC, Wong VW, Wong GL
     Does hepatic steatosis impact chronic hepatitis B?
     Hepatology. 2022 Sep 24. doi: 10.1002/hep.32803.
     PubMed    
     
     
     
536. MAK LY, Hui RW, Lee CH, Mao X, et al
     Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
     Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
     PubMed     Abstract available
     
     
     
537. GAMBINO C, Piano S, Stenico M, Tonon M, et al
     Diagnostic and prognostic performance of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and AKI.
     Hepatology. 2022 Sep 20. doi: 10.1002/hep.32799.
     PubMed     Abstract available
     
     
     
538. MANNA D, Reghupaty SC, Camarena MDC, Mendoza RG, et al
     Melanoma Differentiation Associated Gene-9/Syndecan Binding Protein (MDA-9/SDCBP) Promotes Hepatocellular Carcinoma (HCC).
     Hepatology. 2022 Sep 19. doi: 10.1002/hep.32797.
     PubMed     Abstract available
     
     
     
539. JACHS M, Tillmann HL
     Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
     Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
     PubMed    
     
     
     
540. MAO X, Cheung KS, Peng C, Mak LY, et al
     Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
     Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
     PubMed     Abstract available
     
     
     
541. CHEN YT, Su YC, Or YE, Cheng CF, et al
     CD8(+) T cell memory is sustained in mice by hepatic stellate cells.
     Hepatology. 2022 Sep 15. doi: 10.1002/hep.32788.
     PubMed     Abstract available
     
     
     
542. BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
     Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
     Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
     PubMed     Abstract available
     
     
     
543. LIU Y, Zhang J, Xu Y, Lu X, et al
     Letter to the editor: Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients.
     Hepatology. 2022 Sep 14. doi: 10.1002/hep.32785.
     PubMed    
     
     
     
544. VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
     Reply to the Letter to the Editor: "Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients".
     Hepatology. 2022 Sep 13. doi: 10.1002/hep.32784.
     PubMed    
     
     
     
545. LESLIE J, Hunter JE, Collins A, Rushton A, et al
     c-Rel dependant Chk2 signalling regulates the DNA damage response limiting hepatocarcinogenesis.
     Hepatology. 2022 Sep 11. doi: 10.1002/hep.32781.
     PubMed     Abstract available
     
     
     
546. LEE YT, Fujiwara N, Yang JD, Hoshida Y, et al
     Risk stratification and early detection biomarkers for precision hepatocellular carcinoma screening.
     Hepatology. 2022 Sep 9. doi: 10.1002/hep.32779.
     PubMed     Abstract available
     
     
     
547. DELLINGER RW, Holmes HE, Hu-Seliger T, Butt RW, et al
     NRPT reduces markers of hepatic inflammation in non-alcoholic fatty liver disease: a double-blind, placebo-controlled clinical trial.
     Hepatology. 2022 Sep 9. doi: 10.1002/hep.32778.
     PubMed     Abstract available
     
     
     
548. 
     Retracted: Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
     Hepatology. 2022 Sep 8. doi: 10.1002/hep.32736.
     PubMed    
     
     
     
549. LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
     Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
     Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
     PubMed     Abstract available
     
     
     
550. DUAN Z
     Postvaccination COVID-19 related mortality in patients with cirrhosis:who is the culprit?
     Hepatology. 2022 Sep 5. doi: 10.1002/hep.32750.
     PubMed    
     
     
     
551. HUANG H, Wu L, Lu L, Zhang Z, et al
     Single-cell Transcriptomics Uncovers Cellular Architecture and Developmental Trajectories in Hepatoblastoma.
     Hepatology. 2022 Sep 4. doi: 10.1002/hep.32775.
     PubMed     Abstract available
     
     
     
552. KNORR J, Kaufmann B, Inzaugarat ME, Holtmann TM, et al
     Interleukin-18 signaling promotes activation of hepatic stellate cells in murine liver fibrosis.
     Hepatology. 2022 Sep 4. doi: 10.1002/hep.32776.
     PubMed     Abstract available
     
     
     
553. VAN ZWOL W, Rimbert A, Wolters JC, Smit M, et al
     Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion.
     Hepatology. 2022 Sep 2. doi: 10.1002/hep.32709.
     PubMed     Abstract available
     
     
     
554. JENSEN DM, Rzepczynski A, Jensen EE, Reau N, et al
     The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.
     Hepatology. 2022;76:854-859.
     PubMed    
     
     
     
555. CULLARO G, Verna EC, McCulloch CE, Lai JC, et al
     Improving the Model for End-Stage Liver Disease with sodium by incorporating kidney dysfunction types.
     Hepatology. 2022;76:689-699.
     PubMed     Abstract available
     
     
     
556. ZABALETA N, Torella L, Weber ND, Gonzalez-Aseguinolaza G, et al
     mRNA and gene editing: Late breaking therapies in liver diseases.
     Hepatology. 2022;76:869-887.
     PubMed     Abstract available
     
     
     
557. HARRIS EN
     Will inhibition of cellular crosstalk resolve liver fibrosis?
     Hepatology. 2022;76:558-560.
     PubMed    
     
     
     
558. ZHENG M, Allington G, Vilarinho S
     Genomic medicine for liver disease.
     Hepatology. 2022;76:860-868.
     PubMed    
     
     
     
559. CALCAGNO DM, Chu A, Gaul S, Taghdiri N, et al
     NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH.
     Hepatology. 2022;76:727-741.
     PubMed     Abstract available
     
     
     
560. LIN Y, Dong MQ, Liu ZM, Xu M, et al
     A strategy of vascular-targeted therapy for liver fibrosis.
     Hepatology. 2022;76:660-675.
     PubMed     Abstract available
     
     
     
561. ALVA-RUIZ R, Ahn JC, Udompap P, Diaz LA, et al
     Hepatology highlights.
     Hepatology. 2022;76:539-540.
     PubMed    
     
     
     August 2022
562. QUECK A, Praktiknjo M, Jansen C, Trebicka J, et al
     Response to the letter to the editor: "Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS".
     Hepatology. 2022 Aug 25. doi: 10.1002/hep.32754.
     PubMed    
     
     
     
563. LUO W, Wang Y, Li Y, Zhang T, et al
     Letter to the editor: Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
     Hepatology. 2022 Aug 25. doi: 10.1002/hep.32755.
     PubMed    
     
     
     
564. HU S, Monga SP
     Response to the "Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte beta-catenin".
     Hepatology. 2022 Aug 24. doi: 10.1002/hep.32694.
     PubMed    
     
     
     
565. JOHN BV, Dahman B
     COVID-19 related mortality in Cirrhosis is not associated with Proton Pump Inhibitor Exposure.
     Hepatology. 2022 Aug 24. doi: 10.1002/hep.32748.
     PubMed    
     
     
     
566. LO GH
     Could COVID-19 vaccination reduce post-infection mortality in most cirrhotic patients ?
     Hepatology. 2022 Aug 24. doi: 10.1002/hep.32751.
     PubMed    
     
     
     
567. JOHN BV, Dahman B
     COVID-19 Vaccination and mortality in Decompensated Cirrhosis.
     Hepatology. 2022 Aug 24. doi: 10.1002/hep.32749.
     PubMed    
     
     
     
568. LEE HM, Lidofsky SD, Taddei TH, Townshend-Bulson LJ, et al
     Attacking the Public Health Crisis of Hepatocellular Carcinoma at its Roots.
     Hepatology. 2022 Aug 21. doi: 10.1002/hep.32741.
     PubMed    
     
     
     
569. DONNE R, Lujambio A
     The Liver Cancer Immune Microenvironment: Therapeutic Implications for Hepatocellular Carcinoma.
     Hepatology. 2022 Aug 21. doi: 10.1002/hep.32740.
     PubMed     Abstract available
     
     
     
570. ZONG C, Meng Y, Ye F, Yang X, et al
     AIF1(+) CSF1R(+) MSCs, induced by TNF-alpha, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis.
     Hepatology. 2022 Aug 21. doi: 10.1002/hep.32738.
     PubMed     Abstract available
     
     
     
571. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
     Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
     Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
     PubMed     Abstract available
     
     
     
572. DEMORY A, Peron JM, Calderaro J, Selves J, et al
     Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
     Hepatology. 2022 Aug 18. doi: 10.1002/hep.32734.
     PubMed     Abstract available
     
     
     
573. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
     Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
     Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
     PubMed     Abstract available
     
     
     
574. GOUON-EVANS V, Fiorotto R
     Fibroblasts to hepatocytes: a non-stop flight into cell therapy for liver diseases?
     Hepatology. 2022 Aug 11. doi: 10.1002/hep.32725.
     PubMed    
     
     
     
575. LIU T, Wang Q, Zhou L, Zhang P, et al
     Intrahepatic paracrine signaling by CLCF1 ameliorates diet-induced NASH in mice.
     Hepatology. 2022 Aug 11. doi: 10.1002/hep.32719.
     PubMed     Abstract available
     
     
     
576. WU Y, Hao X, Wei H, Sun R, et al
     TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
     Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
     PubMed     Abstract available
     
     
     
577. RODRIGUEZ TC, Kwan S, Smith JL, Dadafarin S, et al
     Multi-omics characterization of mouse hepatoblastoma identifies novel YAP1 target genes.
     Hepatology. 2022 Aug 6. doi: 10.1002/hep.32713.
     PubMed     Abstract available
     
     
     
578. LIU X, Wang K, Wang L, Kong L, et al
     Hepatocyte Ltb4r1 promotes NAFLD development in obesity.
     Hepatology. 2022 Aug 5. doi: 10.1002/hep.32708.
     PubMed     Abstract available
     
     
     
579. LIANG B, Wang H, Qiao Y, Wang X, et al
     Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation driven hepatocarcinogenesis.
     Hepatology. 2022 Aug 3. doi: 10.1002/hep.32693.
     PubMed     Abstract available
     
     
     
580. VIZZUTTI F, Celsa C, Calvaruso V, Enea M, et al
     Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model.
     Hepatology. 2022 Aug 3. doi: 10.1002/hep.32704.
     PubMed     Abstract available
     
     
     
581. PENUELAS-HARO I, Espinosa-Sotelo R, Crosas-Molist E, Herranz-Iturbide M, et al
     The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing hepatocellular carcinoma progression.
     Hepatology. 2022 Aug 3. doi: 10.1002/hep.32702.
     PubMed     Abstract available
     
     
     
582. NING C, Zhang XM, Sang XT, Zhao HT, et al
     Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte beta-catenin.
     Hepatology. 2022 Aug 2. doi: 10.1002/hep.32695.
     PubMed    
     
     
     
583. PATTOU F, Lasailly G, Raverdy V, Caiazzo R, et al
     Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty.
     Hepatology. 2022;76:E51-E52.
     PubMed    
     
     
     
584. JIANG ST, Zhang JW, Lu X, Xu YY, et al
     Letter to the editor: Discussion on application scenario of cell-free DNA fragmentomics in primary liver cancer.
     Hepatology. 2022;76:E44.
     PubMed    
     
     
     
585. JINDAL A
     Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
     Hepatology. 2022;76:E42.
     PubMed    
     
     
     
586. GUIDOTTI LG, La Vecchia C, Colombo M
     Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?
     Hepatology. 2022;76:300-302.
     PubMed    
     
     
     
587. PANIGRAHI MK, Anirvan P
     Letter to the editor: Using angiotensin-converting enzyme inhibitors to prevent liver-related events in NAFLD-Revisiting the renin-angiotensin-aldosterone system pathways.
     Hepatology. 2022;76:E32-E33.
     PubMed    
     
     
     
588. MAYO MJ
     Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
     Hepatology. 2022;76:518-531.
     PubMed     Abstract available
     
     
     
589. VOS MB, Van Natta ML, Blondet NM, Dasarathy S, et al
     Randomized placebo-controlled trial of losartan for pediatric NAFLD.
     Hepatology. 2022;76:429-444.
     PubMed     Abstract available
     
     
     
590. AGOPIAN VG, Yang JD, Zhu Y, You S, et al
     Early detection of primary liver cancer using plasma cell-free DNA fragmentomics: Do all the pieces come together?
     Hepatology. 2022;76:289-291.
     PubMed    
     
     
     
591. MAO Y, Han CY, Hao L, Lee Y, et al
     p21-activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2-related factor 2 phosphorylation.
     Hepatology. 2022;76:345-356.
     PubMed     Abstract available
     
     
     
592. VALAINATHAN SR, Sartoris R, Elkrief L, Magaz M, et al
     Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study.
     Hepatology. 2022;76:418-428.
     PubMed     Abstract available
     
     
     
593. PAIS R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, et al
     Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
     Hepatology. 2022;76:456-468.
     PubMed     Abstract available
     
     
     
594. GUNEWARDENA S, Huck I, Walesky C, Robarts D, et al
     Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans.
     Hepatology. 2022;76:372-386.
     PubMed     Abstract available
     
     
     
595. SOFTIC S, Kohli R
     Pediatric NASH therapies: A speedbump on the road to success.
     Hepatology. 2022;76:292-294.
     PubMed    
     
     
     
596. ZHANG X, Wang Z, Tang W, Wang X, et al
     Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
     Hepatology. 2022;76:317-329.
     PubMed     Abstract available
     
     
     
597. ZHANG X, Wong GL, Yip TC, Tse YK, et al
     Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
     Hepatology. 2022;76:469-482.
     PubMed     Abstract available
     
     
     
598. HAN B, Francipane MG, Cheikhi A, Johnson J, et al
     Fat-associated lymphoid clusters as expandable niches for ectopic liver development.
     Hepatology. 2022;76:357-371.
     PubMed     Abstract available
     
     
     
599. XIONG H, Zhang C, Han L, Xu T, et al
     Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron-induced hepatotoxicity.
     Hepatology. 2022;76:387-403.
     PubMed     Abstract available
     
     
     July 2022
600. SUN N, Zhang C, Lee YT, Tran BV, et al
     HCC EV ECG Score: An Extracellular Vesicle-based Protein Assay for Detection of Early-Stage Hepatocellular Carcinoma.
     Hepatology. 2022 Jul 31. doi: 10.1002/hep.32692.
     PubMed     Abstract available
     
     
     
601. BAI Y, Yang Z, Xu X, Ding W, et al
     Direct chemical induction of hepatocyte-like cells with capacity for liver repopulation.
     Hepatology. 2022 Jul 26. doi: 10.1002/hep.32686.
     PubMed     Abstract available
     
     
     
602. QUECK A, Schwierz L, Gu W, Ferstl PG, et al
     Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
     Hepatology. 2022 Jul 23. doi: 10.1002/hep.32676.
     PubMed     Abstract available
     
     
     
603. HU S, Cao C, Poddar M, Delgado E, et al
     Hepatocyte beta-Catenin Loss is Compensated by Insulin-mTORC1 Activation to Promote Liver Regeneration.
     Hepatology. 2022 Jul 21. doi: 10.1002/hep.32680.
     PubMed     Abstract available
     
     
     
604. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
     Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
     Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.
     PubMed    
     
     
     
605. LIU X, Tan S, Liu H, Jiang J, et al
     Hepatocyte-derived MASP1-enriched small extracellular vesicles activate hepatic stellate cells to promote liver fibrosis.
     Hepatology. 2022 Jul 18. doi: 10.1002/hep.32662.
     PubMed     Abstract available
     
     
     
606. LAI SW
     Aspirin use and the risk of hepatocellular carcinoma.
     Hepatology. 2022 Jul 17. doi: 10.1002/hep.32674.
     PubMed    
     
     
     
607. ZHONG D, Cai J, Hu C, Chen J, et al
     Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
     Hepatology. 2022 Jul 15. doi: 10.1002/hep.32671.
     PubMed     Abstract available
     
     
     
608. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
     Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
     Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.
     PubMed    
     
     
     
609. POZO-MORALES M, Garteizgogeascoa I, Perazzolo C, So J, et al
     In vivo imaging of calcium dynamics in zebrafish hepatocytes.
     Hepatology. 2022 Jul 13. doi: 10.1002/hep.32663.
     PubMed     Abstract available
     
     
     
610. YANG F, Jiang ST, Lu X, Xu Y, et al
     Letter to the editor: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
     Hepatology. 2022 Jul 11. doi: 10.1002/hep.32659.
     PubMed    
     
     
     
611. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
     Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
     Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
     PubMed     Abstract available
     
     
     
612. CHANG D, Truong E, Mena EA, Pacheco F, et al
     Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis.
     Hepatology. 2022 Jul 9. doi: 10.1002/hep.32655.
     PubMed     Abstract available
     
     
     
613. ZHANG Y, Ye S, Lu W, Zhong J, et al
     RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.
     Hepatology. 2022 Jul 7. doi: 10.1002/hep.32651.
     PubMed     Abstract available
     
     
     
614. KOVALIC AJ, Lee TP, Da BL
     Letter to the editor: L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
     Hepatology. 2022 Jul 5. doi: 10.1002/hep.32643.
     PubMed    
     
     
     
615. RYDELL GE, Ringlander J, Larsson SB, Hellstrand K, et al
     Letter to the editor: Alu-PCR design may have compromised detection of integrated core HBV DNA.
     Hepatology. 2022;76:E23.
     PubMed    
     
     
     
616. DANAN G, Teschke R
     Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation.
     Hepatology. 2022;76:E27.
     PubMed    
     
     
     
617. RASCHI E, Caraceni P
     Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?
     Hepatology. 2022;76:E25-E26.
     PubMed    
     
     
     
618. KIVLIGHN S, Schuur E, Gish RG, Cryer D, et al
     Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention.
     Hepatology. 2022;76:E7-E8.
     PubMed    
     
     
     
619. TAO X, Zhao Y, Chen L, Zeng M, et al
     Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
     Hepatology. 2022;76:E13-E14.
     PubMed    
     
     
     
620. KAPPUS MR, Patel YA, Duarte-Rojo A
     Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention.
     Hepatology. 2022;76:12-14.
     PubMed    
     
     
     
621. PISCAGLIA F
     Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm.
     Hepatology. 2022;76:6-8.
     PubMed    
     
     
     
622. HAYASHI PH, Lucena MI, Fontana RJ, Bjornsson ES, et al
     A revised electronic version of RUCAM for the diagnosis of DILI.
     Hepatology. 2022;76:18-31.
     PubMed     Abstract available
     
     
     
623. SERPER M, Parikh ND, Thiele G, Ovchinsky N, et al
     Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
     Hepatology. 2022;76:251-274.
     PubMed     Abstract available
     
     
     
624. LEWIS JH
     Digitizing DILI: Who can? RUCAM? RECAM?
     Hepatology. 2022;76:3-5.
     PubMed    
     
     
     
625. KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
     Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
     Hepatology. 2022;76:186-195.
     PubMed     Abstract available
     
     
     
626. STINE JG, Schreibman IR, Faust AJ, Dahmus J, et al
     NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
     Hepatology. 2022;76:172-185.
     PubMed     Abstract available
     
     
     
627. DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
     Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
     Hepatology. 2022;76:275-285.
     PubMed    
     
     
     
628. POVERO D, Ahn JC, Arnold J, Udompap P, et al
     Hepatology Highlights.
     Hepatology. 2022;76:1-2.
     PubMed    
     
     
     
629. FAN Y, Jiang ST, Yong-Chang Z
     Letter to the Editor: Some reflection on the research related to METTL1 promoting radiotherapy resistance in hepatocellular carcinoma.
     Hepatology. 2022 Jul 1. doi: 10.1002/hep.32644.
     PubMed    
     
     
     
630. SCHMID CD, Olsavszky V, Reinhart M, Weyer V, et al
     ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver.
     Hepatology. 2022 Jul 1. doi: 10.1002/hep.32641.
     PubMed     Abstract available
     
     
     June 2022
631. TRAN NH, Munoz S, Thompson S, Hallemeier CL, et al
     Hepatocellular Carcinoma Down-Staging for Liver Transplantation in the Era of Systemic Combined Therapy with Anti-VEGF/TKI and Immunotherapy.
     Hepatology. 2022 Jun 28. doi: 10.1002/hep.32613.
     PubMed     Abstract available
     
     
     
632. MALHI H, Gores GJ
     What is Hepatology looking for Version 2.0?
     Hepatology. 2022 Jun 26. doi: 10.1002/hep.32637.
     PubMed    
     
     
     
633. JIANG ST, Xu YY, Lu X
     Letter to the Editor: Using intratumoral steatosis to predict the efficacy of combination therapy in nonviral hepatocellular carcinoma.
     Hepatology. 2022 Jun 25. doi: 10.1002/hep.32628.
     PubMed    
     
     
     
634. ZHAO K, Guo F, Wang J, Zhong Y, et al
     Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
     Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
     PubMed     Abstract available
     
     
     
635. YUAN T, Zhou T, Qian M, Du J, et al
     SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
     Hepatology. 2022 Jun 17. doi: 10.1002/hep.32621.
     PubMed     Abstract available
     
     
     
636. JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
     Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
     Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
     PubMed     Abstract available
     
     
     
637. LI B, Yu D
     Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma?
     Hepatology. 2022 Jun 15. doi: 10.1002/hep.32616.
     PubMed    
     
     
     
638. XU C, Fan J, Liu D, Tuerdi A, et al
     Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
     Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
     PubMed     Abstract available
     
     
     
639. LIAO J, Yi Y, Yue X, Wu X, et al
     METTL1 is required for non-homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy.
     Hepatology. 2022 Jun 14. doi: 10.1002/hep.32615.
     PubMed     Abstract available
     
     
     
640. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
     Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
     Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
     PubMed     Abstract available
     
     
     
641. AHMAD A
     Letter to the Editor: The Precise Relationship Between MELD and Survival Without a Liver Transplant.
     Hepatology. 2022 Jun 11. doi: 10.1002/hep.32602.
     PubMed     Abstract available
     
     
     
642. XU J, Wang Y, Khoshdeli M, Peach M, et al
     IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
     Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
     PubMed     Abstract available
     
     
     
643. HOLMAN A, Parikh N, Clauw DJ, Williams DA, et al
     Rethinking the management of pain in cirrhosis: toward precision therapy for pain.
     Hepatology. 2022 Jun 5. doi: 10.1002/hep.32598.
     PubMed     Abstract available
     
     
     
644. DELTENRE P, Zanetto A, Saltini D, Moreno C, et al
     The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions.
     Hepatology. 2022 Jun 4. doi: 10.1002/hep.32596.
     PubMed     Abstract available
     
     
     
645. TESTINO G
     Letter to the editor: Chronic liver disease among adolescents and young adults: Alcohol use disorder identification.
     Hepatology. 2022;75:1662-1663.
     PubMed    
     
     
     
646. JULIEN J, Ayer T, Tapper EB, Barbosa C, et al
     Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
     Hepatology. 2022;75:1480-1490.
     PubMed     Abstract available
     
     
     
647. SANDAHL TD, Gormsen LC, Kjaergaard K, Vendelbo MH, et al
     The pathophysiology of Wilson's disease visualized: A human (64) Cu PET study.
     Hepatology. 2022;75:1461-1470.
     PubMed     Abstract available
     
     
     
648. QIAN Q, Li Y, Fu J, Leng D, et al
     Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.
     Hepatology. 2022;75:1507-1522.
     PubMed     Abstract available
     
     
     
649. VILAR-GOMEZ E, Nephew LD, Vuppalanchi R, Gawrieh S, et al
     High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population.
     Hepatology. 2022;75:1491-1506.
     PubMed     Abstract available
     
     
     
650. PSARAKI A, Ntari L, Karakostas C, Korrou-Karava D, et al
     Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases.
     Hepatology. 2022;75:1590-1603.
     PubMed     Abstract available
     
     
     
651. ALVA-RUIZ R, Wu T, Idalsoaga F, Ramkissoon R, et al
     Hepatology highlights.
     Hepatology. 2022;75:1363-1364.
     PubMed    
     
     
     May 2022
652. ZHANG JW, Fang J, Xun Z, Xu Y, et al
     Letter to the Editor: Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in the Real World.
     Hepatology. 2022 May 23. doi: 10.1002/hep.32588.
     PubMed    
     
     
     
653. KIMURA Y, Koyama Y, Taura K, Kudoh A, et al
     Characterization and role of collagen gene expressing hepatic cells following partial hepatectomy in mice.
     Hepatology. 2022 May 23. doi: 10.1002/hep.32586.
     PubMed     Abstract available
     
     
     
654. JALAN-SAKRIKAR N, Brevini T, Huebert RC, Sampaziotis F, et al
     Organoids and Regenerative Hepatology.
     Hepatology. 2022 May 21. doi: 10.1002/hep.32583.
     PubMed     Abstract available
     
     
     
655. LI L, Zhang Y, Zhou Y, Hu H, et al
     Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma.
     Hepatology. 2022 May 21. doi: 10.1002/hep.32584.
     PubMed     Abstract available
     
     
     
656. HARTL L, Haslinger K, Angerer M, Semmler G, et al
     Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
     Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
     PubMed     Abstract available
     
     
     
657. XU W, Cui C, Cui C, Chen Z, et al
     Hepatocellular Cystathionine gamma lyase/Hydrogen sulfide Attenuates Non-Alcoholic Fatty Liver Disease by Activating Farnesoid X Receptor.
     Hepatology. 2022 May 19. doi: 10.1002/hep.32577.
     PubMed     Abstract available
     
     
     
658. PILLING LC, Atkins JL, Melzer D
     Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations in a large community cohort.
     Hepatology. 2022 May 14. doi: 10.1002/hep.32575.
     PubMed     Abstract available
     
     
     
659. MURAI H, Kodama T, Maesaka K, Tange S, et al
     Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
     Hepatology. 2022 May 14. doi: 10.1002/hep.32573.
     PubMed     Abstract available
     
     
     
660. BAJAJ JS, Rodriguez MP, Fagan A, McGeorge S, et al
     Impact of Bacterial Infections and SBP Prophylaxis on Phage-Bacterial Dynamics in Cirrhosis.
     Hepatology. 2022 May 13. doi: 10.1002/hep.32571.
     PubMed     Abstract available
     
     
     
661. KIM KE, Lee J, Shin HJ, Jeong EA, et al
     Lipocalin-2 Activates Hepatic stellate cells and Promotes Non-alcoholic Steatohepatitis in High-Fat Diet-Fed ob/ob mice.
     Hepatology. 2022 May 13. doi: 10.1002/hep.32569.
     PubMed     Abstract available
     
     
     
662. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
     Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
     Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
     PubMed     Abstract available
     
     
     
663. MEHTA S, Asrani SK
     The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
     Hepatology. 2022 May 5. doi: 10.1002/hep.32559.
     PubMed    
     
     
     
664. ANDERSEN JB
     Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
     Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
     PubMed    
     
     
     
665. GULATI P, Taneja S, Duseja A, Singh V, et al
     Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
     Hepatology. 2022 May 3. doi: 10.1002/hep.32554.
     PubMed    
     
     
     
666. LIU JJ, Xin B, Du L, Chen L, et al
     Pharmaceutical Shp2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
     Hepatology. 2022 May 3. doi: 10.1002/hep.32555.
     PubMed     Abstract available
     
     
     
667. HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
     Fontan-associated liver disease.
     Hepatology. 2022;75:1300-1321.
     PubMed    
     
     
     
668. LEE CH, Lui DTW, Lam KSL
     Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?
     Hepatology. 2022;75:1340.
     PubMed    
     
     
     
669. CHUNG HH
     Letter to the editor: The multiple mechanisms of fructose disrupt gut-liver axis and metabolic regulation.
     Hepatology. 2022;75:1338-1339.
     PubMed    
     
     
     
670. ASRANI SK, Ghabril MS, Kuo A, Merriman RB, et al
     Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
     Hepatology. 2022;75:1289-1299.
     PubMed     Abstract available
     
     
     
671. PAIK JM, Kabbara K, Eberly KE, Younossi Y, et al
     Global burden of NAFLD and chronic liver disease among adolescents and young adults.
     Hepatology. 2022;75:1204-1217.
     PubMed     Abstract available
     
     
     
672. KUREBAYASHI Y, Matsuda K, Ueno A, Tsujikawa H, et al
     Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments.
     Hepatology. 2022;75:1139-1153.
     PubMed     Abstract available
     
     
     
673. ZHANG JL, Du BB, Zhang DH, Li H, et al
     OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways.
     Hepatology. 2022;75:1218-1234.
     PubMed     Abstract available
     
     
     
674. SONG J, Song H, Wei H, Sun R, et al
     Requirement of RORalpha for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s.
     Hepatology. 2022;75:1181-1193.
     PubMed     Abstract available
     
     
     
675. REN QN, Zhang H, Sun CY, Zhou YF, et al
     Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.
     Hepatology. 2022;75:1123-1138.
     PubMed     Abstract available
     
     
     
676. CONBOY CB, Penrice DD, Watkins R, Diaz LA, et al
     Hepatology highlights.
     Hepatology. 2022;75:1071-1072.
     PubMed    
     
     
     
677. QIN Y, Li A, Liu B, Gao M, et al
     Comment on "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD".
     Hepatology. 2022 May 1. doi: 10.1002/hep.32551.
     PubMed    
     
     
     
678. SANGRO B, Argemi J
     Immunotherapy in hepatocellular carcinoma - No rush despite the hype.
     Hepatology. 2022 May 1. doi: 10.1002/hep.32550.
     PubMed    
     
     
     April 2022
679. SHAH PA, Patil R, Harrison SA
     NAFLD-related hepatocellular carcinoma: The growing challenge.
     Hepatology. 2022 Apr 28. doi: 10.1002/hep.32542.
     PubMed     Abstract available
     
     
     
680. KUMAR A, Rajani D, Kumar S
     Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
     Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
     PubMed    
     
     
     
681. YAN T, Luo Y, Yan N, Hamada K, et al
     Intestinal Peroxisome Proliferator-Activated Receptor alpha-Fatty Acid Binding Protein 1 Axis Modulates Nonalcoholic Steatohepatitis.
     Hepatology. 2022 Apr 23. doi: 10.1002/hep.32538.
     PubMed     Abstract available
     
     
     
682. CHEN L, Dong J, Meng Q, Song Z, et al
     Reply to the comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
     Hepatology. 2022 Apr 19. doi: 10.1002/hep.32530.
     PubMed    
     
     
     
683. IVANICS T, Claasen MP, Patel MS, Hansen BE, et al
     Reply to: Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
     Hepatology. 2022 Apr 18. doi: 10.1002/hep.32532.
     PubMed    
     
     
     
684. JIANG ST, Zhang JW, Lu X, Xu YY, et al
     Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
     Hepatology. 2022 Apr 17. doi: 10.1002/hep.32533.
     PubMed    
     
     
     
685. RAO Z, Li F, Guan Z, Zhou H, et al
     Comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
     Hepatology. 2022 Apr 16. doi: 10.1002/hep.32529.
     PubMed    
     
     
     
686. XU MX, Tan J, Ge CX, Dong W, et al
     TRIM31 confers protection against nonalcoholic steatohepatitis by deactivating MAP3K7.
     Hepatology. 2022 Apr 16. doi: 10.1002/hep.32526.
     PubMed     Abstract available
     
     
     
687. AHN JC, Lauzon M, Luu M, Noureddin M, et al
     Racial and ethnic disparities in early treatment with immunotherapy for advanced hepatocellular carcinoma in the United States.
     Hepatology. 2022 Apr 16. doi: 10.1002/hep.32527.
     PubMed     Abstract available
     
     
     
688. TRIPATHI D, Bureau C
     Prophylactic embolization of large spontaneous portosystemic shunts with TIPS: A panacea for post TIPS hepatic encephalopathy?
     Hepatology. 2022 Apr 16. doi: 10.1002/hep.32525.
     PubMed    
     
     
     
689. ZHU Y, Gu L, Lin X, Zhou X, et al
     P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis.
     Hepatology. 2022 Apr 10. doi: 10.1002/hep.32518.
     PubMed     Abstract available
     
     
     
690. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
     Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
     Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
     PubMed     Abstract available
     
     
     
691. KHADERI S, Kanwal F
     Changing Epidemiology of Hepatocellular Cancer in the United States: winning the battle but it is not over yet.
     Hepatology. 2022 Apr 7. doi: 10.1002/hep.32512.
     PubMed    
     
     
     
692. TCHORZ JS
     Re-tuning hepatocytes improves their functional engraftment.
     Hepatology. 2022 Apr 7. doi: 10.1002/hep.32513.
     PubMed    
     
     
     
693. GOEPPERT B, Roessler S
     New kid on the block: Netrin-1 as a novel player in the delicate molecular network of hepatic inflammation.
     Hepatology. 2022 Apr 6. doi: 10.1002/hep.32509.
     PubMed    
     
     
     
694. MANDATO C, Vajro P
     Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
     Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
     PubMed    
     
     
     
695. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
     Response to letter to the editor from Zhou et al (Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease).
     Hepatology. 2022 Apr 2. doi: 10.1002/hep.32503.
     PubMed    
     
     
     
696. ZHOU Y, Chu W, Wu X, Zhou H, et al
     Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
     Hepatology. 2022 Apr 2. doi: 10.1002/hep.32504.
     PubMed    
     
     
     
697. TOMLINSON JL, Ahn JC, Povero D, Ramkissoon R, et al
     Hepatology Highlights.
     Hepatology. 2022;75:775-776.
     PubMed    
     
     
     
698. AHUJA P, Bi X, Ng CF, Tse MCL, et al
     Src homology 3 domain binding kinase 1 protects against hepatic steatosis and insulin resistance through the Nur77- fibroblast growth factor 21 pathway.
     Hepatology. 2022 Apr 1. doi: 10.1002/hep.32501.
     PubMed     Abstract available
     
     
     
699. SINGAL AK, Kwo P, Kwong A, Liangpunsakul S, et al
     Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
     Hepatology. 2022;75:1026-1037.
     PubMed     Abstract available
     
     
     
700. SINGH SA, Madan K, Gupta S, Indrayan A, et al
     Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
     Hepatology. 2022;75:1067-1068.
     PubMed    
     
     
     
701. WANG S, Whitlock R, Lai JC, Taneja S, et al
     Reply.
     Hepatology. 2022;75:1068-1069.
     PubMed    
     
     
     
702. JAIN A, Sharma BC
     Reply.
     Hepatology. 2022;75:1066-1067.
     PubMed    
     
     
     
703. COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
     Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
     Hepatology. 2022;75:1056-1057.
     PubMed    
     
     
     
704. PAILHORIES H, Boursier J, Diehl AM
     Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle.
     Hepatology. 2022;75:782-784.
     PubMed    
     
     
     
705. NEIL DAH, Minervini M, Smith ML, Hubscher SG, et al
     Banff consensus recommendations for steatosis assessment in donor livers.
     Hepatology. 2022;75:1014-1025.
     PubMed     Abstract available
     
     
     
706. KWAN SY, Jiao J, Joon A, Wei P, et al
     Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
     Hepatology. 2022;75:955-967.
     PubMed     Abstract available
     
     
     
707. ZHOU HZ, Li F, Cheng ST, Xu Y, et al
     DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis.
     Hepatology. 2022;75:847-865.
     PubMed     Abstract available
     
     
     
708. SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
     The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
     Hepatology. 2022;75:881-897.
     PubMed     Abstract available
     
     
     March 2022
709. CULLARO G, Hsu CY, Lai JC
     Variability in Serum Creatinine is Associated with Waitlist and Post-Liver Transplant Mortality in Cirrhosis Patients.
     Hepatology. 2022 Mar 31. doi: 10.1002/hep.32497.
     PubMed     Abstract available
     
     
     
710. LEE SH, Yim SY, Jeong YS, Li QX, et al
     Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
     Hepatology. 2022 Mar 29. doi: 10.1002/hep.32490.
     PubMed     Abstract available
     
     
     
711. JAVITT NB
     Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
     Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
     PubMed    
     
     
     
712. DENG R, Liu S, Shen S, Guo H, et al
     Circulating hepatitis B virus RNA: From biology to clinical applications.
     Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
     PubMed     Abstract available
     
     
     
713. CAI HX, Xin C, Wang XP
     ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a murine model of Wilson's disease.
     Hepatology. 2022 Mar 27. doi: 10.1002/hep.32484.
     PubMed     Abstract available
     
     
     
714. WANG T, Xu C, Zhang Z, Wu H, et al
     Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
     Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
     PubMed     Abstract available
     
     
     
715. D'ALESSIO A, Fulgenzi CAM, Nishida N, Schonlein M, et al
     Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
     Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468.
     PubMed     Abstract available
     
     
     
716. CHEN L, Dong J, Liao S, Wang S, et al
     Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury.
     Hepatology. 2022 Mar 21. doi: 10.1002/hep.32471.
     PubMed     Abstract available
     
     
     
717. FLEMMING JA, Muaddi H, Djerboua M, Neves P, et al
     Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.
     Hepatology. 2022 Mar 21. doi: 10.1002/hep.32469.
     PubMed     Abstract available
     
     
     
718. CREEDEN JF, Kipp ZA, Xu M, Flight RM, et al
     Hepatic Kinome Atlas: An In-Depth Identification of Kinase Pathways in Liver Fibrosis of Humans and Rodents.
     Hepatology. 2022 Mar 21. doi: 10.1002/hep.32467.
     PubMed     Abstract available
     
     
     
719. HOU J
     Drinking vinegar, a potential adjuvant for immunotherapy of hepatocellular carcinoma?
     Hepatology. 2022 Mar 18. doi: 10.1002/hep.32463.
     PubMed    
     
     
     
720. GOLDBERG D, Mantero A, Kaplan D, Delgado C, et al
     Accurate Long-Term Prediction of Death for Patients with Cirrhosis.
     Hepatology. 2022 Mar 12. doi: 10.1002/hep.32457.
     PubMed     Abstract available
     
     
     
721. LV Y, Chen H, Luo B, Bai W, et al
     Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial.
     Hepatology. 2022 Mar 10. doi: 10.1002/hep.32453.
     PubMed     Abstract available
     
     
     
722. BASS LM, Ye W, Hawthorne K, Leung DH, et al
     The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
     Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
     PubMed     Abstract available
     
     
     
723. HU C, Xu B, Wang X, Wan WH, et al
     Gut microbiota-derived short-chain fatty acids regulates group 3 innate lymphoid cells in hepatocellular carcinoma.
     Hepatology. 2022 Mar 9. doi: 10.1002/hep.32449.
     PubMed     Abstract available
     
     
     
724. FOERSTER F, Gairing SJ, Ilyas SI, Galle PR, et al
     Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.
     Hepatology. 2022 Mar 7. doi: 10.1002/hep.32447.
     PubMed     Abstract available
     
     
     
725. BARNAULT R, Verzeroli C, Fournier C, Michelet M, et al
     Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation.
     Hepatology. 2022 Mar 7. doi: 10.1002/hep.32446.
     PubMed     Abstract available
     
     
     
726. HE Y, Luo J, Zhang G, Jin Y, et al
     Single-cell profiling of human CD127(+) innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma.
     Hepatology. 2022 Mar 4. doi: 10.1002/hep.32444.
     PubMed     Abstract available
     
     
     
727. NIE YZ, Zheng YW, Taniguchi H
     Improving the repopulation capacity of elderly human hepatocytes by decoding aging-associated hepatocyte plasticity.
     Hepatology. 2022 Mar 4. doi: 10.1002/hep.32443.
     PubMed     Abstract available
     
     
     
728. LU Z, Liu R, Wang Y, Jiao M, et al
     TET2 Inactivation Restrains IL-10-producing Regulatory B cells to Enable Anti-tumor Immunity in Hepatocellular Carcinoma.
     Hepatology. 2022 Mar 4. doi: 10.1002/hep.32442.
     PubMed     Abstract available
     
     
     
729. PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
     Diabetes Medications and Risk of Hepatocellular Carcinoma.
     Hepatology. 2022 Mar 3. doi: 10.1002/hep.32439.
     PubMed     Abstract available
     
     
     
730. 
     Hepato Liver Cancer logy highlights.
     Hepatology. 2022;75:503-504.
     PubMed    
     
     
     
731. HILSCHER MB, Shah VH
     A NET gain in our understanding of acute liver failure.
     Hepatology. 2022;75:511-513.
     PubMed    
     
     
     
732. LUO MS, Huang GJ
     Letter to the editor: The addition of C-reactive protein and von Willebrand factor to Model for End-Stage Liver Disease-Sodium.
     Hepatology. 2022;75:763-764.
     PubMed    
     
     
     
733. WU JW, Tseng TC, Kao JH
     Letter to the editor: New kid in the playground: HBcrAg and risk of HCC.
     Hepatology. 2022;75:760-761.
     PubMed    
     
     
     
734. BEKKI Y, Fenig Y
     Letter to the editor: The impact of donor liver fibrosis on early allograft dysfunction and ischemia-reperfusion injury.
     Hepatology. 2022;75:754.
     PubMed    
     
     
     
735. 
     Seeking Editor for Clinical Liver Disease.
     Hepatology. 2022;75:i.
     PubMed    
     
     
     
736. VON MEIJENFELDT FA, Stravitz RT, Zhang J, Adelmeijer J, et al
     Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome.
     Hepatology. 2022;75:623-633.
     PubMed     Abstract available
     
     
     
737. GOIKOETXEA-USANDIZAGA N, Serrano-Macia M, Delgado TC, Simon J, et al
     Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.
     Hepatology. 2022;75:550-566.
     PubMed     Abstract available
     
     
     
738. REN R, He Y, Ding D, Cui A, et al
     Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPalpha-miRNA-223 axis.
     Hepatology. 2022;75:646-660.
     PubMed     Abstract available
     
     
     
739. TAMAKI N, Imajo K, Sharpton S, Jung J, et al
     Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
     Hepatology. 2022;75:661-672.
     PubMed     Abstract available
     
     
     
740. WANG C, Zhang L, Sun Z, Yuan X, et al
     Dedifferentiation-associated inflammatory factors of long-term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment.
     Hepatology. 2022 Mar 1. doi: 10.1002/hep.32436.
     PubMed     Abstract available
     
     
     
741. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
     Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
     Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
     PubMed     Abstract available
     
     
     
742. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
     Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
     Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
     PubMed     Abstract available
     
     
     February 2022
743. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
     Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
     Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
     PubMed     Abstract available
     
     
     
744. SUTHEN SD, Lim CJ, Nguyen PHD, Dutertre CA, et al
     Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in hepatocellular carcinoma.
     Hepatology. 2022 Feb 20. doi: 10.1002/hep.32419.
     PubMed     Abstract available
     
     
     
745. FAN L, Pan Q, Yang W, Koo SC, et al
     A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis.
     Hepatology. 2022 Feb 18. doi: 10.1002/hep.32412.
     PubMed     Abstract available
     
     
     
746. IVANICS T, Murillo Perez CF, Claasen MP, Patel MS, et al
     Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resection.
     Hepatology. 2022 Feb 18. doi: 10.1002/hep.32411.
     PubMed     Abstract available
     
     
     
747. EFE C, Harputluoglu M, Karadag Soylu N, Yilmaz S, et al
     Liver transplantation following SARS-CoV-2 vaccination-induced liver failure.
     Hepatology. 2022 Feb 17. doi: 10.1002/hep.32409.
     PubMed    
     
     
     
748. WANG Z, Yu J, Liang P
     Reply to "Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!"
     Hepatology. 2022 Feb 9. doi: 10.1002/hep.32402.
     PubMed    
     
     
     
749. JINDAL A, Mukund A
     Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!
     Hepatology. 2022 Feb 9. doi: 10.1002/hep.32401.
     PubMed    
     
     
     
750. NOUREDDIN M, Abdelmalek MF
     ACE inhibitors: The Secret to Prevent Cirrhosis Complications and Hepatocellular Carcinoma in NAFLD?
     Hepatology. 2022 Feb 6. doi: 10.1002/hep.32399.
     PubMed    
     
     
     
751. YAKOVCHENKO V, Morgan TR, Miech EJ, Neely B, et al
     Core implementation strategies for improving cirrhosis care in the Veterans Health Administration.
     Hepatology. 2022 Feb 6. doi: 10.1002/hep.32395.
     PubMed     Abstract available
     
     
     
752. ALVAREZ CS, Petrick JL, Parisi D, McMahon BJ, et al
     Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018.
     Hepatology. 2022 Feb 5. doi: 10.1002/hep.32394.
     PubMed     Abstract available
     
     
     
753. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
     Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
     Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
     PubMed     Abstract available
     
     
     
754. ZANETTO A, Campello E, Spiezia L, Burra P, et al
     Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?
     Hepatology. 2022 Feb 3. doi: 10.1002/hep.32392.
     PubMed    
     
     
     
755. LEMOINE CP, Superina R
     Letter to the Editor: Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension?
     Hepatology. 2022 Feb 2. doi: 10.1002/hep.32386.
     PubMed    
     
     
     
756. LUO C, Xin H, Zhou Z, Hu Z, et al
     Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
     Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
     PubMed     Abstract available
     
     
     
757. LEE V, Wong TC
     Reply to "prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant".
     Hepatology. 2022 Feb 2. doi: 10.1002/hep.32379.
     PubMed    
     
     
     
758. WATKINS R, Ilyas SI, Penrice DD, Conboy CB, et al
     Hepatology Highlights.
     Hepatology. 2022;75:241-242.
     PubMed    
     
     
     
759. ROGAL S, Hansen L, Patel A, Ufere NN, et al
     AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
     Hepatology. 2022 Feb 1. doi: 10.1002/hep.32378.
     PubMed    
     
     
     
760. KARATAYLI E, Lammert F
     Vulnerability to alcohol-associated liver disease: A tale of two systems.
     Hepatology. 2022;75:246-247.
     PubMed    
     
     
     
761. HEY P, Gow P
     Letter to the Editor: Rethinking public health measures to reduce liver injury from therapeutic acetaminophen ingestion.
     Hepatology. 2022;75:495-496.
     PubMed    
     
     
     
762. GIDENER T, Yin M, Dierkhising RA, Allen AM, et al
     Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
     Hepatology. 2022;75:379-390.
     PubMed     Abstract available
     
     
     
763. VAN KLEEF LA, Ayada I, Alferink LJM, Pan Q, et al
     Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
     Hepatology. 2022;75:419-429.
     PubMed     Abstract available
     
     
     
764. RAMANI K, Robinson AE, Berlind J, Fan W, et al
     S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells.
     Hepatology. 2022;75:280-296.
     PubMed     Abstract available
     
     
     
765. LIN T, Wang S, Munker S, Jung K, et al
     Follistatin-controlled activin-HNF4alpha-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.
     Hepatology. 2022;75:322-337.
     PubMed     Abstract available
     
     
     
766. KIM KY, Kim JO, Kim YS, Choi JE, et al
     Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study.
     Hepatology. 2022;75:391-402.
     PubMed     Abstract available
     
     
     January 2022
767. JIANG SY, Yang X, Yang Z, Li JW, et al
     Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis.
     Hepatology. 2022 Jan 31. doi: 10.1002/hep.32381.
     PubMed     Abstract available
     
     
     
768. DE A, Keisham A, Duseja A
     Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).
     Hepatology. 2022 Jan 31. doi: 10.1002/hep.32374.
     PubMed    
     
     
     
769. JANG H, Lee YB, Moon H, Chung JW, et al
     Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
     Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
     PubMed     Abstract available
     
     
     
770. KUMAR A, Sharma P, Arora A
     Letter to the Editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
     Hepatology. 2022 Jan 29. doi: 10.1002/hep.32375.
     PubMed    
     
     
     
771. LIU F, Zhang W, Liu H
     Letter to the Editor: Hepatocyte Proliferation Peak and beta-Oxidation in Liver Regeneration after Partial Hepatectomy.
     Hepatology. 2022 Jan 26. doi: 10.1002/hep.32357.
     PubMed    
     
     
     
772. PAIK JM, Henry L, Younossi ZM
     Response to: Chronic Liver Disease Among Adolescent and Young Adult: Alcohol Use Disorder Identification- Letter to the Editor. Hepatology 2022.
     Hepatology. 2022 Jan 25. doi: 10.1002/hep.32362.
     PubMed    
     
     
     
773. SAHAI P, Jindal A, Mukund A
     Letter to the Editor: Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
     Hepatology. 2022 Jan 25. doi: 10.1002/hep.32354.
     PubMed    
     
     
     
774. LI YT, Liu CJ, Kao JH, Lin LF, et al
     Metastatic Tumor Antigen 1 Contributes to Hepatocarcinogenesis Posttranscriptionally Through Novel RNA Binding Function.
     Hepatology. 2022 Jan 24. doi: 10.1002/hep.32356.
     PubMed     Abstract available
     
     
     
775. HAN J, Wang B, Liu W, Wang S, et al
     Declining disease burden of hepatocellular carcinoma in the US, 1992-2017: A population-based analysis.
     Hepatology. 2022 Jan 24. doi: 10.1002/hep.32355.
     PubMed     Abstract available
     
     
     
776. FANG Y, Liu W, Tang Z, Ji X, et al
     MCT4 inhibition potentiates hepatocellular carcinoma immunotherapy via enhancing T cell infiltration and immune attack.
     Hepatology. 2022 Jan 19. doi: 10.1002/hep.32348.
     PubMed     Abstract available
     
     
     
777. KHATIB SA, Ma L, Dang H, Forgues M, et al
     Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in hepatocellular carcinoma.
     Hepatology. 2022 Jan 16. doi: 10.1002/hep.32345.
     PubMed     Abstract available
     
     
     
778. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
     Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
     Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
     PubMed     Abstract available
     
     
     
779. WU T, Simonetto DA, Halamka JD, Shah VH, et al
     The Digital Transformation of Hepatology: The Patient is Logged In.
     Hepatology. 2022 Jan 13. doi: 10.1002/hep.32329.
     PubMed     Abstract available
     
     
     
780. JOHN BV, Deng Y, Schwartz KB, Taddei TH, et al
     Post-Vaccination COVID-19 Infection is Associated with Reduced Mortality in Patients With Cirrhosis.
     Hepatology. 2022 Jan 12. doi: 10.1002/hep.32337.
     PubMed     Abstract available
     
     
     
781. RAMADORI P, Kam S, Heikenwalder M
     T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis.
     Hepatology. 2022 Jan 12. doi: 10.1002/hep.32336.
     PubMed     Abstract available
     
     
     
782. SANDMANN L, Cornberg M
     Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
     PubMed    
     
     
     
783. WANG Z, Liu M, Zhang DZ, Wu SS, et al
     Microwave Ablation versus Laparoscopic Resection as First-line Therapy for Solitary 3-5 cm Hepatocellular Carcinoma.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32323.
     PubMed     Abstract available
     
     
     
784. FANG ZQ, Ruan B, Liu JJ, Duan JL, et al
     Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32332.
     PubMed     Abstract available
     
     
     
785. MA H, Kang Z, Foo TK, Shen Z, et al
     Disrupted BRCA1-PALB2 Interaction Induces Tumor Immunosuppression and T-Lymphocyte Infiltration in Hepatocellular Carcinoma Through cGAS-STING Pathway.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32335.
     PubMed     Abstract available
     
     
     
786. ANDERSSON ER
     Outside influence: the extrahepatic duct as a source for bile duct regeneration.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
     PubMed    
     
     
     
787. MOORE MP, Cunningham RP, Meers GM, Johnson SA, et al
     Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
     Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324.
     PubMed     Abstract available
     
     
     
788. TRANAH TH, Shawcross DL
     The rise and fall and rise again of ammonia as a therapeutic target in hepatic encephalopathy.
     Hepatology. 2022 Jan 7. doi: 10.1002/hep.32319.
     PubMed    
     
     
     
789. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
     Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
     Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
     PubMed     Abstract available
     
     
     
790. NG CH, Xiao J, Lim WH, Chin YH, et al
     Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.
     Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.
     PubMed     Abstract available
     
     
     
791. WU H, Li Y, Shi G, Du S, et al
     Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD-1 therapy.
     Hepatology. 2022 Jan 6. doi: 10.1002/hep.32316.
     PubMed     Abstract available
     
     
     
792. 
     Hepatology Highlights.
     Hepatology. 2022;75:1-2.
     PubMed    
     
     
     
793. PHAM L, Kennedy L, Baiocchi L, Meadows V, et al
     Mast cells in liver disease progression: An update on current studies and implications.
     Hepatology. 2022;75:213-218.
     PubMed    
     
     
     December 2021
794. LABENZ C, Labenz J, Galle PR
     Letter to the Editor: Evidence on the use of L-ornithine L-aspartate in overt hepatic encephalopathy - but does it really improve prognosis?
     Hepatology. 2021 Dec 27. doi: 10.1002/hep.32309.
     PubMed    
     
     
     
795. RIDOLA L, Nardelli S, Gioia S, Faccioli J, et al
     Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!
     Hepatology. 2021 Dec 24. doi: 10.1002/hep.32306.
     PubMed    
     
     
     
796. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
     Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
     Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
     PubMed     Abstract available
     
     
     
797. LAEMMLE A, Haberle J, Willenbring H
     Reply to "The Role of Aquaporin 9 in Modeling of Ornithine Transcarbamylase Deficiency".
     Hepatology. 2021 Dec 21. doi: 10.1002/hep.32290.
     PubMed    
     
     
     
798. KODAMA T, Takehara T
     Reply; Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis.
     Hepatology. 2021 Dec 20. doi: 10.1002/hep.32292.
     PubMed    
     
     
     
799. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
     Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
     Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
     PubMed     Abstract available
     
     
     
800. RICH NE, Singal AG
     Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
     Hepatology. 2021 Dec 19. doi: 10.1002/hep.32284.
     PubMed     Abstract available
     
     
     
801. FRIEDMAN SL, Pinzani M
     Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future.
     Hepatology. 2021 Dec 19. doi: 10.1002/hep.32285.
     PubMed     Abstract available
     
     
     
802. CARABALLO GALVA LD, Jiang X, Hussein MS, Zhang H, et al
     Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma.
     Hepatology. 2021 Dec 12. doi: 10.1002/hep.32279.
     PubMed     Abstract available
     
     
     
803. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
     Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
     Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
     PubMed    
     
     
     
804. LAI JC, Shui AM, Duarte-Rojo A, Ganger DR, et al
     Frailty, Mortality, and Healthcare Utilization after Liver Transplantation: From the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study.
     Hepatology. 2021 Dec 4. doi: 10.1002/hep.32268.
     PubMed     Abstract available
     
     
     
805. XIN B, Yang M, Wu P, Du L, et al
     Enhancing the Therapeutic Efficacy of PD-L1 Antibody for Metastasized Liver Cancer by Overcoming Hepatic Immunotolerance.
     Hepatology. 2021 Dec 3. doi: 10.1002/hep.32266.
     PubMed     Abstract available
     
     
     
806. SAPISOCHIN G, Ivanics T, Heimbach J
     Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
     Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
     PubMed     Abstract available
     
     
     
807. KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
     Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
     Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
     PubMed     Abstract available
     
     
     
808. 
     2021 Hepatology Referees (Volumes 73 and 74).
     Hepatology. 2021;74:3565-3569.
     PubMed    
     
     
     
809. CODISPODO G, Brown RS Jr, Hans A, Roccaro G, et al
     Hepatology Highlights.
     Hepatology. 2021;74:2931-2934.
     PubMed    
     
     
     
810. KUMAR K, Kulkarni A, Jagdish RK
     Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH.
     Hepatology. 2021;74:3559-3560.
     PubMed    
     
     
     
811. AGARWAL A, Sharma S, Saraya A
     Letter to the Editor: Defining the Futility for Rescue Transjugular Intrahepatic Portosystemic Shunt Using the Model for End-Stage Liver Disease Score and Lactate in Variceal Bleed.
     Hepatology. 2021;74:3556-3557.
     PubMed    
     
     
     
812. JINDAL A, Sarin SK, Mukund A
     Letter to the Editor: Salvage TIPS for Refractory Variceal Bleed-More Questions Than Answers!
     Hepatology. 2021;74:3557-3558.
     PubMed    
     
     
     
813. VALENTI LVC, Cherubini A
     To Be or Not to Be: The Quest for Patatin-Like Phospholipase Domain Containing 3 p.I148M Function.
     Hepatology. 2021;74:2942-2944.
     PubMed    
     
     
     
814. GOH GB, Chan WK, Wong VW
     Breastfeeding to Prevent NAFLD.
     Hepatology. 2021;74:2939-2941.
     PubMed    
     
     
     
815. SONG J, Liu Y, Wan J, Zhao GN, et al
     SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR.
     Hepatology. 2021;74:3091-3109.
     PubMed     Abstract available
     
     
     
816. WAN J, Zhang Y, Yang D, Liang Y, et al
     Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
     Hepatology. 2021;74:3074-3090.
     PubMed     Abstract available
     
     
     
817. TILSON SG, Morell CM, Lenaerts AS, Park SB, et al
     Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
     Hepatology. 2021;74:2998-3017.
     PubMed     Abstract available
     
     
     
818. SHAH NL, Miller JB, Kalman RS, Kumar S, et al
     AASLD Educating and Engaging in the Digital Age: Editorial from Communications and Technology Committee.
     Hepatology. 2021;74:2935-2938.
     PubMed    
     
     
     
819. PARK Y, Sinn DH, Oh JH, Goh MJ, et al
     The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.
     Hepatology. 2021;74:2988-2997.
     PubMed     Abstract available
     
     
     
820. WU T, Luo G, Lian Q, Sui C, et al
     Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.
     Hepatology. 2021;74:3249-3268.
     PubMed     Abstract available
     
     
     
821. KUMAR S, Wong R, Newberry C, Yeung M, et al
     Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD.
     Hepatology. 2021;74:3472-3478.
     PubMed    
     
     
     
822. OTT P, Ala A, Askari FK, Czlonkowska A, et al
     Designing Clinical Trials in Wilson's Disease.
     Hepatology. 2021;74:3460-3471.
     PubMed     Abstract available
     
     
     
823. GARCIA-MACIA M, Santos-Ledo A, Leslie J, Paish HL, et al
     A Mammalian Target of Rapamycin-Perilipin 3 (mTORC1-Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis.
     Hepatology. 2021;74:3441-3459.
     PubMed     Abstract available
     
     
     
824. LANGE AP, Usmani AA, Wald C, Gordon FD, et al
     Sinusoidal Obstruction Syndrome in a Young Woman With Antiphospholipid Syndrome on Oral Contraceptives.
     Hepatology. 2021;74:3539-3541.
     PubMed    
     
     
     
825. HAKIM A, Moll M, Brancale J, Liu J, et al
     Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.
     Hepatology. 2021;74:3394-3408.
     PubMed     Abstract available
     
     
     
826. BAI W, Al-Karaghouli M, Stach J, Sung S, et al
     Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
     Hepatology. 2021;74:3301-3315.
     PubMed     Abstract available
     
     
     
827. RUSYN I, Arzuaga X, Cattley RC, Corton JC, et al
     Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity.
     Hepatology. 2021;74:3486-3496.
     PubMed     Abstract available
     
     
     November 2021
828. JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
     "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
     Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
     PubMed     Abstract available
     
     
     
829. GHANY MG, King WC, Lisker-Melman M, Sf Lok A, et al
     Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk.
     Hepatology. 2021 Nov 20. doi: 10.1002/hep.32251.
     PubMed     Abstract available
     
     
     
830. LAEMMLE A, Poms M, Hsu B, Borsuk M, et al
     Aquaporin 9 Induction in Human iPSC-derived Hepatocytes Facilitates Modeling of Ornithine Transcarbamylase Deficiency.
     Hepatology. 2021 Nov 16. doi: 10.1002/hep.32247.
     PubMed     Abstract available
     
     
     
831. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
     Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
     Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244.
     PubMed     Abstract available
     
     
     
832. KIM ER, Park JS, Kim JH, Oh JY, et al
     A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
     Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
     PubMed     Abstract available
     
     
     
833. TIAN L, Zhao L, Sze KM, Kam CS, et al
     Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
     Hepatology. 2021 Nov 12. doi: 10.1002/hep.32236.
     PubMed     Abstract available
     
     
     
834. YANG J, Ye J, Ma T, Tang F, et al
     TRIM11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome mediated degradation of PHLPP1.
     Hepatology. 2021 Nov 12. doi: 10.1002/hep.32234.
     PubMed     Abstract available
     
     
     
835. LI H, Lan T, Liu H, Liu C, et al
     IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
     PubMed     Abstract available
     
     
     
836. WU N, Carpino G, Ceci L, Baiocchi L, et al
     MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
     Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
     PubMed     Abstract available
     
     
     
837. DING MJ, Fang HR, Zhang JK, Shi JH, et al
     E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
     Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
     PubMed     Abstract available
     
     
     
838. KAPLAN A, Brown RS Jr, Buckholz A, Hang TP, et al
     Hepatology Highlights.
     Hepatology. 2021;74:2329-2332.
     PubMed    
     
     
     
839. BERNUAU J, Cazals-Hatem D, Vigrain V, Durand F, et al
     Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone.
     Hepatology. 2021;74:2922.
     PubMed    
     
     
     
840. JINDAL A
     Letter to the Editor: Infections in Severe Forms of Alcohol-Associated Liver Disease: Need a Closer Look!
     Hepatology. 2021;74:2926-2927.
     PubMed    
     
     
     
841. BAZARBASHI AN, Li M, Ryou M
     Letter to the Editor: Endoscopic Ultrasound-Guided Coil Therapy for Secondary Prevention After Gastric Variceal Bleeding: A Promising Alternative.
     Hepatology. 2021;74:2914.
     PubMed    
     
     
     
842. LOU L, Li X
     Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto-sinusoidal Vascular Liver Disease.
     Hepatology. 2021;74:2910-2911.
     PubMed    
     
     
     
843. CHINNADURAI KK, De A, Duseja A, Singh V, et al
     Letter to the Editor: Is Balloon-Occluded Retrograde Transvenous Obliteration Superior to Endoscopic Cyanoacrylate in Gastric Varices?
     Hepatology. 2021;74:2907-2908.
     PubMed    
     
     
     
844. VOJJALA N, Mehtani R, Singh V
     Letter to the Editor: Acute Liver Injury Due to Therapeutic Doses of Acetaminophen-Confounders Must Be Ruled Out!
     Hepatology. 2021;74:2904.
     PubMed    
     
     
     
845. ZHOU J, Bai L, Zhang XJ, Li H, et al
     Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications.
     Hepatology. 2021;74:2839-2847.
     PubMed    
     
     
     
846. INARRAIRAEGUI M, Sangro B
     Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?
     Hepatology. 2021;74:2333-2335.
     PubMed    
     
     
     
847. HU Y, He W, Huang Y, Xiang H, et al
     Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
     Hepatology. 2021;74:2508-2525.
     PubMed     Abstract available
     
     
     
848. DIAZ LA, Idalsoaga F, Fuentes-Lopez E, Marquez-Lomas A, et al
     Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study.
     Hepatology. 2021;74:2478-2490.
     PubMed     Abstract available
     
     
     
849. PAISANT A, Bellal S, Lebigot J, Canivet CM, et al
     Imaging Features of Hepatic Small Vessel Neoplasm: Case Series.
     Hepatology. 2021;74:2894-2896.
     PubMed    
     
     
     
850. VAN DALEM J, Driessen JHM, Burden AM, Stehouwer CDA, et al
     Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
     Hepatology. 2021;74:2467-2477.
     PubMed     Abstract available
     
     
     
851. SUN H, Meng Q, Shi C, Yang H, et al
     Hypoxia-Inducible Exosomes Facilitate Liver-Tropic Premetastatic Niche in Colorectal Cancer.
     Hepatology. 2021;74:2633-2651.
     PubMed     Abstract available
     
     
     
852. BURYSKA S, Ahn JC, Allen AM, Simha V, et al
     Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH.
     Hepatology. 2021;74:2897-2898.
     PubMed    
     
     
     
853. BARCENA-VARELA M, Lujambio A
     Dissecting Early Relapse in Liver Cancer, One Cell at a Time.
     Hepatology. 2021;74:2891-2893.
     PubMed    
     
     
     
854. DRISCOLL J, Wehrkamp C, Ota Y, Thomas JN, et al
     Biological Nanotherapeutics for Liver Disease.
     Hepatology. 2021;74:2863-2875.
     PubMed     Abstract available
     
     
     
855. SIMON TG, Roelstraete B, Sharma R, Khalili H, et al
     Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
     Hepatology. 2021;74:2410-2423.
     PubMed     Abstract available
     
     
     
856. JAGDISH RK, Maras JS, Sarin SK
     Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!
     Hepatology. 2021;74:2848-2862.
     PubMed     Abstract available
     
     
     October 2021
857. LAN T, Jiang S, Zhang J, Weng Q, et al
     Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
     Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
     PubMed     Abstract available
     
     
     
858. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
     Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
     Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
     PubMed     Abstract available
     
     
     
859. MANCUSO A
     Portal vein thrombosis in cirrhosis: the issue of treatment.
     Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
     PubMed     Abstract available
     
     
     
860. LI M, Wong D, Vogel AS, Sack JS, et al
     Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
     Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
     PubMed     Abstract available
     
     
     
861. LUCE E, Steichen C, Allouche M, Messina A, et al
     In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.
     Hepatology. 2021 Oct 23. doi: 10.1002/hep.32211.
     PubMed     Abstract available
     
     
     
862. SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
     Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
     Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
     PubMed     Abstract available
     
     
     
863. ZHOU J, Guo L, Ma T, Qiu T, et al
     N-Acetylgalactosaminyltransferase-4 protects against hepatic ischaemia/reperfusion injury via blocking ASK1 N-terminal dimerization.
     Hepatology. 2021 Oct 18. doi: 10.1002/hep.32202.
     PubMed     Abstract available
     
     
     
864. 
     Correction of HEPATOLOGY 2020;71:259-274.
     Hepatology. 2021 Oct 12. doi: 10.1002/hep.32036.
     PubMed    
     
     
     
865. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
     Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
     Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
     PubMed     Abstract available
     
     
     
866. SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
     GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
     Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
     PubMed     Abstract available
     
     
     
867. LIU N, Steer CJ, Song G
     MicroRNA-206 Enhances Antitumor Immunity by Disrupting the Communication between Malignant Hepatocytes and Tregs in c-Myc Mice.
     Hepatology. 2021 Oct 4. doi: 10.1002/hep.32182.
     PubMed     Abstract available
     
     
     
868. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
     BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
     Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
     PubMed     Abstract available
     
     
     
869. ALLAMNENI C, Vora RS, Bamidele AO, Schwartz RE, et al
     Hepatology Highlights.
     Hepatology. 2021;74:1727-1729.
     PubMed    
     
     
     
870. MCCARRON S, Bathon B, Conlon DM, Abbey D, et al
     Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.
     Hepatology. 2021;74:1825-1844.
     PubMed     Abstract available
     
     
     
871. EDELSON JC, Rockey DC
     Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.
     Hepatology. 2021;74:2313-2314.
     PubMed    
     
     
     
872. LLEO A, Hirschfield GM
     Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
     Hepatology. 2021;74:2307.
     PubMed    
     
     
     
873. VILARINHO S, Ajmera V, Zheng M, Loomba R, et al
     Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.
     Hepatology. 2021;74:2241-2250.
     PubMed    
     
     
     
874. FRANCQUE S
     Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!
     Hepatology. 2021;74:1730-1733.
     PubMed    
     
     
     
875. ZHOU J, Hu M, He M, Wang X, et al
     TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.
     Hepatology. 2021;74:2133-2153.
     PubMed     Abstract available
     
     
     
876. MALESPIN M, May EJ, Nephew LD, Paul S, et al
     AASLD Deepens Commitment to Diversity, Equity, and Inclusion.
     Hepatology. 2021;74:2216-2225.
     PubMed    
     
     
     
877. WALTER A, Rudler M, Olivas P, Moga L, et al
     Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.
     Hepatology. 2021;74:2085-2101.
     PubMed     Abstract available
     
     
     
878. GEURTSEN ML, Wahab RJ, Felix JF, Gaillard R, et al
     Maternal Early-Pregnancy Glucose Concentrations and Liver Fat Among School-Age Children.
     Hepatology. 2021;74:1902-1913.
     PubMed     Abstract available
     
     
     
879. NI M, Zhang J, Sosa R, Zhang H, et al
     T-Cell Immunoglobulin and Mucin Domain-Containing Protein-4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury.
     Hepatology. 2021;74:2118-2132.
     PubMed     Abstract available
     
     
     
880. COLUCCI S, Altamura S, Marques O, Dropmann A, et al
     Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFbeta Pathway Activation.
     Hepatology. 2021;74:2186-2200.
     PubMed     Abstract available
     
     
     
881. IM YR, Hunter H, de Gracia Hahn D, Duret A, et al
     A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD.
     Hepatology. 2021;74:1884-1901.
     PubMed     Abstract available
     
     
     
882. BARROW F, Khan S, Wang H, Revelo XS, et al
     The Emerging Role of B Cells in the Pathogenesis of NAFLD.
     Hepatology. 2021;74:2277-2286.
     PubMed     Abstract available
     
     
     
883. CHOI WM, Ryu T, Lee JH, Shim YR, et al
     Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells.
     Hepatology. 2021;74:2170-2185.
     PubMed     Abstract available
     
     
     
884. CHEN L, Wu N, Kennedy L, Francis H, et al
     Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
     Hepatology. 2021;74:1845-1863.
     PubMed     Abstract available
     
     
     
885. DINANI AM, Kowdley KV, Noureddin M
     Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
     Hepatology. 2021;74:2233-2240.
     PubMed     Abstract available
     
     
     
886. YU H, He J, Liu W, Feng S, et al
     The Transcriptional Coactivator, ALL1-Fused Gene From Chromosome 9, Simultaneously Sustains Hypoxia Tolerance and Metabolic Advantages in Liver Cancer.
     Hepatology. 2021;74:1952-1970.
     PubMed     Abstract available
     
     
     
887. GAWRIEH S, Noureddin M, Loo N, Mohseni R, et al
     Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
     Hepatology. 2021;74:1809-1824.
     PubMed     Abstract available
     
     
     
888. LUO X, Xiang T, Wu J, Wang X, et al
     Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial.
     Hepatology. 2021;74:2074-2084.
     PubMed     Abstract available
     
     
     September 2021
889. FANG Y, Zhan Y, Xie Y, Du S, et al
     Integration of Glucose and Cardiolipin Anabolism Confers Radiation Resistance of Hepatocellular Carcinoma.
     Hepatology. 2021 Sep 28. doi: 10.1002/hep.32177.
     PubMed     Abstract available
     
     
     
890. LI H, Liu G, Wan X, Zhou L, et al
     ZBTB20 regulates plasma triglyceride metabolism by repressing lipoprotein lipase gene transcription in hepatocytes.
     Hepatology. 2021 Sep 28. doi: 10.1002/hep.32176.
     PubMed     Abstract available
     
     
     
891. GARCIA-TSAO G
     Can we rely on changes in HVPG in patients with cirrhosis?
     Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
     PubMed     Abstract available
     
     
     
892. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
     Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
     Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
     PubMed     Abstract available
     
     
     
893. DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
     Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
     Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
     PubMed     Abstract available
     
     
     
894. ZHAO Y, Gao L, Jiang C, Chen J, et al
     The Transcription Factor ZHX2 Alleviates Nonalcoholic Steatohepatitis by Transcriptional Activation of PTEN.
     Hepatology. 2021 Sep 21. doi: 10.1002/hep.32165.
     PubMed     Abstract available
     
     
     
895. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
     Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
     PubMed     Abstract available
     
     
     
896. ZHAI LL, Zhen SH, Tang ZG
     Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.
     Hepatology. 2021 Sep 18. doi: 10.1002/hep.32158.
     PubMed     Abstract available
     
     
     
897. FANG AP, Zhang YJ, Chen MS, Zhu HL, et al
     Response to "Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival".
     Hepatology. 2021 Sep 18. doi: 10.1002/hep.32160.
     PubMed     Abstract available
     
     
     
898. WANG S, Whitlock R, Xu C, Taneja S, et al
     Frailty is associated with increased risk of cirrhosis disease progression and death.
     Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
     PubMed     Abstract available
     
     
     
899. HUANG R, Liu J, Wang J, Li J, et al
     Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
     Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
     PubMed     Abstract available
     
     
     
900. DUAN J, Wang Z, Duan R, Yang C, et al
     Therapeutic Targeting of Hepatic ACSL4 Ameliorates Non-alcoholic Steatohepatitis in Mice.
     Hepatology. 2021 Sep 12. doi: 10.1002/hep.32148.
     PubMed     Abstract available
     
     
     
901. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
     The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
     Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
     PubMed     Abstract available
     
     
     
902. BLOOM PP, Fontana RJ
     With Alcohol as the fuel, COVID is the match: Liver Transplantation for Alcoholic liver disease is increasing in the United States.
     Hepatology. 2021 Sep 8. doi: 10.1002/hep.32141.
     PubMed     Abstract available
     
     
     
903. SHAH BJ, Onken JE, Edgar L, Jou JH, et al
     Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows.
     Hepatology. 2021 Sep 7. doi: 10.1002/hep.32097.
     PubMed    
     
     
     
904. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
     Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
     Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
     PubMed     Abstract available
     
     
     
905. ZHANG X, Yang H, Zeng S, Tian S, et al
     Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.
     Hepatology. 2021 Sep 5. doi: 10.1002/hep.32139.
     PubMed     Abstract available
     
     
     
906. AN J, Kim D, Oh B, Oh YJ, et al
     Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
     Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
     PubMed     Abstract available
     
     
     
907. GORES GJ, Malhi H
     Presenting the New Incoming Editorial Team for HEPATOLOGY: Team Members and Perspectives.
     Hepatology. 2021 Sep 2. doi: 10.1002/hep.32137.
     PubMed     Abstract available
     
     
     
908. KHAN IW, Ali MA, Lau DTY, Hang TP, et al
     Hepatology Highlights.
     Hepatology. 2021;74:1137-1140.
     PubMed    
     
     
     
909. RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
     Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
     Hepatology. 2021;74:1674-1686.
     PubMed     Abstract available
     
     
     
910. SHARMA S, Gunjan D, Saraya A
     Letter to the Editor: Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Rebleeding: A Paradigm Shift?
     Hepatology. 2021;74:1721-1722.
     PubMed    
     
     
     
911. ZHANG XP, Zhao GD, Liu Q, Liu R, et al
     Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion.
     Hepatology. 2021;74:1719.
     PubMed    
     
     
     
912. SEKAR D, K AP
     Letter to the Editor: H19 Promotes HCC Bone Metastasis by Reducing Osteoprotegerin Expression in a PPP1CA/p38MAPK-Dependent Manner and Sponging miR-200b-3p.
     Hepatology. 2021;74:1713.
     PubMed    
     
     
     
913. CRAXI L
     Letter to the Editor: Comment on "The Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases".
     Hepatology. 2021;74:1710.
     PubMed    
     
     
     
914. ALLEN AM, Neuschwander-Tetri BA
     The Importance of Glycemic Equipoise in NASH.
     Hepatology. 2021;74:1145-1147.
     PubMed    
     
     
     
915. JIANG X, Qian H, Ding WX
     New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer.
     Hepatology. 2021;74:1141-1144.
     PubMed    
     
     
     
916. WANG SS, Tang XT, Lin M, Yuan J, et al
     Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
     Hepatology. 2021;74:1578-1594.
     PubMed     Abstract available
     
     
     
917. NIU Y, Lin Z, Wan A, Sun L, et al
     Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.
     Hepatology. 2021;74:1461-1479.
     PubMed     Abstract available
     
     
     
918. STARLINGER P, Ahn JC, Mullan A, Gyoeri GP, et al
     The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
     Hepatology. 2021;74:1533-1545.
     PubMed     Abstract available
     
     
     
919. LAGO-HERNANDEZ C, Nguyen NH, Khera R, Loomba R, et al
     Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States.
     Hepatology. 2021;74:1509-1522.
     PubMed     Abstract available
     
     
     
920. LIU Y, Song J, Yang J, Zheng J, et al
     Tumor Necrosis Factor alpha-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
     Hepatology. 2021;74:1300-1318.
     PubMed     Abstract available
     
     
     
921. BEALS JW, Smith GI, Shankaran M, Fuchs A, et al
     Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease.
     Hepatology. 2021;74:1287-1299.
     PubMed     Abstract available
     
     
     
922. ANDREWS TS, MacParland SA
     A Spotlight on the Drivers of Inflammation in Acute Liver Failure.
     Hepatology. 2021;74:1687-1689.
     PubMed    
     
     
     
923. STRATAKIS N, Golden-Mason L, Margetaki K, Zhao Y, et al
     In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood.
     Hepatology. 2021;74:1546-1559.
     PubMed     Abstract available
     
     
     
924. KUSUMANCHI P, Liang T, Zhang T, Ross RA, et al
     Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling.
     Hepatology. 2021;74:1234-1250.
     PubMed     Abstract available
     
     
     
925. WANG Y, Hylemon PB, Zhou H
     Long Noncoding RNA H19: A Key Player in Liver Diseases.
     Hepatology. 2021;74:1652-1659.
     PubMed    
     
     
     August 2021
926. INNES H, Crooks CJ, Aspinall E, Card TR, et al
     Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
     Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
     PubMed     Abstract available
     
     
     
927. VARGHESE J, Malleswaran S, Mouleeswaran K
     Letter to the Editor: Toxin-induced Graft Injury following Liver Transplantation for Yellow Phosphorus Poisoning.
     Hepatology. 2021 Aug 28. doi: 10.1002/hep.32124.
     PubMed     Abstract available
     
     
     
928. PLUMMER MD, Regenstein F
     Light chain deposition disease: an unusual cause of portal hypertension.
     Hepatology. 2021 Aug 27. doi: 10.1002/hep.32118.
     PubMed     Abstract available
     
     
     
929. FU J, Hu F, Ma T, Zhao WJ, et al
     A conventional immune regulator MAVS blocks hepatic steatosis via maintaining mitochondrial homeostasis.
     Hepatology. 2021 Aug 26. doi: 10.1002/hep.32126.
     PubMed     Abstract available
     
     
     
930. IMAI N, Nicholls HT, Alves-Bezerra M, Li Y, et al
     Upregulation of Thioesterase Superfamily Member 2 in Skeletal Muscle Promotes Hepatic Steatosis and Insulin Resistance.
     Hepatology. 2021 Aug 25. doi: 10.1002/hep.32122.
     PubMed     Abstract available
     
     
     
931. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
     Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
     Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
     PubMed     Abstract available
     
     
     
932. FAN S, Gao Y, Qu A, Jiang Y, et al
     YAP-TEAD mediates peroxisome proliferator-activated receptor alpha-induced hepatomegaly and liver regeneration in mice.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32105.
     PubMed     Abstract available
     
     
     
933. FUCHS CD, Radun R, Dixon ED, Mlitz V, et al
     Hepatocyte-specific deletion of adipose triglyceride lipase (ATGL/PNPLA2) ameliorates dietary induced steatohepatitis in mice.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32112.
     PubMed     Abstract available
     
     
     
934. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
     Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
     PubMed     Abstract available
     
     
     
935. LIN Y, Cai Q, Chen Y, Shi T, et al
     CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
     PubMed     Abstract available
     
     
     
936. WADHWANI SI, Ge J, Gottlieb L, Lyles C, et al
     Racial/Ethnic Disparities in Wait List Outcomes Are Only Partly Explained by Socioeconomic Deprivation Among Children Awaiting Liver Transplantation.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32106.
     PubMed     Abstract available
     
     
     
937. ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
     Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
     Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
     PubMed     Abstract available
     
     
     
938. BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
     A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
     Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
     PubMed     Abstract available
     
     
     
939. WAHID N, Jesudian A, Buckholz A, Brown RS Jr, et al
     Hepatology Highlights.
     Hepatology. 2021;74:539-542.
     PubMed    
     
     
     
940. FIX OK, Blumberg EA, Chang KM, Chu J, et al
     American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.
     Hepatology. 2021;74:1049-1064.
     PubMed     Abstract available
     
     
     
941. SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
     Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
     Hepatology. 2021;74:1088-1100.
     PubMed     Abstract available
     
     
     
942. TROVATO FM, Zia R, Napoli S, Wolfer K, et al
     Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
     Hepatology. 2021;74:907-925.
     PubMed     Abstract available
     
     
     
943. CARTER J, Wang S, Friedman SL
     Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis.
     Hepatology. 2021;74:543-546.
     PubMed    
     
     
     
944. FONTANA RJ, Stravitz RT, Durkalski V, Hanje J, et al
     Prognostic Value of the (13) C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury.
     Hepatology. 2021;74:961-972.
     PubMed     Abstract available
     
     
     
945. REN H, Hu F, Wang D, Kang X, et al
     Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4alpha.
     Hepatology. 2021;74:723-740.
     PubMed     Abstract available
     
     
     
946. STRAVITZ RT, Fontana RJ, Meinzer C, Durkalski-Mauldin V, et al
     Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure.
     Hepatology. 2021;74:937-949.
     PubMed     Abstract available
     
     
     
947. LEE D, Zhang MS, Tsang FH, Bao MH, et al
     Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species.
     Hepatology. 2021;74:776-796.
     PubMed     Abstract available
     
     
     
948. VEERAMACHANENI H, Subramanian RM
     Combined High-Dose Continuous Renal Replacement Therapy and Plasma Exchange in the Management of Severe Multiorgan System Dysfunction Associated With Acute Liver Failure.
     Hepatology. 2021;74:1124-1126.
     PubMed    
     
     
     
949. TRIANTOS C, Aggeletopoulou I, Thomopoulos K, Mouzaki A, et al
     Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action.
     Hepatology. 2021;74:1065-1073.
     PubMed    
     
     
     July 2021
950. WIN S, Min RWM, Zhang J, Kanel G, et al
     Hepatic mitochondrial SAB deletion or knockdown alleviates diet induced metabolic syndrome, steatohepatitis and hepatic fibrosis.
     Hepatology. 2021 Jul 31. doi: 10.1002/hep.32083.
     PubMed     Abstract available
     
     
     
951. ZHANG Z, Ji Z, He J, Lu Y, et al
     GNAI2 exacerbates non-alcoholic steatohepatitis progression via regulating PRDX1-related inflammation and lipophagy.
     Hepatology. 2021 Jul 29. doi: 10.1002/hep.32078.
     PubMed     Abstract available
     
     
     
952. SUDA T, Yoshikawa S, Kanefuji T, Abe S, et al
     Suppression of Noncoding RNAs as Shared Early Genetic Events in Multistep Hepatocarcinogenesis.
     Hepatology. 2021 Jul 29. doi: 10.1002/hep.32077.
     PubMed     Abstract available
     
     
     
953. MA L, Xu A, Kang L, Cong R, et al
     LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.
     Hepatology. 2021 Jul 29. doi: 10.1002/hep.32079.
     PubMed     Abstract available
     
     
     
954. LIU G, Wang N, Zhang C, Li M, et al
     ALDOB depletion promotes hepatocellular carcinogenesis through activating insulin receptor signaling and lipogenesis.
     Hepatology. 2021 Jul 22. doi: 10.1002/hep.32064.
     PubMed     Abstract available
     
     
     
955. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
     Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
     Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
     PubMed     Abstract available
     
     
     
956. HU M, Zhang D, Xu H, Zhang Y, et al
     Salidroside activates the AMP-activated protein kinase pathway to suppress non-alcoholic steatohepatitis.
     Hepatology. 2021 Jul 22. doi: 10.1002/hep.32066.
     PubMed     Abstract available
     
     
     
957. HE Q, Liu M, Huang W, Chen X, et al
     IL-1beta-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1.
     Hepatology. 2021 Jul 20. doi: 10.1002/hep.32062.
     PubMed     Abstract available
     
     
     
958. YANG Q, Chen X, Zhang Y, Hu S, et al
     The E3 ubiquitin ligase RNF5 ameliorates nonalcoholic steatohepatitis via ubiquitin-mediated degradation of HRD1.
     Hepatology. 2021 Jul 17. doi: 10.1002/hep.32061.
     PubMed     Abstract available
     
     
     
959. PIANO S, Cardenas A
     Metabolomics to predict acute kidney injury in cirrhosis.
     Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
     PubMed     Abstract available
     
     
     
960. MILLER BM, Oderberg IM, Goessling W
     The Hepatic Nervous System in Development, Regeneration, and Disease.
     Hepatology. 2021 Jul 13. doi: 10.1002/hep.32055.
     PubMed     Abstract available
     
     
     
961. ZHENG J, Daniel CR, Hatia RI, Stuff J, et al
     Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study.
     Hepatology. 2021 Jul 7. doi: 10.1002/hep.32046.
     PubMed     Abstract available
     
     
     
962. LAI JC, Tandon P, Bernal W, Tapper EB, et al
     Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
     Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
     PubMed     Abstract available
     
     
     
963. KIM OK, Nam DE, Hahn YS
     The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
     Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
     PubMed     Abstract available
     
     
     
964. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
     Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
     Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
     PubMed     Abstract available
     
     
     
965. BUCKHOLZ A, Lucero C, Yang LM, Lau DTY, et al
     Hepatology Highlights.
     Hepatology. 2021;74:1-4.
     PubMed    
     
     
     
966. WILSON A, Beaton M, Brahmania M
     Letter to the Editor: Nonalcoholic Fatty Liver Disease-One Size May Not Fit All.
     Hepatology. 2021;74:528.
     PubMed    
     
     
     
967. DIENSTAG JL
     Introducing Raymond T. Chung, M.D., Our 2021 AASLD President.
     Hepatology. 2021;74:12-18.
     PubMed    
     
     
     
968. SZABO G
     Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD.
     Hepatology. 2021;74:5-8.
     PubMed    
     
     
     
969. PARTHASARATHY G, Malhi H
     Macrophage Heterogeneity in NASH: More Than Just Nomenclature.
     Hepatology. 2021;74:515-518.
     PubMed    
     
     
     
970. NOUREDDIN M
     Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans.
     Hepatology. 2021;74:9-11.
     PubMed    
     
     
     
971. HUANG Z, Chu L, Liang J, Tan X, et al
     H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.
     Hepatology. 2021;74:214-232.
     PubMed     Abstract available
     
     
     
972. TAYLOR-WEINER A, Pokkalla H, Han L, Jia C, et al
     A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
     Hepatology. 2021;74:133-147.
     PubMed     Abstract available
     
     
     
973. COPPLE IM, Park BK, Goldring CE
     Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening.
     Hepatology. 2021;74:513-515.
     PubMed    
     
     
     
974. HAGSTROM H, Adams LA, Allen AM, Byrne CD, et al
     Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.
     Hepatology. 2021;74:474-482.
     PubMed     Abstract available
     
     
     
975. HE Y, Shi M, Wu X, Ma J, et al
     Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer.
     Hepatology. 2021;74:264-280.
     PubMed     Abstract available
     
     
     
976. KENNEDY L, Meadows V, Sybenga A, Demieville J, et al
     Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
     Hepatology. 2021;74:164-182.
     PubMed     Abstract available
     
     
     
977. WANG H, Song X, Liao H, Wang P, et al
     Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
     Hepatology. 2021;74:248-263.
     PubMed     Abstract available
     
     
     
978. JIANG T, Sanchez-Rivera FJ, Soto-Feliciano YM, Yang Q, et al
     Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.
     Hepatology. 2021;74:233-247.
     PubMed     Abstract available
     
     
     
979. GOUDSMIT BFJ, Putter H, Tushuizen ME, Vogelaar S, et al
     Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.
     Hepatology. 2021;74:351-363.
     PubMed     Abstract available
     
     
     
980. BERNARDO-SEISDEDOS G, Bilbao J, Fernandez-Ramos D, Lopitz-Otsoa F, et al
     Metabolic Landscape of the Mouse Liver by Quantitative (31) P Nuclear Magnetic Resonance Analysis of the Phosphorome.
     Hepatology. 2021;74:148-163.
     PubMed     Abstract available
     
     
     
981. HOU X, Yin S, Ren R, Liu S, et al
     Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.
     Hepatology. 2021;74:116-132.
     PubMed     Abstract available
     
     
     
982. WOOD NL, Kernodle AB, Hartley AJ, Segev DL, et al
     Heterogeneous Circles for Liver Allocation.
     Hepatology. 2021;74:312-321.
     PubMed     Abstract available
     
     
     
983. POSE E, Coll M, Martinez-Sanchez C, Zeng Z, et al
     Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
     Hepatology. 2021;74:296-311.
     PubMed     Abstract available
     
     
     June 2021
984. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
     NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
     Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
     PubMed     Abstract available
     
     
     
985. GARATE-RASCON M, Recalde M, Jimenez M, Elizalde M, et al
     SLU7 prevents oxidative stress-mediated HNF4alpha degradation preserving hepatic differentiation and protecting from liver damage.
     Hepatology. 2021 Jun 25. doi: 10.1002/hep.32029.
     PubMed     Abstract available
     
     
     
986. HIRAO H, Ito T, Kadono K, Kojima H, et al
     Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
     Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
     PubMed     Abstract available
     
     
     
987. KRIEGERMEIER A, Hyon A, Sommars M, Hubchak S, et al
     Hepatic X-box binding protein 1 and unfolded protein response is impaired in weanling mice with resultant hepatic injury.
     Hepatology. 2021 Jun 25. doi: 10.1002/hep.32031.
     PubMed     Abstract available
     
     
     
988. CHOLANKERIL G, Kanwal F
     Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025.
     PubMed     Abstract available
     
     
     
989. TORRENS L, Montironi C, Puigvehi M, Mesropian A, et al
     Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.
     Hepatology. 2021 Jun 22. doi: 10.1002/hep.32023.
     PubMed     Abstract available
     
     
     
990. LIU H, Lee SS
     Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
     Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
     PubMed     Abstract available
     
     
     
991. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
     Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
     Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
     PubMed     Abstract available
     
     
     
992. SHI YF, Xie WZ
     Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
     Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
     PubMed     Abstract available
     
     
     
993. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
     Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
     Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
     PubMed     Abstract available
     
     
     
994. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
     The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
     Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
     PubMed     Abstract available
     
     
     
995. LEE YT, Wang JJ, Luu M, Noureddin M, et al
     Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
     Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
     PubMed     Abstract available
     
     
     
996. JINDAL A, Sharma S
     Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
     PubMed     Abstract available
     
     
     
997. SOLIPURAM V, Baretti M, Kim AY, Chen LX, et al
     Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.31998.
     PubMed     Abstract available
     
     
     
998. SHAH V, Iwakiri Y, Boyer JL
     Obituary for Roberto J. Groszmann - the Father of Portal Hypertension.
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.31996.
     PubMed     Abstract available
     
     
     
999. KOZUMI K, Kodama T, Murai H, Sakane S, et al
     Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
     Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
     PubMed     Abstract available
     
     
     
1000. CHO K, Ro SW, Lee HW, Moon H, et al
      YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation.
      Hepatology. 2021 Jun 8. doi: 10.1002/hep.32000.
      PubMed     Abstract available
      
      
      
1001. CHEN B, Wu JX, Cheng SH, Wang LM, et al
      Phase II study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma.
      Hepatology. 2021 Jun 7. doi: 10.1002/hep.31993.
      PubMed     Abstract available
      
      
      
1002. JINDAL A, Jagdish RK
      Response to terlipressin plus albumin in Hepatorenal syndrome - Need a closer look!
      Hepatology. 2021 Jun 6. doi: 10.1002/hep.31990.
      PubMed     Abstract available
      
      
      
1003. WONG TC, Lee VH, Law AL, Pang HH, et al
      Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
      Hepatology. 2021 Jun 6. doi: 10.1002/hep.31992.
      PubMed     Abstract available
      
      
      
1004. YANG W, He H, Wang T, Su N, et al
      Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
      Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
      PubMed     Abstract available
      
      
      
1005. MUHAMMAD KHAN M, Alejandra Luna-Cuadros M, Lau DTY, Sehrawat TS, et al
      Hepatology Highlights.
      Hepatology. 2021;73:2085-2088.
      PubMed    
      
      
      
1006. ROSENBLATT R, Lee H, Liapakis A, Lunsford KE, et al
      Equitable access to liver transplant: Bridging the gaps in the social determinants of health.
      Hepatology. 2021 Jun 1. doi: 10.1002/hep.31986.
      PubMed     Abstract available
      
      
      
1007. KULKARNI AV, Kumar P, Sharma M, Menon B, et al
      Letter to the Editor: Living Donor Liver Transplantation or Deceased Donor Liver Transplantation in High Model for End-Stage Liver Disease Score-Which Is Better?
      Hepatology. 2021;73:2619-2620.
      PubMed    
      
      
      
1008. VUPPALANCHI R, Loomba R
      Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box.
      Hepatology. 2021;73:2095-2098.
      PubMed    
      
      
      
1009. CASSINOTTO C, Boursier J, Paisant A, Guiu B, et al
      Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
      Hepatology. 2021;73:2196-2205.
      PubMed     Abstract available
      
      
      
1010. LIN Q, Huang Z, Cai G, Fan X, et al
      Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
      Hepatology. 2021;73:2206-2222.
      PubMed     Abstract available
      
      
      
1011. KENNEDY L, Francis H, Alpini G
      Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn't So Sweet.
      Hepatology. 2021;73:2092-2094.
      PubMed    
      
      
      
1012. CHO YE, Kim DK, Seo W, Gao B, et al
      Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress.
      Hepatology. 2021;73:2180-2195.
      PubMed     Abstract available
      
      
      
1013. MARTINS PN, Clavien PA, Jalan R, Ghinolfi D, et al
      A Call for Randomization in Clinical Trials of Liver Machine Perfusion Preservation.
      Hepatology. 2021;73:2586-2591.
      PubMed    
      
      
      
1014. MOON JH, Stormon MO
      Sucrose Toxicity in Infants.
      Hepatology. 2021;73:2607-2609.
      PubMed    
      
      
      
1015. AHN JC, Connell A, Simonetto DA, Hughes C, et al
      Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases.
      Hepatology. 2021;73:2546-2563.
      PubMed     Abstract available
      
      
      
1016. HOOFNAGLE JH, Bonkovsky HL, Phillips EJ, Li YJ, et al
      HLA-B*35:01 and Green Tea-Induced Liver Injury.
      Hepatology. 2021;73:2484-2493.
      PubMed     Abstract available
      
      
      
1017. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
      Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
      Hepatology. 2021;73:2397-2410.
      PubMed     Abstract available
      
      
      May 2021
1018. VIVEIROS A, Schaefer B, Panzer M, Henninger B, et al
      MRI-based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of non-HFE Hemochromatosis Genes.
      Hepatology. 2021 May 28. doi: 10.1002/hep.31982.
      PubMed     Abstract available
      
      
      
1019. LEPORE A, Choy PM, Lee NC, Carella MA, et al
      Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
      Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
      PubMed     Abstract available
      
      
      
1020. JOHNSTON ME 2ND, Rivas MP, Nicolle D, Gorse A, et al
      Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient Derived Xenograft Models.
      Hepatology. 2021 May 26. doi: 10.1002/hep.31919.
      PubMed     Abstract available
      
      
      
1021. YI C, Chen L, Ling Z, Liu L, et al
      Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma.
      Hepatology. 2021 May 26. doi: 10.1002/hep.31921.
      PubMed     Abstract available
      
      
      
1022. SUN LY, Hu JY, Liang L, Tong XM, et al
      Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
      Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
      PubMed     Abstract available
      
      
      
1023. JOHN BV, Deng Y, Martin P, Levy C, et al
      Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
      Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
      PubMed     Abstract available
      
      
      
1024. MEHTA G, Jalan R
      The 'Alter Ego' of Albumin in Cirrhosis.
      Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
      PubMed     Abstract available
      
      
      
1025. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
      Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
      Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
      PubMed     Abstract available
      
      
      
1026. JANSSON H, Sparrelid E
      Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
      Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
      PubMed     Abstract available
      
      
      
1027. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
      Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
      Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
      PubMed     Abstract available
      
      
      
1028. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
      Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
      Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
      PubMed     Abstract available
      
      
      
1029. PEISELER M, Tacke F
      An unexpected line of defense: hepatoprotective eosinophils in ischemia-reperfusion injury.
      Hepatology. 2021 May 11. doi: 10.1002/hep.31895.
      PubMed     Abstract available
      
      
      
1030. VALSAN A, Verma N, Singh V
      Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
      Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
      PubMed     Abstract available
      
      
      
1031. ELKRIEF L, Lazareth M, Rautou PE
      Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
      Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
      PubMed     Abstract available
      
      
      
1032. DICHTEL LE
      The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
      Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
      PubMed     Abstract available
      
      
      
1033. BIGGINS SW, Angeli P, Garcia-Tsao G, Gines P, et al
      Diagnosis, evaluation, and management of ascites and hepatorenal syndrome.
      Hepatology. 2021 May 3. doi: 10.1002/hep.31884.
      PubMed     Abstract available
      
      
      
1034. LIU Y, Dou X, Zhou WY, Ding M, et al
      Hepatic SENP2 Controls Systemic Metabolism via SUMOylation-dependent Regulation of Liver-Adipose Tissue Crosstalk.
      Hepatology. 2021 May 2. doi: 10.1002/hep.31881.
      PubMed     Abstract available
      
      
      
1035. BUCKHOLZ A, Jesudian A, Sehrawat TS, Sehrawat O, et al
      Hepatology Highlights.
      Hepatology. 2021;73:1627-1630.
      PubMed    
      
      
      
1036. 
      Seeking Editor for Hepatology Communications.
      Hepatology. 2021;73:i.
      PubMed    
      
      
      
1037. LEI MML, Lee TKW
      Cancer-Associated Fibroblasts: Orchestrating the Crosstalk Between Liver Cancer Cells and Neutrophils Through the Cardiotrophin-Like Cytokine Factor 1-Mediated Chemokine (C-X-C motif) Ligand 6/TGF-beta Axis.
      Hepatology. 2021;73:1631-1633.
      PubMed    
      
      
      
1038. LEE WM, Kaplowitz N
      Alcohol, Fasting, and Therapeutic Dosing of Acetaminophen: A Perfect Storm.
      Hepatology. 2021;73:1634-1636.
      PubMed    
      
      
      
1039. LOUVET A, Ntandja Wandji LC, Lemaitre E, Khaldi M, et al
      Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study.
      Hepatology. 2021;73:1945-1955.
      PubMed     Abstract available
      
      
      
1040. ASRANI SK, Mellinger J, Arab JP, Shah VH, et al
      Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action.
      Hepatology. 2021;73:2039-2050.
      PubMed     Abstract available
      
      
      
1041. SUNDARAM V, Jalan R, Shah P, Singal AK, et al
      Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality.
      Hepatology. 2021;73:1932-1944.
      PubMed     Abstract available
      
      
      
1042. HAFNER S, Seufferlein T, Kleger A, Muller M, et al
      Aseptic Liver Abscesses as an Exceptional Finding in Cogan's Syndrome.
      Hepatology. 2021;73:2067-2070.
      PubMed    
      
      
      
1043. LI Z, Lu X, Liu Y, Zhao J, et al
      Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex.
      Hepatology. 2021;73:1764-1782.
      PubMed     Abstract available
      
      
      
1044. DAVULURI G, Welch N, Sekar J, Gangadhariah M, et al
      Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate-Activated Protein Kinase, Causing Sarcopenia in Alcohol-Associated Liver Disease.
      Hepatology. 2021;73:1892-1908.
      PubMed     Abstract available
      
      
      
1045. MA Y, Brown PM, Lin DD, Ma J, et al
      17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
      Hepatology. 2021;73:1701-1716.
      PubMed     Abstract available
      
      
      
1046. DRIEVER EG, Stravitz RT, Zhang J, Adelmeijer J, et al
      VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.
      Hepatology. 2021;73:1882-1891.
      PubMed     Abstract available
      
      
      April 2021
1047. SHENG J, Kohno S, Okada N, Okahashi N, et al
      Treatment of RB1-intact hepatocellular carcinoma with CDK4/6 inhibitor combination therapy.
      Hepatology. 2021 Apr 30. doi: 10.1002/hep.31872.
      PubMed     Abstract available
      
      
      
1048. BUCKARMA E, Smoot R
      Hepatocytes Induce Change in Their Neighbors by YAP-ing at Them.
      Hepatology. 2021 Apr 30. doi: 10.1002/hep.31874.
      PubMed     Abstract available
      
      
      
1049. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
      Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
      Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
      PubMed     Abstract available
      
      
      
1050. LUO Y, Gao Y, Liu W, Yang Y, et al
      MYC-Protein Arginine Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
      Hepatology. 2021 Apr 25. doi: 10.1002/hep.31864.
      PubMed     Abstract available
      
      
      
1051. YANG X, Sun D, Xiang H, Wang S, et al
      Hepatocyte SH3RF2 Deficiency is a Key Aggravator for Nonalcoholic Fatty Liver Disease.
      Hepatology. 2021 Apr 24. doi: 10.1002/hep.31863.
      PubMed     Abstract available
      
      
      
1052. LIU D, Pang J, Shao W, Gu J, et al
      Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge.
      Hepatology. 2021 Apr 13. doi: 10.1002/hep.31856.
      PubMed     Abstract available
      
      
      
1053. XU X, Ye L, Zhang Q, Shen H, et al
      Group-2 Innate Lymphoid Cells Promote Hepatocellular Carcinoma Progression via CXCL2-Neutrophil Induced Immunosuppression.
      Hepatology. 2021 Apr 8. doi: 10.1002/hep.31855.
      PubMed     Abstract available
      
      
      
1054. SUN D, Yang X, Wu B, Zhang XJ, et al
      Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis.
      Hepatology. 2021 Apr 7. doi: 10.1002/hep.31852.
      PubMed     Abstract available
      
      
      
1055. WING-SUM CHEU J, Chak-Lui Wong C
      Mechanistic Rationales guiding Combination Hepatocellular Carcinoma Therapies involving Immune Checkpoint Inhibitors.
      Hepatology. 2021 Apr 3. doi: 10.1002/hep.31840.
      PubMed     Abstract available
      
      
      
1056. KOVALIC AJ, Huang G, Thuluvath PJ, Satapathy SK, et al
      Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.
      Hepatology. 2021;73:1521-1530.
      PubMed     Abstract available
      
      
      
1057. FU Y, Zhu R, Bai T, Han P, et al
      Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
      Hepatology. 2021;73:1509-1520.
      PubMed     Abstract available
      
      
      
1058. KAUR SP, Trivedi H, Lau DTY, Bamidele AO, et al
      Hepatology Highlights.
      Hepatology. 2021;73:1245-1247.
      PubMed    
      
      
      
1059. 
      Seeking Editor for Hepatology Communications.
      Hepatology. 2021;73:i.
      PubMed    
      
      
      
1060. DE ZEGHER F, Ibanez L
      Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss.
      Hepatology. 2021;73:1623-1624.
      PubMed    
      
      
      
1061. GOLRIZ M, Ramouz A, Mehrabi A
      Letter to the Editor: Surgical Method for Establishing Posthepatectomy Liver Failure.
      Hepatology. 2021;73:1621.
      PubMed    
      
      
      
1062. DHAR D, Loomba R
      Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH.
      Hepatology. 2021;73:1248-1250.
      PubMed    
      
      
      
1063. XU H, Tian Y, Tang D, Zou S, et al
      An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD.
      Hepatology. 2021;73:1327-1345.
      PubMed     Abstract available
      
      
      
1064. SONG Z, Chen W, Athavale D, Ge X, et al
      Osteopontin Takes Center Stage in Chronic Liver Disease.
      Hepatology. 2021;73:1594-1608.
      PubMed     Abstract available
      
      
      
1065. ALKHOURI N, Reddy GK, Lawitz E
      Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases.
      Hepatology. 2021;73:1581-1593.
      PubMed    
      
      
      
1066. ARJUNAN V, Hansen A, Deutzmann A, Sze DY, et al
      Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer.
      Hepatology. 2021;73:1611-1614.
      PubMed    
      
      
      
1067. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
      Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
      Hepatology. 2021;73:1399-1418.
      PubMed     Abstract available
      
      
      
1068. CHEN L, Guo P, Li W, Fang F, et al
      Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
      Hepatology. 2021;73:1551-1569.
      PubMed     Abstract available
      
      
      March 2021
1069. ROSENBLATT R, Wahid N, Halazun KJ, Kaplan A, et al
      Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States.
      Hepatology. 2021 Mar 29. doi: 10.1002/hep.31837.
      PubMed     Abstract available
      
      
      
1070. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
      A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
      Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
      PubMed     Abstract available
      
      
      
1071. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
      Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
      Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
      PubMed     Abstract available
      
      
      
1072. KENDRE G, Marhenke S, Lorz G, Becker D, et al
      The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
      Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
      PubMed     Abstract available
      
      
      
1073. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
      Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
      Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
      PubMed     Abstract available
      
      
      
1074. VANDERWERKEN D, Wood NL, Segev D, Gentry S, et al
      The Precise Relationship Between MELD and Survival Without a Liver Transplant.
      Hepatology. 2021 Mar 2. doi: 10.1002/hep.31781.
      PubMed     Abstract available
      
      
      
1075. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
      Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
      Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
      PubMed     Abstract available
      
      
      
1076. MCHENRY SA, Davidson NO
      Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Diet-Induced NASH.
      Hepatology. 2021;73:884-886.
      PubMed    
      
      
      
1077. MELLINGER J, Winder GS, Fernandez AC
      Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research.
      Hepatology. 2021;73:1207-1212.
      PubMed    
      
      
      
1078. WEGERMANN K, Suzuki A, Mavis AM, Abdelmalek MF, et al
      Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations.
      Hepatology. 2021;73:1199-1206.
      PubMed    
      
      
      
1079. PAPAROUPA M, Schrader J, Jung C, Boenisch O, et al
      Bilateral Hematothorax Without Hematemesis-An Unusual Presentation of Variceal Bleeding.
      Hepatology. 2021;73:1233-1235.
      PubMed    
      
      
      
1080. GODBEE M, Jakate S, Eswaran S
      A Case of Electronic Nicotine Delivery Systems (ENDS) Liver Injury.
      Hepatology. 2021;73:1230-1232.
      PubMed    
      
      
      
1081. YOUNOSSI ZM, Rinella ME, Sanyal AJ, Harrison SA, et al
      From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
      Hepatology. 2021;73:1194-1198.
      PubMed     Abstract available
      
      
      
1082. PROTCHENKO O, Baratz E, Jadhav S, Li F, et al
      Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis.
      Hepatology. 2021;73:1176-1193.
      PubMed     Abstract available
      
      
      February 2021
1083. HERCUN J, Parikh E, Kleiner DE, Fuss I, et al
      Recurrent nodular regenerative hyperplasia post-liver transplantation in common variable immunodeficiency.
      Hepatology. 2021 Feb 27. doi: 10.1002/hep.31775.
      PubMed     Abstract available
      
      
      
1084. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
      HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
      Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
      PubMed     Abstract available
      
      
      
1085. NASSER-GHODSI N, Mara K, Watt KD
      De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
      Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
      PubMed     Abstract available
      
      
      
1086. DI GUGLIELMO MD, Perito ER
      To Juice or Not to Juice: Fatty Liver Repercussions for Infants.
      Hepatology. 2021;73:483-485.
      PubMed    
      
      
      
1087. PIROLA CJ, Sookoian S
      NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
      Hepatology. 2021;73:479-482.
      PubMed    
      
      
      
1088. GEURTSEN ML, Santos S, Gaillard R, Felix JF, et al
      Associations Between Intake of Sugar-Containing Beverages in Infancy With Liver Fat Accumulation at School Age.
      Hepatology. 2021;73:560-570.
      PubMed     Abstract available
      
      
      
1089. TILG H, Adolph TE, Moschen AR
      Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade.
      Hepatology. 2021;73:833-842.
      PubMed    
      
      
      
1090. AL-NAAMANI N, Krowka MJ, Forde KA, Krok KL, et al
      Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
      Hepatology. 2021;73:726-737.
      PubMed     Abstract available
      
      
      
1091. JUNG YS, Stratton SA, Lee SH, Kim MJ, et al
      TMEM9-v-ATPase Activates Wnt/beta-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis.
      Hepatology. 2021;73:776-794.
      PubMed     Abstract available
      
      
      
1092. HU W, Zheng S, Guo H, Dai B, et al
      PLAGL2-EGFR-HIF-1/2alpha Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
      Hepatology. 2021;73:674-691.
      PubMed     Abstract available
      
      
      
1093. ZUO Q, He J, Zhang S, Wang H, et al
      PPARgamma Coactivator-1alpha Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARgamma-Dependent WNT/beta-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.
      Hepatology. 2021;73:644-660.
      PubMed     Abstract available
      
      
      January 2021
1094. ITOH A, Adams D, Huang W, Wu Y, et al
      Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
      Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
      PubMed     Abstract available
      
      
      
1095. JAESCHKE H, Ramachandran A
      Letter to the Editor: Does c-Jun N-Terminal Kinase Regulate Acetaminophen Hepatotoxicity by Modulating Nuclear Factor Erythroid 2-Related Factor 2-Dependent Genes or Mitochondrial Oxidant Stress?
      Hepatology. 2021;73:467-468.
      PubMed    
      
      
      
1096. TANG X, Wang XJ
      REPLY.
      Hepatology. 2021;73:468-469.
      PubMed    
      
      
      
1097. CHOI J, Lim YS
      REPLY.
      Hepatology. 2021;73:467.
      PubMed    
      
      
      
1098. CASEY L, Aday A, Rule J, Lee WM, et al
      Letter to the Editor: Response to Letter Concerning Our Pregnancy Manuscript.
      Hepatology. 2021;73:465.
      PubMed    
      
      
      
1099. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
      Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
      Hepatology. 2021;73:366-413.
      PubMed    
      
      
      
1100. SARKAR M, Brady CW, Fleckenstein J, Forde KA, et al
      Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.
      Hepatology. 2021;73:318-365.
      PubMed    
      
      
      
1101. DE JONGHE S, Weinstock D, Aligo J, Washington K, et al
      Biopsy Pathology and Immunohistochemistry of a Case of Immune-Mediated Drug-Induced Liver Injury With Atabecestat.
      Hepatology. 2021;73:452-455.
      PubMed    
      
      
      
1102. LEONIS MA, Miethke AG, Fei L, Maynor S, et al
      Four Biomarkers Linked to Activation of Cluster of Differentiation 8-Positive Lymphocytes Predict Clinical Outcomes in Pediatric Acute Liver Failure.
      Hepatology. 2021;73:233-246.
      PubMed     Abstract available
      
      
      
1103. LI YJ, Phillips EJ, Dellinger A, Nicoletti P, et al
      Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
      Hepatology. 2021;73:268-281.
      PubMed     Abstract available
      
      
      
1104. MORENO E, Toussaint MJM, van Essen SC, Bongiovanni L, et al
      E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
      Hepatology. 2021;73:303-317.
      PubMed     Abstract available
      
      
      
1105. GU L, Zhu Y, Lin X, Lu B, et al
      The IKKbeta-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.
      Hepatology. 2021;73:160-174.
      PubMed     Abstract available
      
      
      
1106. ZHOU B, Liu C, Xu L, Yuan Y, et al
      N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes.
      Hepatology. 2021;73:91-103.
      PubMed     Abstract available
      
      
      
1107. CABALLERO-CAMINO FJ, Rivilla I, Herraez E, Briz O, et al
      Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
      Hepatology. 2021;73:186-203.
      PubMed     Abstract available
      
      
      
1108. FENG GS, Hanley KL, Liang Y, Lin X, et al
      Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
      Hepatology. 2021;73 Suppl 1:104-114.
      PubMed     Abstract available
      
      
      
1109. RIZVI S, Wang J, El-Khoueiry AB
      Liver Cancer Immunity.
      Hepatology. 2021;73 Suppl 1:86-103.
      PubMed    
      
      
      
1110. CARUSO S, O'Brien DR, Cleary SP, Roberts LR, et al
      Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity.
      Hepatology. 2021;73 Suppl 1:14-26.
      PubMed    
      
      
      
1111. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
      Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
      Hepatology. 2021;73 Suppl 1:49-61.
      PubMed     Abstract available
      
      
      
1112. PEA A, Jamieson NB, Braconi C
      Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma.
      Hepatology. 2021;73 Suppl 1:38-48.
      PubMed     Abstract available
      
      
      December 2020
1113. NOUREDDIN N, Alkhouri N, Brown KA, Noureddin M, et al
      Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.
      Hepatology. 2020;72:2228-2230.
      PubMed    
      
      
      
1114. MEHTA N, Yao FY
      Reply.
      Hepatology. 2020;72:2243-2244.
      PubMed    
      
      
      
1115. SELCK TJ, Bok J, Amintavakoli R
      Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
      Hepatology. 2020;72:2239.
      PubMed    
      
      
      
1116. VENTURA-COTS M, Abraldes JG, Bataller R
      Reply.
      Hepatology. 2020;72:2239-2240.
      PubMed    
      
      
      November 2020
1117. KWON HM, Moon YJ, Kim KS, Shin WJ, et al
      Prognostic value of B-type natriuretic peptide in liver transplant patients: Implication in post-transplant mortality.
      Hepatology. 2020 Nov 28. doi: 10.1002/hep.31661.
      PubMed     Abstract available
      
      
      
1118. BARMAN PM, VanWagner LB
      Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.
      Hepatology. 2020 Nov 20. doi: 10.1002/hep.31647.
      PubMed     Abstract available
      
      
      
1119. LOUSTAUD-RATTI V, Anneraud A, Carrier P, Debette-Gratien M, et al
      Letter to the Editor: Post-Liver Transplantation Sinusoidal Obstruction Syndrome and immunosuppressive drugs: causality of MMF or tacrolimus?
      Hepatology. 2020 Nov 13. doi: 10.1002/hep.31633.
      PubMed     Abstract available
      
      
      
1120. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
      Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
      Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
      PubMed     Abstract available
      
      
      
1121. CAVE MC
      Environmental Pollution and the Developmental Origins of Childhood Liver Disease.
      Hepatology. 2020;72:1518-1521.
      PubMed    
      
      
      
1122. JAESCHKE H, Ramachandran A
      Pleiotropic Roles of Platelets and Neutrophils in Cell Death and Recovery During Acetaminophen Hepatotoxicity.
      Hepatology. 2020;72:1873-1876.
      PubMed    
      
      
      
1123. SINGH S, Verma N, Singh V
      Letter to the Editor: MELD-Lactate-the New Kid on the Block.
      Hepatology. 2020;72:1883.
      PubMed    
      
      
      October 2020
1124. ANTKOWIAK M, Green RM
      Telomeres, p53, Hepatocyte Nuclear Factor 4alpha, and Liver Disease.
      Hepatology. 2020;72:1166-1168.
      PubMed    
      
      
      
1125. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
      Reply.
      Hepatology. 2020;72:1494-1495.
      PubMed    
      
      
      
1126. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
      Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
      Hepatology. 2020;72:1310-1326.
      PubMed     Abstract available
      
      
      September 2020
1127. JASPER S, Hakeem AR, Vij M, Sachan D, et al
      First report of toxin-induced graft injury following liver transplantation for Yellow Phosphorus Poisoning.
      Hepatology. 2020 Sep 16. doi: 10.1002/hep.31553.
      PubMed     Abstract available
      
      
      
1128. CHEN L, Zhou T, White T, O'Brien A, et al
      The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
      Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
      PubMed     Abstract available
      
      
      
1129. JIANG X, Ding WX
      Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids?
      Hepatology. 2020;72:797-800.
      PubMed    
      
      
      
1130. GUICCIARDI ME, Nakao Y, Gores GJ
      The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis.
      Hepatology. 2020;72:1139-1141.
      PubMed    
      
      
      
1131. KUMAR M
      Reply.
      Hepatology. 2020;72:1160.
      PubMed    
      
      
      
1132. WEISS TS, Melter M, Dayoub R
      Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression?
      Hepatology. 2020;72:1156-1157.
      PubMed    
      
      
      
1133. VERMA AK, Gandhi CR
      Reply.
      Hepatology. 2020;72:1157-1158.
      PubMed    
      
      
      August 2020
1134. FRISSEN M, Liao L, Schneider KM, Djudjaj S, et al
      Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury.
      Hepatology. 2020 Aug 4. doi: 10.1002/hep.31494.
      PubMed     Abstract available
      
      
      
1135. WEN Y, Ju C
      MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
      Hepatology. 2020;72:772-774.
      PubMed    
      
      
      
1136. SINHA RA, Bruinstroop E, Singh BK, Yen PM, et al
      Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
      Hepatology. 2020;72:770-771.
      PubMed    
      
      
      
1137. GAWRIEH S, Kleiner DE, Chalasani N, Vanderbeck S, et al
      Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease.
      Hepatology. 2020;72:785.
      PubMed    
      
      
      
1138. WEI L, Chang PEJ, Anstee QM
      Reply.
      Hepatology. 2020;72:786.
      PubMed    
      
      
      
1139. KWON HM, Hwang GS
      Reply.
      Hepatology. 2020;72:784.
      PubMed    
      
      
      
1140. HUANG JF, Dai CY, Yu ML, Chuang WL, et al
      Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
      Hepatology. 2020;72:781.
      PubMed    
      
      
      July 2020
1141. AMZAL R, Thebaut A, Lapalus M, Almes M, et al
      Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
      Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
      PubMed     Abstract available
      
      
      
1142. WANG Y
      Letter to the Editor: Issues of Circular RNAs as MicroRNA Sponges.
      Hepatology. 2020;72:365.
      PubMed    
      
      
      
1143. LI L, Wei Y, Wang H
      REPLY.
      Hepatology. 2020;72:366.
      PubMed    
      
      
      
1144. HOOFNAGLE JH
      FXR Agonists as Therapy for Liver Disease.
      Hepatology. 2020;72:1-3.
      PubMed    
      
      
      
1145. MALLAT A, Lotersztajn S
      Glutamate Signaling in Alcohol-associated Fatty Liver: "Pas de Deux".
      Hepatology. 2020;72:350-352.
      PubMed    
      
      
      
1146. SU T, Iwakiri Y
      Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
      Hepatology. 2020;72:347-349.
      PubMed    
      
      
      
1147. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
      Reply.
      Hepatology. 2020;72:364-365.
      PubMed    
      
      
      
1148. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
      REPLY.
      Hepatology. 2020;72:362-363.
      PubMed    
      
      
      
1149. ARASE Y, Kagawa T, Tanaka A
      Reply.
      Hepatology. 2020;72:360-361.
      PubMed    
      
      
      
1150. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
      Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
      Hepatology. 2020;72:359-360.
      PubMed    
      
      
      June 2020
1151. ABUD A, Maddur H, Salem R
      Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
      Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
      PubMed     Abstract available
      
      
      
1152. KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
      Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
      Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
      PubMed     Abstract available
      
      
      
1153. THALJI L, Thalji NM, Heimbach JK, Ibrahim SH, et al
      Renal Function Parameters and Serum Sodium Enhance Prediction of Waitlist Outcomes in Pediatric Liver Transplantation.
      Hepatology. 2020 Jun 2. doi: 10.1002/hep.31397.
      PubMed     Abstract available
      
      
      
1154. LUCEY MR, Singal AK
      Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
      Hepatology. 2020;71:1891-1893.
      PubMed    
      
      
      May 2020
1155. GABR A, Kulik L, Mouli S, Riaz A, et al
      Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort.
      Hepatology. 2020 May 16. doi: 10.1002/hep.31318.
      PubMed     Abstract available
      
      
      
1156. ZHOU J, Zhou F, Wang W, Zhang XJ, et al
      Epidemiological Features of NAFLD From 1999 to 2018 in China.
      Hepatology. 2020;71:1851-1864.
      PubMed     Abstract available
      
      
      
1157. CHEN Y, Liu K, Zhang J, Hai Y, et al
      c-Jun NH2 -Terminal Protein Kinase Phosphorylates the Nrf2-ECH Homology 6 Domain of Nuclear Factor Erythroid 2-Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen-Induced Liver Injury in Mice.
      Hepatology. 2020;71:1787-1801.
      PubMed     Abstract available
      
      
      
1158. GAO W, Jia Z, Tian Y, Yang P, et al
      HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
      Hepatology. 2020;71:1678-1695.
      PubMed     Abstract available
      
      
      
1159. FLEMING BD, Urban DJ, Hall MD, Longerich T, et al
      Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
      Hepatology. 2020;71:1696-1711.
      PubMed     Abstract available
      
      
      
1160. XIE C, Zhang LZ, Chen ZL, Zhong WJ, et al
      A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
      Hepatology. 2020;71:1660-1677.
      PubMed     Abstract available
      
      
      April 2020
1161. KHALAF RT, Sokol RJ
      New Insights Into Intestinal Failure-Associated Liver Disease in Children.
      Hepatology. 2020;71:1486-1498.
      PubMed     Abstract available
      
      
      
1162. XIONG X, Kuang H, Liu T, Lin JD, et al
      A Single-Cell Perspective of the Mammalian Liver in Health and Disease.
      Hepatology. 2020;71:1467-1473.
      PubMed    
      
      
      
1163. IBRAHIM SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, et al
      Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.
      Hepatology. 2020;71:1474-1485.
      PubMed     Abstract available
      
      
      
1164. XIONG J, Liu T, Mi L, Kuang H, et al
      hnRNPU/TrkB Defines a Chromatin Accessibility Checkpoint for Liver Injury and Nonalcoholic Steatohepatitis Pathogenesis.
      Hepatology. 2020;71:1228-1246.
      PubMed     Abstract available
      
      
      
1165. LIU J, Wu Z, Han D, Wei C, et al
      Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-kappaB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
      Hepatology. 2020;71:1262-1278.
      PubMed     Abstract available
      
      
      
1166. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
      Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
      Hepatology. 2020;71:1331-1349.
      PubMed     Abstract available
      
      
      
1167. CHEN F, Esmaili S, Rogers GB, Bugianesi E, et al
      Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
      Hepatology. 2020;71:1213-1227.
      PubMed     Abstract available
      
      
      
1168. ZHANG C, Lin R, Li Z, Yang S, et al
      Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
      Hepatology. 2020;71:1297-1315.
      PubMed     Abstract available
      
      
      
1169. SHIGETA K, Datta M, Hato T, Kitahara S, et al
      Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
      Hepatology. 2020;71:1247-1261.
      PubMed     Abstract available
      
      
      March 2020
1170. SCHWACHA-EIPPER B, Minciuna I, Banz V, Dufour JF, et al
      Immunotherapy as a downstaging therapy for liver transplantation.
      Hepatology. 2020 Mar 14. doi: 10.1002/hep.31234.
      PubMed     Abstract available
      
      
      
1171. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
      Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
      Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
      PubMed     Abstract available
      
      
      February 2020
1172. NAULT JC, Villanueva A
      Biomarkers for hepatobiliary cancers.
      Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
      PubMed     Abstract available
      
      
      
1173. DEROO R, Trepo E, Holvoet T, De Pauw M, et al
      Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.
      Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164.
      PubMed     Abstract available
      
      
      January 2020
1174. WALLACE D, Cowling T, PcPhail MJ, Brown SE, et al
      Assessing the time-dependent impact of performance status on outcomes after liver transplantation.
      Hepatology. 2020 Jan 22. doi: 10.1002/hep.31124.
      PubMed     Abstract available
      
      
      December 2019
1175. GAO E, Cheema H, Waheed N, Mushtaq I, et al
      OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
      Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
      PubMed     Abstract available
      
      
      November 2019
1176. GYORI GP, Pereyra D, Rumpf B, Hackl H, et al
      Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.
      Hepatology. 2019 Nov 27. doi: 10.1002/hep.31047.
      PubMed     Abstract available
      
      
      
1177. LEE BP, Vittinghoff E, Pletcher MJ, Dodge JL, et al
      Medicaid Policy and Liver Transplant for Alcohol-Related Liver Disease.
      Hepatology. 2019 Nov 8. doi: 10.1002/hep.31027.
      PubMed     Abstract available
      
      
      
1178. KUTKUT I, Rachwan RJ, Timsina LR, Ghabril MS, et al
      Pre-Liver Transplant Cardiac Catheterization is Associated with Low Rate of Myocardial Infarction and Cardiac Mortality.
      Hepatology. 2019 Nov 7. doi: 10.1002/hep.31023.
      PubMed     Abstract available
      
      
      
1179. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
      Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
      Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
      PubMed     Abstract available
      
      
      October 2019
1180. POLI E, Kounis I, Guettier C, Verstuyft C, et al
      Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
      Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
      PubMed     Abstract available
      
      
      
1181. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
      Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
      Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
      PubMed     Abstract available
      
      
      September 2019
1182. KIM YC, Jung H, Seok S, Zhang Y, et al
      MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
      Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
      PubMed     Abstract available
      
      
      
1183. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
      Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
      Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
      PubMed     Abstract available
      
      
      
1184. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
      MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
      Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
      PubMed     Abstract available
      
      
      
1185. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
      Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
      Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
      PubMed     Abstract available
      
      
      August 2019
1186. KWON HM, Moon YJ, Jung KW, Park YS, et al
      Appraisal of cardiac ejection fraction with liver disease severity: Implication in post-liver transplantation mortality.
      Hepatology. 2019 Aug 28. doi: 10.1002/hep.30913.
      PubMed     Abstract available
      
      
      
1187. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
      Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
      Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
      PubMed     Abstract available